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Abstract 
The voltage-gated sodium channel, Nav 1.8, is known to play an important role in pain 
signalling. In this thesis, the functional properties and drug binding sites of wild type and 
mutant Nav 1.8 sodium channel currents were studied in mammalian sensory neuron-derived 
ND7/23 cells using whole-cell patch clamp. 
While the voltage-dependence of activation was similar for wild type human and rat Nay 1.8 
channels, the voltage-dependence of steady-state inactivation was more hyperpolarised for 
hNav 1.8 compared to rNav 1.8. Furthermore, as a consequence of the different time course for 
inactivation between human and rat channels, inhibition during frequent stimulation was less 
pronounced for hNav 1.8 than for rNav 1.8. Thus, this would imply that the human channel is 
more inactivated at normal resting potentials, and can support higher firing frequencies than the 
rat channel. 
The action of tetracaine, ralfmamide, 227c89, Vl02862, and Nav1. 8-selective compound A-
803467 on wild type hNav 1.8 and rNav 1.8 channels was studied. All compounds showed 
preferential block of inactivated channels rather than resting channels. Compound A-803467 
showed greater affinity for inactivated hNav 1.8 channels than for inactivated rNav 1.8 channels. 
Unexpectedly, an increase in current was observed for V102862 and A-803467 during recovery 
from inactivation, likely due to "disinhibition" of resting block. For A-803467, rather than use-
dependent inhibition, this disinhibition increased the current during frequent stimulation, while 
for VI 02862 it led to the absence of inhibition during low frequency stimulation. Thus while 
both V 102862 and A-803467 are potent inhibitors ofNav 1.8, V102862, rather than A-803467 
might be a more useful blocker where physiological firing frequencies are higher. 
Alanine mutations at residues 1381, N390, L14l0, V14l4, Il706, F1710 and Y1717 were 
made in the pore-lining S6 segments of the hN av 1. 8 channel, and at the corresponding positions 
in the rNav 1.8 channel. Many of the mutations caused shifts in voltage-dependence of activation 
and inactivation, and gave a faster time course of inactivation, indicating that the native residues 
at these positions are important for both activation and inactivation in Nav 1.8 sodium channels. 
The affinity of tetracaine for the resting and inactivated channels was reduced by hNav1.8 
mutations 138lA, F1710A and Y1717A (only inactivated state affinity was measured for the 
latter), and by mutation F17l0A for A-803467. For mutation L1410A both compounds caused 
complete resting block at very low concentrations; this block was removed by further 
stimulation. While tetracaine did not show disinhibition for wild type channels during recovery 
from inactivation, it was seen particularly for mutants L1410 and F1710A. All mutations 
increased the extent of disinhibition of A-803467. These results suggest that the Nav 1.8-
selective compound A-803467 acts within the pore S6 segments with a differing but partially 
overlapping site to that of the local anaesthetic tetracaine. 
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CHAPTER! 
GENERAL INTRODUCTION 
2 
1. Introduction 
Action potentials are the rapidly propagating signals that underlie the ability for nerve, 
muscle and other electrically excitable cell types to process and transmit information. Ion 
channels are integral proteins that regulate these processes; they mediate the passive flux of 
ions, such as K+, Na +, Ca2+ and cr, across the cell membrane down their electrochemical 
gradients. The classical studies on the giant squid axon in the 1950s by Hodgkin and Huxley 
established the role ofNa+ ion influx in the initiation of the action potential (Hodgkin and 
Huxley, 1952). Indeed, voltage-gated Na+ channels are responsible for the generation and 
propagation of action potentials in excitable cells (Hille, 2001). Therefore they are important as 
the site of action for many therapeutically important drugs. 
1.1 Voltage-gated N a + channel family 
In 1984, the first voltage-gated Na + channel encoding cDNA was cloned from the electroplax 
organ of Electrophorus electric us (Noda et aI., 1984). To date, nine mammalian Nav a-subunit 
subtypes have been cloned, functionally expressed and classified as members of a single 
mammalian gene family according to sequence and their functional and pharmacological 
properties (Table 1.1). The voltage-gated Na + channel family members will be referred to using 
the widely accepted nomenclature of Goldin et ai. (2000), where the prefix Nav denotes the 
chemical symbol of the principle permeating ion (Na+) and the predominant environmental 
regulator (gated by voltage). The first number indicates the gene subfamily, and the second 
number indicates the channel subtype (Goldin et aI., 2000). For example, Nav 1.8 (previously 
named SNS1, PN3 and NaNG) is a voltage-gated ion channel principally selective for the 
conduction ofNa + ions, which is the eighth subtype to be identified in the first subfamily (Nav 1 
is currently the only subfamily). In addition to the nine mammalian Nav 1 subtypes identified 
and functionally expressed, atypical sodium channel-like proteins (Nax) have been identified but 
not yet functionally expressed. The Nax protein shows approximately 50% identity to the Nav 1 
channel subfamily (Catterall et aI., 2005). 
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TABLE 1.1 
Voltage-gated sodium channel family 
Subtype Gene name Chromosome location TTX IC50 (nM) Primary tissue 
Nay!. 1 SCNIA 2q24 6 CNS 
Nay !. 2 SCN2A 2q23-24 12 CNS 
Nay!.3 SCN3A 2q24 4 CNS 
Nay!'4 SCN4A 17q23-25 5 Skeletal muscle 
Nay!. 5 SCN5A 3p21 2000 Heart 
Nay 1.6 SCN8A 12q13 1 CNS, PNS 
Nay !. 7 SCN9A 2q24 4 PNS 
Nay !. 8 SCNIOA 3p22-24 60,000 PNS (DRG) 
Nay !. 9 SCNllA 3p21-24 40,000 PNS 
Nax SCN7A 2q21-23 ? Widely expressed 
1.1.1 Voltage-gated Na + channel family members and their distribution 
The nine mammalian Nav a-subunit subtypes share more than 50% identity between the 
amino acid sequence of transmembrane and extracellular domains (Catterall et aI., 2005). The 
Nav1.1, Nav1.2, Nav1.3 and Nav 1. 7 channel amino acid sequences are closely related (Fig. 1.1); 
they all encode tetrodotoxin (TTX)-sensitive channels, and their genes are all located on human 
chromosome 2q23-24, consistent with a common evolutionary origin (Goldin, 2002). 
Furthermore, the Nav 1.5, Nav 1.8 and Nav 1.9 channel subtypes are also closely related in amino 
acid sequence (Fig. 1.1); they are insensitive to TTX to differing extents, and their genes are all 
located on human chromosome 3p21-24 (Goldin, 2002). The Nav1.4 and Nav1.6 channel genes 
are located on human chromosome 17q23-25 and 12q13 respectively, and they are TTX-
sensitive (Table 1.1, Goldin, 2002). It seems likely that the single Nav channel subfamily has 
arisen from gene duplications and chromosomal rearrangements (Goldin, 2002). 
To understand the function of voltage-gated Na+ channels in more detail, the expression 
pattern of specific subtypes has been determined. Seven of the cloned subtypes are expressed in 
the nervous system; Nav1.1, Nav1.2, Nav1.3, and Nav1.6 channels are predominantly expressed 
in the central nervous system (CNS), whereas Nav1.7, Nav1.8 and Nad.9 channels are 
principally found in the peripheral nervous system (PNS) (Catterall, 2005). In contrast, the 
Nay 1.4 channel is expressed in skeletal muscle cells, and the Nay 1.5 channel in cardiac muscle 
cells (Catterall, 2005). 
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the resting state. Recovery from inactivation may take the order of milliseconds to minutes 
depending on the inactivation state of the channel. Fast inactivation states are induced following 
short depolarisations and take milliseconds to recover. In contrast, voltage-gated Na+ channels 
also enter multiple slow inactivated states following prolonged depolarisation, which may take 
seconds to minutes to recover from (Ulbricht, 2005). Fast and slow forms of inactivation are 
structurally and functionally different. Fast inactivation is abolished following the proteolytic 
treatment of the intracellular surface ofNav channels (Armstrong, 1981; Armstrong et ai., 
1973). Indeed, fast inactivation is disturbed by site-directed antibodies and site-directed 
mutagenesis of the cytoplasmic linker connecting domains III and IV, indicating the role of this 
linker (Stuhmer et aI., 1989; Vassilev et aI., 1988). Mutation of the hydrophobic IFM 
(isoleucine, phenylalanine and methionine) motif in the DIll-IV linker removes fast inactivation 
(West et aI., 1992), and peptides containing the IFM sequence are sufficient to restore fast 
inactivation (Eaholtz et aI., 1994). The IFM residues in the DIll-IV linker are thought to form 
hydrophobic interactions with residues within or around the intracellular region of the pore 
(Eaholtz et aI., 1994; West et aI., 1992). This fast inactivation gate moves to occlude the ion-
conducting pathway and immobilises gating charge (Cahalan and Almers, 1979; Hille, 2001). 
Fast inactivation contributes to action potential termination, spike frequency, and regulation of 
resting excitability (Nau and Wang, 2004). 
The structural determinants of slow inactivation apparently involve residues within the P-
loop, S4 segments, S6 segments, and residues adjacent to the IFM motif (Nau and Wang, 2004; 
Ulbricht, 2005), although it is not yet fully understood. Furthermore activation, fast inactivation 
and slow inactivation states are proposed to be coupled at the pore-lining S6 segments (Bai et 
aI., 2003; Ulbricht, 2005; Wang et aI., 2000; Yarov-Yarovoy et aI., 2001). Slow inactivation is 
thought to be involved in the regulation of membrane excitability, spike frequency adaptation 
and fIring properties (Nau and Wang, 2004). 
Overall, the voltage-dependent properties ofNav channels enable them to sequence through 
conducting and non-conducting states, thus sending rapid trains of action potentials, necessary 
for normal physiological functions (Clare et aI., 2000). 
1.2.4 Functional role of the fJ-subunits 
The auxiliary ~-subunits, despite not being necessary for ion conduction, play an important 
role in channel modulation and cellular localisation. Co-expression of ~-subunits with the a-
subunit has been shown to modify the voltage-dependence of activation, voltage-dependence of 
inactivation and the inactivation kinetics (Isom et aI., 1995b; Patton et aI., 1994). In addition, 
the ~-subunits interact with adaptor proteins (such as contactin and ankyrin-G), for the 
localisation of the Nav channel, for instance, at the nodes of Ranvier (lsom, 2001). To date, four 
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~-subunit gene family members have been cloned and functionally expressed; ~1-~4 (with splice 
variants ~1 and ~IA) (lsom et aI., 1992; Isom et aI., 1995a; Kazen-Gillespie et aI., 2000; Morgan 
et aI., 2000; Wollner et aI., 1987; Yu et aI., 2003). The ~-subunits are composed ofa single 
membrane-spanning domain and an extracellular domain. The extracellular domain contains an 
immunoglobulin domain, which is likely to playa role in cell adhesion (Isom and Catterall, 
1996; Isom, 2002). The ~l-' ~IA- and ~3-subunits associate with the a-subunit by non-covalent 
interactions, whereas the ~2-and ~4-subunits associate covalently (Isom, 2002; Yu et aI., 2003). 
1.2.5 Regulation o/voltage-gated Na+ channels 
Regulation of neuronal action potential firing and conduction can be achieved by the 
modulation of voltage-gated Na+ channels. In addition to modulation by ~-subunits, Nay 
channel a-subunits are also modulated by phosphorylation, G proteins, receptors, cytoskeletal 
elements and adaptor proteins. The Nav channel a-subunit linkers connecting domains I and II, 
and linkers connecting domains II and III have been shown to be sites of phosphorylation 
(Chahine et aI., 2005). Phosphorylation may occur following the activation of serine/threonine 
protein kinases PKA and PKC, and tyrosine kinase Fyn (Beacham et ai., 2007; Cantrell et aI., 
2002; Murphy and Catterall, 1992; West et aI., 1991). The linker connecting domains II and III 
is also important for the trafficking of most Nav channel subtypes (Chahine et aI., 2005). The 
linker contains a consensus sequence required for the binding of adaptor protein ankyrin-G to 
the Nav channel a-subunit binding of actin-based cytoskeletons and other membrane proteins 
(Chahine et aI., 2005; Cusdin et aI., 2008). The C-terminus appears to be the principal site of 
interaction with cytoplamic modulatory proteins. It is comprises a highly conserved acidic 
(glutamic acid-rich) proximal half, and distal half with little conservation. The C-terminus 
contains motifs for the binding of G proteins, calmodulin and ubiquitin-ligase, and interacts 
directly with several cytoskeletal and adaptor proteins (Chahine et aI., 2005). A carboxy-
terminal a-helical segement of the C-terminus also appears to interact with the N-terminus in 
Nav 1.4 (Zhang et aI., 2000). 
1.3 Voltage-gated Na + channel pharmacology 
Although voltage-clamp techniques were widely used in the studies of the giant squid axon 
during the 1940s and 1950s, it was not until 1959 that they were used to study ion channel 
pharmacology; cocaine and procaine were shown to block Na + and K+ currents in the squid 
giant axon at clinically relevant concentrations (Shanes et aI., 1959; Taylor, 1959). Considering 
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voltage-gated Na + channels are expressed throughout the nervous system, and cardiac and 
skeletal muscle tissues, it is not surprising that these drugs showed unwanted actions when used 
as local anaesthetics. Voltage-gated Na+ channels are still highly studied targets for the 
development of compounds for use in local anaesthesia, cardiac arrhythmias, epilepsy, 
ischaemic events and other conditions (Clare et aI., 2000). 
1.3.1 Voltage-gated Na + channel neurotoxin receptor sites 
Chemicals (neurotoxins and drugs) that act on the Nav channel have been classified 
according to the receptor sites to which they bind (Table 1.2) (Catterall, 1992). Receptor site 1 
binds the non-peptides tetrodotoxin and saxitoxin, and the peptide /l-conotoxins, which all 
selectively block Nav channels by occluding the pore from the extracellular site (Catterall, 
2000; Catterall et aI., 2005; Fozzard and Hanck, 1996; Terlau and Stuhmer, 1998). Receptor site 
2 binds the lipid-soluble toxins veratridine, batrachotoxin, aconitine and grayanotoxin, which all 
modulate the activation kinetics and inhibit inactivation ofNav channels from a receptor within 
the pore (Catterall et aI., 2005; Narahashi, 1998). Receptor site 3 binds the a-scorpion toxin 
(class 1) and sea anemone toxin peptides, which act extracellularly to prevent the outward 
movement of the IVS4 voltage sensor, slowing the coupling of activation and inactivation 
(Catterall et aI., 2005; Clare et aI., 2000; Narahashi, 1998). Receptor site 4 binds ~-scorpion 
toxin peptides (class 2 and 3), which alter the voltage-dependence of activation (class 2), and 
additionally, the voltage-dependence of inactivation (class 3) by interacting with an extracellular 
receptor (Catterall et aI., 2005; Narahashi, 1998). Receptor site 5 binds polyether brevetoxins 
and ciguatoxin, which alter activation kinetics and inhibit inactivation by acting on an 
intracellular receptor (Catterall et aI., 2005; Narahashi, 1998). Receptor site 6 binds 8-
conotoxins, which decrease the rate of inactivation, and perhaps actually bind to a similar site as 
the a-scorpion toxin (Catterall et aI., 2005). In contrast to the lethal effects of many of these 
neurotoxins, voltage-gated Na + channel function may be subtly modulated by local anaesthetics 
and other structurally-related agents acting on the local anaesthetic receptor site, which will be 
discussed in detail in the next section. 
Site 
2 
3 
4 
5 
6 
11 
TABLE 1.2 
Receptor sites on sodium channels 
Neurotoxin or Drug Source Domains 
Tetrodotoxin Fish (Tetraodontiformes family) IS2-S6, IIS2-S6 
Saxitoxin 
Jl-conotoxins 
Veratridine 
Batrachotoxin 
Grayanotoxin 
a-scorpion toxin (class 1) 
Sea anemone toxins 
Dinoflagellates and cyanobacteria IIIS2-S6, IVS2-S6 
Marine snails (Conus family) 
P-scorpion toxins (class 2) 
P-scorpion toxins (class 3) 
Brevetoxins 
Ciguatoxin 
&-conotoxins 
Plants (Liliaceae family) IS6, IVS6 
Frogs (Dendrobatidae family) 
Plants (Ericaceae family) 
Dinoflagellates 
Dinoflagellates 
Marine snails (Conus family) 
IS5-IS6,IVS3-S4 
IVS5-S6 
IIS1-S2,IIS3-S4 
IS6, IVS5 
IVS3-S4 
Local anaesthetic Local anaesthetic drugs IS6, IIIS6 IVS6 
receptor Anticonvulsant drugs 
Antiarrythmic drugs 
1.3.2 Local anaesthetic, antiarrhythmic and anticonvulsant drugs acting on voltage-
gated Na + channels 
Local anaesthetic, antiarrhythmic and anticonvulsant drugs reversibly reduce the peak Na + 
current in a concentration-dependent manner during a single depolarisation known as "tonic 
block". Tonic block is voltage-dependent since more depolarised holding potentials increase the 
extent of block. Tonic block is a reduction of the open-probability at equilibrium of channel 
states. Block is also augmented by frequent depolarisation known as "use-dependent" or 
"phasic" block. These properties enable preferential inhibition ofNav channels during periods 
of sustained depolarisation, repetitive firing or both, without inhibiting normal physiological 
function. 
Common structural features of clinically useful local anaesthetics include a hydrophobic 
aromatic group, an intermediate linker containing an ester or amide group, and a hydrophilic 
tertiary amine group. Local anaesthetic drugs include ester-containing tetracaine, benzocaine 
and procaine, and amide-containing lidocaine, etidocaine, and the derivatives bupivacaine, 
mepivacaine, and ropivacaine. 
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Anticonvulsant drugs are compounds that effectively reduce the occurrence of seizure 
activity without causing sedation or diminishing normal brain activity (Clare et ai., 2000). These 
include lidocaine, phenytoin and lamotrigine. All classes of clinically effective anticomulsants 
are lipid-soluble compounds, a number of which act to selectively block Nav channels. Many 
anticonvulsants (such as lidocaine and phenytoin) are also used as antiarrythmics. Class I 
antiarrhythmic drugs are compounds that reduce the occurrence of cardiac arrhythmia at clinical 
concentrations by acting on voltage-gated Na + channels. Antiarrythmic drugs, such as quinidine, 
primarily inhibit Nav channels in the heart. 
Improvements in both depressive and manic phases of bipolar disorder were also observed in 
patients taking anticonvulsants carbamazepine, valproate, lamotrigine or oxycarbazepine (Perez-
Ceballos et aI., 2006). Moreover, the symptoms of neuroleptic-resistant schizophrenia have been 
reported to be reduced by anticonvulsants lamotrigine, carbamazepine, and particularly 
valproate (Rogawski and Loscher, 2004). Voltage-gated Na+ channels are also thought to be 
involved in excitotoxic damage following ischaemic events. Indeed, sipatrigine, crobenetine, 
and compound 202W92 have been shown to inhibit Nav channels in a use-dependent manner, 
preventing neuronal degradation (Carter et aI., 2000; Clare et aI., 2000; Liu et ai., 2003; Yarov-
Yarovoy et aI., 2001; Yarov-Yarovoy et aI., 2002). In addition, Nav channel inhibitors have 
been reported to treat a variety of other conditions. For example, phenytoin and carbamazepine 
have been shown to effectively reduce neuromuscular disorders (myotonia, myokymia and 
dystonia) and pain conditions (neuropathic pain and trigeminal neuralgia) (Rogawski and 
Loscher, 2004). This range of conditions is likely the consequence of the distribution of 
different Nav channel subtypes and differences between the actions of these drugs. 
1.3.3 Mechanism of action of drug block 
Almost all clinically useful local anaesthetics are tertiary amine compounds and are 
uncharged (lipid-soluble) at high pH and charged (lipid-insoluble) at low pH. Quaternary local 
anaesthetics (such as QX-314) are permanently charged, and only inhibit Nav channel current 
when applied internally, suggesting the local anaesthetic drug may only access the binding site 
from the intracellular side of the channel (Fig. 1.5) (Frazier et aI., 1970). Following internal 
application of a quaternary local anaesthetic, drug block and drug dissociation may only occur 
when the channel is open (Strichartz, 1973). The dissociation of quaternary local anaesthetic 
drugs from the open channel is increased with a higher concentration of external Na + ions. In 
contrast, tertiary amine local anaesthetics do not require the channel to be open in order to 
dissociate; they can "leak" from closed channels. The leak of tertiary local anaesthetics from 
closed channels is slower in the presence of a low external pH, suggesting protons have access 
to the bound drug from the external side. In contrast, low internal pH has little effect on drug 
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In order to determine whether other S6 segments are also involved in drug interactions, 
mutagenesis studies of the other three domains was carried out. The inactivated state affinity of 
a number oflocal anaesthetics was reduced by mutation oflS6 isoleucine residue (1381) in 
Navl.2 and Navl.4 channels, as was the use-dependent block (Wright et aI., 1998; Yarov-
Yarovoy et aI., 2001). The IS6 asparagine residue (N390) also showed a reduction in the 
inactivated state affinity for local anaesthetics when mutated to lysine in Nay 1.4, Nay 1.5 and 
Nayl.7 channels (Nau et aI., 1999,2000; Sheets et aI., 2007; Wang et aI., 1998b). Furthermore, 
the latter residue showed less pronounced use-dependent block when mutated to lysine or 
alanine (Sheets et aI., 2007; Wang et aI., 1998b; Yarov-Yarovoy et aI., 2002). For the IIIS6 
segment, mutation of the leucine or isoleucine residues (at positions 1410 and 1414 
respectively) reduced the inactivated state affinity of local anaesthetics for Nay channels, and 
gave less use-dependent block (Nau et aI., 2003; Wang et aI., 2000; Y arov-Yarovoy et aI., 
2001). The IIIS6 asparagine residue (N1411) also reduced the affinity oflocal anaesthetics for 
inactivated Nay channels, but in contrast to other mutations, did not show altered use-dependent 
block (Nau et aI., 2000; Yarov-Yarovoy et aI., 2001). The IIS6 segment does not appear to be 
involved in local anaesthetic binding, which may perhaps be understood since it is orientated 
directly opposite the IVS6 segment (the principle site of action) (Wang et aI., 2001; Yarov-
Yarovoy et aI., 2002), and so the drugs may be "drawn away" from IIS6. 
It is also of note that while asparagine (N390) is proposed to be oriented towards the pore 
lumen in the Nayl.4 channel (Nau et aI., 2003), apparently contradictory orientations have been 
suggested in the same channel (Kondratiev and Tomaselli, 2003) and the Nay 1.2 channel 
(Yarov-Yarovoy et aI., 2002). Interestingly, NMR spectroscopy ofa 12 residue peptide 
analogous to part of the Nayl.2 channel IS6 segment (amino acid residues G384 to V495) 
suggested it was 31O-helcial in structure and molecular modelling suggested that the asparagine 
(N390) is a molecular determinant for drug block (Lou et aI., 2005). 
Additional residues with less established roles in the binding of local anaesthetics include the 
IS6 isoleucine, serine, phenylalanine and leucine residues (positions 330, 385, 386 and 393, 
respectively), the IIS6 isoleucine and valine residues (positions 876 and 880, respectively), and 
the IVS6 asparagine residue (position 1715) (Kondratiev and Tomaselli, 2003; Nau et aI., 2000; 
Wang et aI., 1998b; Wang et aI., 2007) 
1.3.5 Strnctural determinants of anticonvulsant and antiarrhythmic drngs acting on 
voltage-gated Na + channels 
Remarkably, the phenylalanine and tyrosine residues of the IVS6 segment (F171O and 
Y 1717) are also important for the voltage- and use-dependent properties of a number of other 
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Nav channel inhibitors including anticonvulsants (lidocaine, phenytoin and lamotrigine), 
antiarrhythmics (quinidine, flecainide and mexiletine), anti-ischaemic drugs (sipatrigine and 
crobenetine), and tricyclic antidepressant drugs (amitriptyline) (Carter et aI., 2000; Liu et aI., 
2003; Ragsdale et aI., 1996; Wang et aI., 2004; Weiser et aI., 1999), perhaps by means of an 
overlapping but non-identical binding site. Indeed, the phenylalanine residue (F 171 0) appears to 
be the primary determinant of drug binding, since no voltage-dependent pore-blocking drug has 
been unaffected by its mutation to alanine. 
Anticonvulsant and antiarrhythmic drugs generally have more complex structures than local 
anaesthetics, thus, it was hypothesised that they may interact with additional residues. Mutation 
ofIIIS6 segment leucine and isoleucine residues (at positions 1410 and 1414, respectively) 
reduced the affinity of lamotrigine derivatives sipatrigine (an anti-ischaemic), 227c89 (an 
analgesic), and 4030w92 (an analgesic and anticonvulsant) (Yarov-Yarovoy et aI., 2001). 
Mutation of the asparagine residue (N1411) did not affect the affmity of inactivated Nav1.2 
channels for sipatrigine or 227c89 as it did with 4030w92 (Yarov-Yarovoy et ai., 2001). 
Furthermore, mutations in the IS6 and IIS6 segments did not appear to affect the inactivated 
state binding affinity or the extent of use-dependent block of lamotrigine derivative, sipatrigine, 
suggesting it may not directly interact with these segments (Yarov-Yarovoy et ai., 2002). 
The IS6 asparagine (N390), and IVS6 isoleucine (11706), phenylalanine (F 171 0), tyrosine 
(Y 171 7) residues have been shown to be important for both fast and slow inactivation properties 
of the Nav channel (Bai et ai., 2003; Carboni et aI., 2005; Wang and Wang, 1997). In fact in the 
absence of drug almost all mutations at sites involved in drug binding affect the activation 
properties, inactivation properties or both (Nau and Wang, 2004). While this has led to concerns 
to whether these residues are really involved in drug interactions, it seems likely that the S6 
segments are required for both gating processes and drug binding. Since the effect of the S6 
segment residues on drug binding is state-dependent, conformational changes in the S6 segment 
are expected to expose these residues to the conduction pathway where pore-blocking drugs 
may bind with greater affinity (Liu et ai., 2003). Indeed, the S6 segments ofK+ and Ca2+ 
channels are also essential for the state-dependent action of drugs (Chen et aI., 2002; 
Hockerman et ai., 1997). 
Functional studies have demonstrated that although the local anaesthetic binding site may 
predominantly involve S6 segments, it is not exclusive to them. The Nav 1.4 channel residue 
K1237 (of the selectivity filter DEKA motif) is involved in interactions with lidocaine, 
suggesting the selectivity filter may be adjacent to the drug binding site (Sunami et aI., 1997). 
Mutation of the rat Nav1.4 channel residue W1531 (located in the external pore vestibule) was 
found to reduce local anaesthetic block (Tsang et ai., 2005). Furthermore, the intracellular 
IVS4/S5 linker has also shown to make interactions with local anaesthetics (Fraceto et ai., 
2006). 
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It is noteworthy that some studies have reported apparently contradictory findings. 
Anticonvulsants phenytoin, carbamazepine and lamotrigine were not effective in inhibiting Nav 
channel current internally, suggesting an external drug binding site for these drugs (Kuo, 1998). 
Furthermore, it was reported that batrachotoxin (binding site 2) and brevetoxin toxins (binding 
site 5) acting on their intracellular binding sites did not affect the binding of radio labelled 
lamotrigine derivative, 202W92. However, extracellular binding of a-scorpion (binding site 3) 
and ~-scorpion (binding site 4) significantly impaired 202W92 binding. These findings suggest 
the presence of more than one drug receptor on Na+ channels where 202W92 binds to a novel 
extracellular binding site on rat brain Na+ channels (Riddall et aI., 2006). Therefore, work in the 
future is required to understand these more controversial findings. 
1.3.6 Mechanism 0/ action o/pore-blocking drugs at the S6 segments 
In order to understand the detailed mechanisms for drug block at the IVS6 segment, a 
number of structure-function studies have been carried out. The phenol derivative, 2,6-
dimethylphenol (resembling the aromatic tail of a local anaesthetic), was reported to show 
similar properties to lidocaine (Haeseler et aI., 2002). Indeed, the voltage- and use-dependent 
effects of toluene (methylbenzene) are dependent on the IVS6 segment phenylalanine residue 
(F 171 0) in the Nav 1.4 channel (Gauthereau et aI., 2005). Structure-function studies indicate that 
both the amine head and aromatic tail groups interact with the Nav channel (Li et aI., 1999). 
These findings suggest that while the aromatic head group is sufficient for state-dependent 
block, the hydrophilic tertiary amine is not necessary but it can also interact with the channel. 
The hydrophobic and aromatic properties of the phenylalanine residue (F 171 0) were found to 
be important for local anaesthetic binding to open/inactivated states, by either cation-1t 
interaction or 1t-1t stacking while the contribution of tyrosine residue (Y 1 71 7) to the drug 
receptor was unclear (Li et aI., 1999). Furthermore, mutation of the phenylalanine residue 
reduced the open/inactivated state affinity by a greater percentage compared to the reduction in 
the resting state affinity. The greater effect on the inactivated state affinity indicates that the 
phenylalanine residue (F1710) may contribute to the preference of drugs for the 
open/inactivated states (Li et aI., 1999). More recently, the phenylalanine (FI71O) and tyrosine 
(Y1717) residues were substituted with a number of unnatural derivatives with reduced 
electrostatic potentials (Ahem et aI., 2008). This study suggests that phenylalanine interacts 
with lidocaine by cation-1t interactions, while tyrosine does not appear to interact with lidocaine 
by either cation-1t interactions or 1t -1t stacking. 
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1.3.7 Molecular modelling of drug binding 
Molecular modelling studies of drugs bound to Nav channels have been used more 
extensively to support the mutagenesis studies and have important uses for predicting the 
physicochemical mechanisms of block. By homology with the crystallographic structure of the 
closed KcsA channel, Lipkind and Fozzard (2005) used the structure of the open MthK channel 
to develop an open channel model of a Nav channel P-Ioops and S5 and S6 segments 
(characterised by bends at the S6 segment glycine or serine residues). After docking a number 
of local anaesthetics, they proposed that the amine head group of local anaesthetic drugs 
interacts with the IVS6 phenylalanine (F17l0) and IIIS6leucine (L141O) residues, while the 
aromatic tail group interacts with IVS6 tyrosine (Y1717) and asparagine (N390) residues 
(Lipkind and F ozzard, 2005). Molecular modelling of the human N av 1. 8 channel by homology 
with the structure of the open MthK channel, suggested that tetracaine interacts with selectivity 
filter residues D356 and E849, IVS6 phenylalanine (FI71O) and tyrosine (Y1717) residues, the 
IIIS6 segment asparagine (N14l1) residues, and inactivation gate residues 11433 and F1434 of 
the IFM motif (Scheib et aI., 2006). Importantly, these two studies are both consistent with the 
findings of the mutagenesis studies. The docked local anaesthetic drug appeared to be too small 
to completely physically occlude the ion conduction pathway, suggesting ion conduction may 
be reduced by an electrostatic barrier (Lipkind and Fozzard, 2005). In order to experimentally 
test this, the phenylalanine residue was substituted for a cationic amino acid (lysine or arginine) 
or an anionic amino acid (aspartic acid or glutamic acid) (McNulty et aI., 2007). The latter 
authors showed that the unitary conductance was reduced by the cationic amino acid and 
conversely, increased by the anionic amino acid. Taken together, local anaesthetic drugs appear 
to reduce Na + permeation by partly physically blocking the ion conduction pathway, while the 
charged amine produces an electrostatic barrier (McNulty et aI., 2007). 
The molecular models described above have been based on bacterial potassium channel 
structures. More recently however, Frank Blaney (GlaxoSmithKline, Harlow) developed a 
model of the human Navl.8 sodium channel based on its homology with structure of the 
mammalian Kvl.2 potassium channel (Fig. 1.9). Hydropathy plots of the hNavl.8 and rKvl.2 
channel sequences were used to identify the S5-P-Ioop-S6 region of each domain and alignment 
of the S6 regions was based on the conserved S6 glycine and serine residues (Fig. 1.9A). The 
model (Fig. 1.9B) was used for comparison with the fmdings of this thesis. 
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1.4.1 Functional properties of Nav1. 8 sodium channels 
In comparison to other Nav channel subtypes, the Nav 1.S channel has distinct biophysical 
properties. The Nav 1.S channel shows both slower kinetics and more depolarised voltage-
dependent activation and inactivation in rat DRG or when expressed in Xenopus oocytes than 
the other Nav channel subtypes (Akopian et aI., 1996; Elliott and Elliott, 1993; Sangameswaran 
et aI., 1996). The Nav 1.S channel recovers from inactivation with a fast and slow component. 
Recovery from fast inactivation is rapid, and suitable for high action potential firing frequencies 
(Cummins and Waxman, 1997; Elliott and Elliott, 1993). The Nav1.S channel has more 
pronounced slow inactivation than other Nav subtypes (Leffler et aI., 2007), and its recovery is 
slower even during short depolarising pulses from normal resting membrane potentials (Blair 
and Bean, 2003). 
1.4.2 Role of the Nad.8 sodium channel in pain pathways 
Nav 1.S channels are predominantly expressed in dorsal root, trigeminal and nodose ganglia 
(Akopian et aI., 1996; Sangameswaran et aI., 1996). Following nerve damage, the functional 
expression ofNav 1.S channels is reduced in injured neurons but increased in uninjured axons, 
indicating that the activity of uninjured neurons might be important for neuropathic pain (Gold 
et aI., 2003). Intrathecal administration ofNav 1.S-specific antisense oligodeoxynuc1eotides was 
found to reverse hyperalgesia and allodynia in nerve-injured animal models, without influencing 
non-noxious sensation or response to acute pain (Joshi et aI., 2006; Lai et aI., 2002; Porreca et 
aI., 1999). Similarly, mechanical allodynia in rat models of neuropathic pain was attenuated by 
siRNA-mediated selective knockdown ofNa\·I.S channels (Dong et aI., 2007). In contrast, 
Navl.S null mice do not have a significant neuropathic pain phenotype though they do show 
resistance to noxious mechanical stimuli, nerve growth factor-induced thermal hyperalgesia and 
visceral pain (Akopian et aI., 1999; Kerr et aI., 2001; Laird et aI., 2002; Nassar et aI., 2005). 
More recently, neurons expressing Na\·l.S were shown to be necessary for the sensations of 
noxious mechanical and cold stimuli, thermal and mechanical allodynia following 
inflammation, but not neuropathic pain or heat sensing (Abrahamsen et aI., 200S). Indeed, due 
to the cold-resistant properties of the Nav 1.S channel, Nay 1.S is critical for the perception of 
pain at low temperatures (Zimmermann et aI., 2007). 
Pharmacological agents that block Nay I.S channels have also been shown to be anti-
hyperalgesic and anti-allodynic in animal models of inflammatory and neuropathic pain. For 
instance, the anti-nociceptive properties of ralfinamide (NW -1029) are proposed to result from a 
pronounced inhibition ofTTX-resistant Na + currents (Stummann et aI., 2005). The Nay 1.S-
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selctive ~O-conotoxin MrVIB, and small-molecule compound A-803467, have both been 
shown to effectively reduce pain in animal models; MrVIB reduced allodynia and hyperalgesia 
in both neuropathic and chronic inflammatory pain models (Ekberg et ai., 2006), and A-803467 
reduced thermal hyperalgesia in inflammatory models of pain and mechanical allodynia in 
neuropathic models of pain (Jarvis et ai., 2007). Furthermore, consistent with the findings of 
Zimmerman et ai. (2005) and Abrahamsen et ai. (2008), the latter compound reduced acute 
mechanical pain and cold allodynia, but not acute thermal pain (Jarvis et ai., 2007). 
1.4.3 Role of the inactivation properties ofNad.8 channels 
The generation and propagation of action potentials in excitable cells is largely influenced by 
the voltage-dependent gating mechanisms of voltage-gated Na+ channels. Compared with other 
Nav channel subtypes, the relatively depolarised inactivation of Nay 1. 8 indicates that fewer 
channels will be inactivated at normal sensory neuron resting membrane potentials (Harty and 
Waxman, 2007). Therefore, a greater proportion of Nay 1.8 channels are available to activate; 
indeed, the Nay 1.8 channel contributes significantly to the action potential upstroke, even at 
depolarised sensory neuron resting potentials (Harty and Waxman, 2007). 
The more pronounced slow inactivation of the Nay 1.8 channel has both physiological and 
pharmacological significance. At normal physiological action potential firing frequencies, a 
large proportion of Nay 1. 8 channels enter slow inactivation states (Tripathi et ai., 2006). The 
extent of current inhibition at a known firing frequency depends on the rate of entry into 
inactivated states and the rate of recovery from inactivated states. While the extent of slow 
inactivation is greater for Nay 1.8 channels, the TTX-sensitive Na + channels fully recover 
between depolarisations at normal frequencies. Recently the use-dependent properties of TTX-
resistant Na + (likely Nay 1.8) channels were shown to cause a decrease in the speed of action 
potential conduction along axons following activity ("activity-dependent slowing of conduction 
velocity") (De Col et aI., 2008). In addition to the physiological importance, the more 
pronounced slow inactivation ofNav1.8 has important implications for its pharmacology. As 
discussed above, drugs such as lidocaine, carbamezipine and lacosamide bind with a greater 
preference for slow inactivation states over other states (Cardenas et aI., 2006; Errington et ai., 
2008; Leffler et aI., 2007). Thus, this dependence on the type of inactivation state provides a 
basis for subtype-specific selectivity of these drugs between Nay channels; indeed, lidocaine 
and carbamezipine have a greater potency for Nay 1.8 channels, than for other Nay channel 
subtypes (Cardenas et ai., 2006; Leffler et aI., 2007). The different functional properties of 
Nay 1.8 might also be responsible for the highly selective block of compound A-803467, 
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although it seems likely that differences in the protein sequence and conformation also 
contribute. 
1.4.4 Heterologous expression o/human and rat Nad.8 channels 
The cloning of rat Nav 1.8 channel enabled its functional expression in Xenopus laevis 
oocytes (Akopian et aI., 1996; Sangameswaran et aI., 1996). Both of the latter authors showed 
rat Nav 1.8 channel currents that were small in amplitude, suggesting low levels of expression. 
The rat Nav 1. 8 channel has been functionally expressed in a number of mammalian cell lines . , 
chinese hamster ovary (CHO), African green monkey kidney (COS-7), human embryonic 
kidney (HEK-293) cells (Okuse et aI., 2002). More recently, the dorsal root ganglion 
neuroblastoma ND7/23 cell line was shown successfully to express rat Nav 1.8 channels (Choi et 
aI., 2004; John et aI., 2004; Leffler et aI., 2007). 
For the human Nav 1.8 channel, the functional properties were also first examined in Xenopus 
laevis oocytes (Rabert et aI., 1998). In addition, human Nav 1.8 channels have been functionally 
expressed in mammalian CHO and neuroblastoma SH-SY5Y cells (Akiba et aI., 2003; Dekker 
et aI., 2005). It is noteworthy that authors have noted the difficulty in expressing both human 
and rat Nav 1.8 channels in mammalian cell lines (Dekker et aI., 2005; Leffler et aI., 2007); this 
has hindered the number of functional studies ofNav 1.8 channels. 
It is important to consider whether the heterologous expression ofNav 1.8 shows functional 
properties which are similar to those in native neurons. The heterologous expression of rat 
Nav 1.8 channels in ND7/23 cells showed that steady-state inactivation was half-maximal at -
54mV (John et aI., 2004). The latter authors showed that using the same steady-state 
inactivation protocol the TTX-resistant Na+ current of rat DRG neurons were also half-maximal 
at -54mV. Thus, John et aI. (2004) suggest that the rat Nad.8 channel expressed in the ND7/23 
cell line showed functional properties that closely resemble the native TTX-resistant Na+ 
currents in DRG neurons. The values for half-maximal inactivation in TTX-resistant DRG 
neurons are reported to be more depolarised in other studies. For instance, the voltage for half-
maximal inactivation for TTX-resistant currents in rat DRG was shown to be -29mV (Elliott 
and Elliott, 1993) and -43mV (Choi et aI., 2006). It seems likely that the different values are a 
consequence of the range of experimental conditions, such as the pulse protocols and solutions 
used. 
In the recordings from two-electrode voltage-clamped oocytes the value for half-maximal 
inactivation was more hyperpolarised for the human channel (Rabert et aI., 1998) as compared 
with the value for the rat channel (Akopian et aI., 1996). Moreover, Akiba et al. (2003) also 
noted that human Na\-l. 8 channels expressed in CHO cells appear to have more hyperpolarised 
inactivation than the rat Nad.8 channel observed by Akopian et al. (1996). However, no direct 
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comparison of the human and rat Nav 1.8 channel properties has been carried out in mammalian 
cells (or indeed between any two Nav channel orthologues), and comparison of values for 
inactivation is not easy because of the wide range of experimental conditions used. 
1.4.5 Modulation of the Navl.8 sodium channel 
As discussed above, the ~-subunits alter both the functional properties and cellular 
localisation. In situ hybridisation and immunochemistry have shown that the small and large 
fibers ofDRG neurons express ~l-, ~r and ~3-subunits; functional expression of the Nav 1.8 a-
subunit is increased by ~l' and its voltage-dependence of inactivation is shifted to more 
hyperpolarised potentials by ~l and ~3, and to more depolarised potentials by ~2 (Vijayaragavan 
et aI., 2004b). The ~3 subunit also appears to be important in cellular localisation since a 
significant increase in ~rsubunit:neurofilament ratio was observed after injury of human 
sensory neurons (Casula et aI., 2004). 
A variety of proteins have also been shown to interact with the intracellular linkers of the 
Nav 1.8 channel, and in particular, the C-terminus. The proximal (conserved) half of the C-
terminus ofNav 1.8 has been shown to associate with cytoskeletal and adaptor proteins (such as 
dynein intermediate chain, a-tubulin, and moesin), enzymes (inositol polyphosphate 5-
phosphate and thousand and one protein kinase) and membrane proteins (voltage-dependent 
anion channel VDAC3V, tetraspanin and connexin 43) (Malik-Hall et aI., 2003). The distal 
(non-conserved) half of the C-terminus ofNav 1.8 interacts with calmodulin, which has been 
been shown to regulate current density and functional properties of several Nay channel 
subtypes in a subtype-specific manner (Choi et aI., 2006). For the Nav 1.8 channel, calmodulin 
interacts with channels in native neurons and significantly increases current density, slows the 
second component of recovery from inactivation, and increases use-dependent current inhibition 
(Choi et aI., 2006). 
Other intracellular regions also appear to be important sites ofNad.8 channel regulation. 
The N-terminus of the Nav1.8 channel binds to the light chain of annex in II (p11), which is a 
cytoskeletal (F-actin) receptor that associates with the membrane in a Ca2+-dependent manner 
(Okuse et aI., 2002; Poon et aI., 2004). The interaction of pI I with Nav1.8 appears to promote 
its translocation to the cell membrane of small fibers ofDRG neurons, while it does not appear 
to interact with several other Nav channel subtypes (Okuse et aI., 2002; Poon et aI., 2004). 
Further, deletion ofpII causes deficits in acute and neuropathic pain (Foulkes et al., 2006). 
Activation of G proteins by GTPyS has also been reported to increase Nay 1.8 channel current 
amplitude (Saab et aI., 2003). More recently it was shown that Nav 1.8 current density was 
increased after phosphorylation of two serine residues in the DI-II linker (S551 and S556) by 
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p38 mitogen-activated protein kinase, which is activated following nerve injury and 
inflammation (Hudmon et aI., 2008). 
1.5 Summary of aims of this thesis 
This thesis aims to describe the structural determinants for drugs acting on the Nay 1.8 
channel. For this work, owing to reported difficulties with the expression of Nay 1.8 channels, an 
appropriate expression system was first required. Therefore the expression ofNav 1.8 channels 
was compared in the Xenopus laevis oocyte expression system and the transient transfected 
mammalian sensory neuron-derived cell line, ND7/23. 
Using ND7/23 cells, it was possible to carry out a detailed analysis and comparison of the 
electrophysiological properties of the wild type human and rat Nav 1.8 channels using whole-cell 
patch clamp. This is the first time a direct, cross-species comparison of the functional properties 
of a Nav subtype has been carried out in the same mammalian background. 
The pharmacological actions of drugs were then compared in the human and rat Nav 1.8 
channels, using tetracaine (a local anaesthetic), ralfinamide (an analgesic), 227c89 (a 
lamotrigine derivate with analgesic properties), VI02862 (an anticonvulsant), and A-803467 (a 
potent and selective inhibitor ofNav 1.8). The resting and inactivated state affinities were 
studied as well as the effects on use-dependent inhibition and recovery from inactivation. 
Seven alanine mutations (I38IA, N390A, L1410A, V1414A, Il706A, FI710A and Y1717A) 
were generated in the human and rat Nav 1.8 channel corresponding to positions in other Nav 
channel subtypes where local anaesthetics have been found to act in the S6 segments of domains 
I, III and IV. The effect of these mutations of the S6 segment on the activation and inactivation 
of human and rat Navl.8 was examined. 
Finally, the effects of these same S6 segment mutations on the action of tetracaine and the 
Nav 1.8-selective blocker A-803467, were studied. Here the sites of action of tetracaine and 
compound A-803467 were determined in the Nav 1.8 channel. The resting and inactivated state 
affinities were investigated, as were and the effects on use-dependent inhibition and recovery 
from inactivation. 
Much of the work in this thesis has already been submitted for publication, as described 
below. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Chemicals and reagents 
Collagenase Type lA, ethidium bromide, tricaine (3-aminobenzoic acid ethyl ester), 
kanamycin, penicillin-streptomycin and sigmacote~ were all obtained from Sigma (Poole, UK). 
Ampicillin was obtained from Stratagene (La Jolla, CA). EZ-Glass milk TM was purchased from 
Qbiogene (Cambridge, UK). Agarose and dynabeads® CD8 were purchased from Invitrogen 
(San Diego, CA). Escherichia coli MAX efficiency® Stbl2™ competent cells were obtained from 
Invitrogen and XLIO-Gold® competent cells from Stratagene (La Jolla, CA). Transfection 
reagent Lipofectamine™ 2000 was purchased from Invitrogen (San Diego, CA). Tetrodotoxin 
citrate was obtained from Tocris Bioscience (Bristol, UK). 
2.1.2 Voltage-gated sodium channel blocking drugs 
Tetracaine (4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester), compound A-803467 
(5 -( 4-Chloropheny 1)-N -(3,5 -dimethoxypheny 1)-2 -furancarbo xamide), compound V I 02862 (4-
(4-Fluorophenoxy)benzaldehyde semicarbazone), ralfinamide ((S)-(-i-)-2-(4-(2-fluorobenzoxy)-
benzylamino )-propanamide) and 227 c89 (5-(2,6-dichlorophenyl)-6-methylpyrimidine-2,4-
diamine) were all synthesised at GlaxoSmithKline. 
2.1.3 Enzymes and kits 
Restriction enzymes were obtained from Roche (Mannheim, Germany), unless otherwise 
stated. The restriction enzyme buffers were supplied with the enzymes. For the generation of 
point mutations, the QuikChange® XL Site-Directed Mutagenesis Kit was purchased from 
Stratagene (La Jolla, CA). Calf Alkaline Phosphatase and T4 DNA Ligase were obtained from 
Roche (Mannheim, Germany). The MEGAscript® SP6 Transcription Kit was obtained from 
Ambion (Huntingdon, UK). The QIAquick® Gel Extration Kit, QIAprep~ Miniprep Kit, 
HiSpeed® Plasmid Maxi Kit and Robot QIAprep~ 8 Turbo Kit were all obtained from Qiagen 
(Crawley, UK). 
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2.1.4 Oligonucleotides alld sequencing 
Mutagenesis and sequencing primers were designed using Vector NTI (Invitrogen), and 
synthesised by Invitrogen. Sequencing primers for the entire Nav 1.8-encoding cDNA were 
designed 400bp apart, for the contiguous defragmentation of sequences (showing a typical 
overlap of three fragments). Sequencing and mutagenesis primers are shown in Tables 2.la and 
2.lb. Oligonucleotide primers were resuspended in Tris-EDTA, briefly centrifuged and gently 
vortexed to give O.1mM of each primer. Sequencing of plasmid DNA was carried out at 
GlaxoSrnithKline Harlow. 
TABLE 2.1a 
Sequences of oligonucleotide primers for sequencing 
Primer Name Primer Sequence (5' to 3') 
hNa v1.8 seq1 TAATACGACTCACTATAGGG 
hNa 1,1.8 seq2 GGTITAGTGCCACTCGGGC 
hNa v1.8 seq3 
hNa v1.8 seq4 
hNa 1,1.8 seq5 
hNa v1.8 seq6 
hNa v1.8 seq 7 
hNa ,.1.8 seq8 
hNa v1.8 seq9 
hNa 171.8 seq10 
hNa ,.1.8 seqJJ 
hNa ,.1.8 seq12 
hNa 1,1.8 seqJ3 
hNa ,.1.8 seq14 
hNa v1.8 seq15 
hNa 1,1.8 seq16 
rNa 1,1.8 seq1 
rNa v1.8 seq2 
rNa 1,1.8 seq3 
rNa v1.8 seq4 
rNa 1,1.8 seq5 
rNa 1.1.8 seq6 
rNa ,.1.8 seq 7 
rNa 1,1.8 seq8 
rNa 1,1.8 seq9 
rNa ,.1.8 seq10 
rNa ,.1.8 seq1 1 
rNa ,.1.8 seq12 
rNa ,.1.8 seqJ3 
rNa ,.1.8 seq14 
rNa ,.1.8 seq15 
rNa 1,1.8 seq16 
CCCTGATTCACTCAGTGAAG 
CTATATGATCTTTITTGTGCTCG 
GTTCCATTTCCGGTCCCC 
GTCTCAGAAGTATCTGATCTGG 
CCCACCTTAAACACACTCATC 
GATGGGGAGGTGAACAACCTG 
GGTGTGGGGACCACCTGAC 
CTITGAAGACTATTACCTGGAC 
CTTCGCAGGGAAGTTTTGG 
GCAGAAGAAATACTACAATGCC 
CTCTTCAGAGTCATCCGCC 
CCTACATCATCATCTCCTTCC 
CATCCTATGAACCAATAGCAAC 
GCCCTATTCTATAGTGTCACC 
TGGCGGCCGCATCACGAAGC 
CTGTCCATTCCTGGTTCTCC 
TGCCTGAGCGTCTTCGCCTT 
GGTCACCATGGCGTATGAAG 
CAGGAAAGCCGTCGAGGTTC 
TGACTGACCCCTTCGCAGAG 
CTITATCCTGGCCATCATCG 
TACATCAGCAGCCACTGCCG 
GGGTGAGAGCTGGAAGAGGA 
CATCTTCGTCTTTGAGATGCTGC 
GTCCGAGTGTCACAATCAAAACAG 
GAATAAGTACCAAGGCTTCGTGTTTG 
GCTCTTTGCCCTCATGATGTCCC 
TCAACGTAGCCACCGAGGAGAGCAC 
GAGCTACATGCTGCACCGCT 
CATTAACCCATCTAGCTCAATGC 
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TABLE 2.lb 
Sequences of oligonucleotide primers for mutagenesis 
Primer N arne Primer Sequence (5' to 3') 
hNa v1.8 1381A S GTGCTCGTAGCCTTCCTGGGATC 
hNa 1,].8 1381A AS 
hNa /"1.8 N390A S 
hNa 1,1.8 N390A AS 
hNa v1.8 LJ4JOA S 
hNa 1'1.8 LJ410A AS 
hNa v1.8 V1414A S 
hNa /"1.8 V1414A AS 
hNa 1'1.81J706A S 
hNa v 1.8 11706A AS 
hNa 1'1.8 F17JOA S 
hNa 1,1.8 F1710A AS 
hNa v1.8 Y1717A S 
hNa v1.8 YI717A AS 
rNa /.1.81380A S 
rNa 1-1.8 1380A AS 
rNa d.8 N389A S 
rNa 1,1.8 N389A AS 
rNa v1.8 LJ41lA S 
rNa v1.8 L141lA AS 
rNa 1'1.8 V1415A S 
rNa v1.8 V1415A AS 
rNa 171.8 11707A S 
rNa 1,1.811707A AS 
rNa 1,1.8 FI711A S 
rNa 1,].8 F1711A AS 
rNa v1.8 Y1718A S 
GATCCCAGGAAGGCTACGAGCAC 
CTACCTGGTCGCCTTGATCTTGGC 
GCCAAGATCAAGGCGACCAGGTAG 
GGCTTCTTCACAGCGAATCTCTTTG 
CAAAGAGATTTCGCTGTGAAGAAGCC 
GAATCTCTTTGCTGGGGTCATAATTG 
CAATTATGACCCCAGCAAAGAGATTC 
CACCACCTACGCCATCATCTCCTTC 
GAAGGAGATGATGGCGTAGGTGGTG 
CATCATCTCCGCCCTCATCGTGG 
CCACGATGAGGGCGGAGATGATG 
GGTCAACATGGCCATTGCAGTGATTC 
GAATCACTGCAATGGCCATGTTGACC 
CGTGCTGGTTGCTTTCCTTGGATCG 
CGATCCAAGGAAAGCAACCAGCACG 
CTACCTGGTCGCTTTGATCTTGGC 
GCCAAGATCAAAGCGACCAGGTAG 
GCTTCTTCACGGCGAATCTCTTTG 
CAAAGAGATTCGCCGTGAAGAAGC 
CTGAATCTCTTTGCTGGGGTCATAATC 
GATTATGACCCCAGCAAAGAGATTCAG 
CACCACCTACGCCATCATCTCCTTC 
GAAGGAGATGATGGCGTAGGTGGTG 
CATCATCTCCGCCCTCATCGTGGTC 
GACCACGATGAGGGCGGAGATGATG 
GGTCAACATGGCCATCGCAGTGATTC 
rNa 1,].8 YI718A AS GAATCACTGCGATGGCCATGTTGACC 
The codon encoding the substituted residue is underlined and 
the bases which differ from wild type sequence are shown in 
red. 
2.1.5 Human and rat NaT'l.8 eDNA clones 
The human Nav 1.8 (hNav 1.8) and rat Nav 1.8 (rNav 1.8) channel a-subunits were cloned at 
GlaxoSmithKline. The a-subunit cDNAs used were human Nav 1.8 (Accession number 
Q9Y5Y9, polymorph 1073V), and rat Nav 1.8 (Accession No. Q62968, polymorph 18961 and 
1901D). The pFastBacMam1-hNad.8, pSP64T-hNav1.8 and pCIN5-rNavl.8 constructs were 
from GlaxoSmithKline. The pFastBacMam1-h~1 and pFastBacMam1-h~3 subunits were a gift 
from Fiona Cusdin (University of Cambridge). The pFastBacMaml vector (Condreay et aI., 
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1999), EBO-pCD-Leu2 plasmid (American Type Culture Collection) and pEGFP-Nl plasmid 
(Clontech) were also used. 
2.1.6 Growth media, solutions and buffers 
TABLE2.2a 
Growth media for E. coli cells 
Luria Broth (LB) Media 
LB-Agar Plate 
Bacto-Tryptone (10g/L), Bacto-Yeast extact (5giL) 
and NaCl (5g/L) 
Agar (1.5%), LB media and antibiotic 
TABLE 2.2b 
Preparation and analysis of DNA and RNA 
Tris-Acetate-EDTA (TAE) Buffer (50x) 
RNA New Wash 
Denaturing Solution 
Tris (252g/L), Na2EDTA (pH 8.0, 50mM) and glacial 
acetic acid (5.71%) 
Ethanol (50%), Tris-HCI (PH 8.0, 10mM), NaCI 
(100mM) and EDTA (PH 8.0, 2.5mM) 
Guanidine thiocyanate (5mM), N-Iauryl sarcosine 
(0.05%), sodium citrate (l25mM) and 2-
mercaptoethanol (0.007%) 
TABLE2.2c 
Media for ND7123 mammalian cells 
Growth Media 
Freezing Media 
Dulbecco's modified Eagle medium (DMEM, 
4500mg/L glucose, 89%), heat-inactivated foetal 
bovine serum (HI-FBS, 10%) and non-essential 
amino acids (NEAA, lx, 1 %). Filter sterilised. 
Dulbecco's modified Eagle medium (DMEM, 
4500mg/L glucose, 40%), heat-inactivated foetal 
bovine serum (HI-FBS, 50%) and DMSO (10%). 
TABLE 2.2d 
Electrophysiological recording solutions 
OR2 (Calcium-free Ringer) Solution 
Barth's Solution 
Frog Ringer Solution 
Patch Clamp Internal Solution 
Patch Clamp External Solution 
NaCI (82mM), KCI (2mM), HEPES (5mM) and 
MgCl2 (1mM), pH adjusted to 7.2 with NaOH. 
NaCI (88mM), KCI (lmM), NaHC03 (2.4mM), 
MgCl2 (0. 82mM), Ca(N03)~ (0.33mM), penicillin 
(lOflglml), streptomycin (lOflglml), Tris-HCl (pH 7.6, 
7.25mM) and CaCl2 (OAlmM) 
NaCI (90mM), KCI (2mM), CaCh (1.8mM), MgCl2 
(2mM), HEPES (5mM), adjusted to pH 7.6 using 
NaOH. 
CsF (120mM), HEPES (1 0mM) EGTA (1 0mM) and 
NaCI (l5mM), adjusted to pH 7.2 with CsOH. Filter 
steriled 
NaCl (140mM), HEPES (5mM), MgCl2 (1.3mM), 
CaCl2 (1mM), Glucose (llmM) and KCI (4.7mM), 
adjusted to pH 7.4 with NaOH. Filter sterilised or 
used within 48hrs. 
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2.2 General Molecular Biology Methods 
2.2.1 Transformation ofplasmid DNA into competent bacterial cells 
Due to the size and instability of the constructs, plasmid DNA was transfonned into E. coli 
MAX Efficiency® Stbl2™ (>lxI09 cfuJ~g; Invitrogen) or XLIO-Gold® (~5x109 cfuJ~g; 
Stratagene) competent cells (Table 2.3). The competent cells were thawed on ice for 10 minutes 
and transferred to a pre-chilled 1.5rnl microcentrifuge tube. Plasmid DNA was added to the 
cells, and the mixture was incubated on wet ice for 30 minutes. The cells were heat-shocked at 
42°C for 25-30 seconds and then returned to ice for 2 minutes. Pre-wanned media was then 
added to the mixture and incubated at 28°C for 90 minutes while shaking at 225-25Orpm. After 
this recovery period, the cell culture was centrifuged for 3 minutes at 4,000rpm. The supernatant 
was removed and the cell pellet resuspended in 150~1 fresh media. Cell culture (50~1 and 
100~1) was spread out on LB agar plates (Table 2.2a) containing antibiotic (lOOJ-lg/ml ampicillin 
or 50~g/rnl kanamycin depending on the antibiotic resistance gene present in the transfonned 
plasmid DNA) and incubated at 28°C for 24-48 hours. 
TABLE 2.3 
Escherichia coli competent cells for plasmid DNA transformations 
Experiment Cells 
Plasmid DNA grow up 
Following ligation (2.3.6) 
Following site-directed mutagenesis (2.2.7) 
Stbl2 (l6).tl) 
Stbl2 (100)11) 
XLIO-Gold (45)11) 
2.2.2 Inoculation of LB media for small-scale growth of a single bacterial colony 
In order to gain a sufficient quantity of transfonned cells for DNA extraction, a randomly 
selected individual colony was removed from the plate with a 200~1 micropipette tip and 
introduced to 2ml LB media (Table 2.2a) containing antibiotic (lOO~g/ml ampicillin or 50~g/ml 
kanamycin depending on the antibiotic resistance gene). The culture was incubated overnight at 
28°C while shaking at 225-250 rpm. 
35 
2.2.3 Mini-prep extraction ofplasmid DNA from transformed bacterial cell culture 
The overnight culture was transferred into a I.Sml microcentrifuge tube and the cells were 
harvested by centrifugation at 8,000rpm for 3 minutes at room temperature. Remaining culture 
(approx. SOOml) was stored at 4°C for large-scale culture of cells. Plasmid DNA was extracted 
and purified using the QIAprep~ Miniprep Kit (Qiagen) according to the manufacturer's 
protocol or using a QIAprep® 8 Turbo Kit (Qiagen) on a Qiagen BioRobot 9600. 
2.2.4 Restriction digest ofplasmid DNA 
Following manipulation of plasmid DNA (e.g. small-scale amplification of DNA), restriction 
mapping of DNA was carried out on an agarose gel. Restriction digest of plasmid DNA was 
carried out for both subcloning and RNA synthesis according to manufacture's instructions. The 
plasmid DNA, appropriate enzyme buffer, one or more restriction enzymes and DNA-grade 
water (to give final reaction volume) were mixed in a O.Sml tube and incubated at optimum 
temperature for the enzyme. For verification of plasmid DNA a small volume of DNA (typically 
2S0ng) and two enzymes were mixed in a total volume of 10J.!1 for incubation for 2 hours. In 
contrast, subcloning and RNA synthesis required larger amounts of DNA (3J.!g and O.SJ.!g 
respectively) incubated overnight in reaction volumes of 30J.!1 and SOJ.!1 respectively. 
2.2.5 Agarose gel electrophoresis to confirm DNA 
The semi-quantitative analysis oflinear and non-linear DNA was carried out on a 0.7% or 
1% agarose gel with ethidium bromide (6,.1l, 10mg/ml). The agarose gel was transferred to an 
Anachem Origo H2SET electrophoresis gel tank, containing Ix TAE (Table 2.2b). To the DNA 
samples, 6x gel loading solution (Sigma) was added and the mixture was loaded into separate 
lanes alongside a DNA ladder. The gels were run for 3~S minutes at 80V and visualised using 
Quantity One 4.4.l Imaging Software on a BioRad Gel Doc 1000. 
2.2.6 Preparation ofcRNAfor microinjection 
The DNA preparation was purified to RNA grade with the addition of 200111 denaturing 
solution (see Table 2.2b) and ISI11 glass milk and incubating on ice for S minutes and 
centrifuging and washing the pellet in RNA New Wash (Table 2.2b) 3 times before 
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resuspending the dry pellet in 20Jli RNA grade water. A lJlI aliquot was run on a 0.7% agarose 
gel to confirm the presence of DNA. Wild type hNav 1.8 cRNA was synthesised in vitro using 
SP6 polymerase with the MEGAscript~ transcription kit (Ambion) according to the 
manufacturer's protocol. A lfll aliquot was run on a 0.7% agarose gel for 15 minutes and 
visualised on a BioRad Gel Doc 2000 to estimate the cRNA concentration. The remaining 
cRNA was stored at -20°C. 
2.2.7 Site-directed mutagenesis 
The role of a single amino acid residue in protein structure and function may be studied by 
its substitution to a residue with different properties. Point mutations to alanine were generated 
using the QuikChange® method (Fig. 2.1) developed by Stratagene (La Jolla, CA). Due to the 
size (l3kb) of the plasmid DNA, the XL version of the QuikChange® Mutagenesis Kit 
(Stratagene) was used to substitute nucleotides. To a O.2ml PCR tube, reaction buffer (5JlI, lOx), 
plasmid DNA (lJlI, 50ng), sense mutagenic primer (0.5JlI, O.lmM), antisense mutagenic primer 
(0.5JlI, O.lmM), dNTP mix (lJ..ll), DMSO (2.5Jll) and water (39.5JlI) were added. Thermal 
cycling was carried out in a PTC-200 (MJ Research) PCR machine as shown in Table 2.4, 
where PfuTurbo® DNA polymerase (lJ..lI) was added after Segment 1. 
TABLE 2.4 
General thermal cycling parameters for site-directed mutagenesis 
Segment Cycles Temperature Time 
1 1 95°C 5m 
2 15 95°C 50s 
50°C - 60°C 1m 
68°C 14m 
3 1 7m 
After thermal cycling the non-mutated dam-methylated parental DNA was digested by adding 
DpnI endonuclease (lJ..lI) and incubating overnight at 37°C. The remaining plasmid DNA was 
then transformed into XLlO-Gold® competent cells (see Section 2.2.1). 
2.2.8 Inoculation of LB media for large-scale growth of a single bacterial colony 
While the small-scale Ecoli culture was sufficient for preparation of<lOJlg of plasmid 
DNA, preparation of>200flg plasmid DNA required a large-scale growth of the transformed 
Ecoli culture. Small-scale Ecoli culture (50-l00JlI) was introduced to a 2L flask containing 
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200ml LB media and 100flg/ml ampicillin. The flask was incubated for 18 hours at 28°C while 
shaking at 225rpm. 
2.2.9 Maxi-prep extraction ofplasmid DNA from transformed bacterial cell culture 
Overnight large-scale culture was transferred to lL centrifuge tube and bacterial cells were 
harvested by centrifugation at 4,000rpm for 10 minutes at 4°C. Plasmid DNA was extracted and 
purified using the HiSpeed® Plasmid Purification Kit (Qiagen) according to the manufacturer's 
protocol. The plasmid DNA was eluted with Tris-EDTA Oml) and the concentration was 
determined by measuring the absorbance at 260nm using a GeneQuant RNAIDNA Calculator 
(Pharmacia Biotech). 
2.2.10 Glycerol Stocks 
In order to store transformed E.coli cells for long periods oftime, 700fll was vortexed with 
300fll sterile glycerol in a 2ml cryotube and frozen at -80°C. When the cells were required the 
culture was thawed and 2fll inoculated (see Section 2.2.2) 
2.3 Specific Molecular Biology Methods 
2.3.1 Purification of a DNA digest 
Following the incubation of DNA with a restriction enzyme, the buffer and enzyme must be 
removed before incubation with a different enzyme. The purification of DNA was carried out 
using the QIAquick® Gel Extraction Kit (QIAGEN) according to the manufacturer's protocol; 
the Buffer QG (300fll) was added directly to the 30fll reaction volume containing the DNA. 
2.3.2 Blunting of "sticky" ends 
Many restriction enzymes cut double stranded DNA leaving an "overhang" or "sticky" end. 
Therefore, in order to enable a sticky end to ligate to another blunt end, it should be blunted 
with a DNA polymerase. A 0.2ml PCR reaction tube containing DNA (28fll), dNTP (I fll, 
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lOmM) and buffer (5111, lOx) was incubated in a PTC-200 (MJ Research) PCR machine as 
shown in Table 2.5, where PfuTurbo® DNA polymerase (1 ~l) was added after Segment 1. 
TABLE 2.5 
Thennal cycling parameters for blunting of "sticky" ends 
Segment Temperature Time 
1 ~~ ~ 
2 75°C 30m 
2.3.3 Dephosphorylation of a DNA fragment 
To ensure that the vector fragment or insert fragment do not ligate to themselves during 
subc1oning, the vector fragment was dephosphorylated. To the vector fragment (30~1), alkaline 
phosphatase (I Ill, Roche) was added and incubated at room temperature for 2 hours. The vector 
and insert fragments were validated and purified by running them on a 1 % agarose gel, excising 
the bands, and extracting DNA fragments from each band. 
2.3.4 Excision and purification of a DNA fragment 
A DNA fragment of interest can be excised directly from an agarose gel and purified. 
Following the separation of DNA fragments on an agarose gel, the band of interest was 
removed using a sterile scalpel blade. The QIAquickB Gel Extraction Kit (QIAGEN) was used 
to extract the DNA from the agarose gel, according to the manufacturer's protocol. The purified 
DNA fragment was eluted in 30111 DNA-grade water, and 1 III run on a 1 % agarose gel to 
estimate the DNA concentration. 
2.3.5 Ligation of DNA fragments 
In order to ligate the vector and insert DNA fragments, an approximate 10: I concentration 
ratio of insert to vector was added to a 0.5rn1 tube containing T4 DNA ligase buffer (2111), T4 
DNA ligase (1 Ill) and DNA-grade water (to give a total reaction tube volume of 10111). The 
reaction tube was incubated at 16°C overnight. 
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2.4.3 Maintaining mammalian cells 
Mammalian cells were passaged when they reached approximately 90% confluence (every 
2-3 days). Old growth media was removed and the cells were washed with PBS (GIBCO). In 
order to detach the cells from the T75 flask, 2ml pre-warmed versene was introduced and the 
flask incubated at 37°C (5% CO2) for 4 minutes. Growth media (4ml) was added and the cells 
were gently resuspended. To a T75 flask containing 11m1 growth media, 1ml of the resuspended 
cells were added to give a 1:6 dilution. Rather than the 1:6 dilution described, a 1:8 dilution is 
more appropriate at later passage numbers, when cells grow faster. Cells with a passage number 
greater than 30 were discarded. 
2.4.4 Storing mammalian cells 
In order to store ND7/23 cells for later use, cells at approximately 80% confluence were 
washed with versene and detached from the T75 flask. Following resuspension of cells in pre-
warmed growth media, the cells were centrifuged at 1,000rpm for 5 minutes. The media was 
removed and cells carefully resuspended in 1ml fresh cell freezing media (Table 2.2c) and 
transferred to a cryotube. Cells were frozen overnight at -80°C in a freezing container (Nalgene) 
and then transferred to -140°C for storage. 
2.4.5 Transfection of mammalian cells 
Cells were seeded in a 35mm dish at 60% confluence and incubated at 37°C (5% CO2) 
overnight. Cells were co-transfected the following day with 3.01lg Nav1.8 channel DNA in the 
pFastBacMaml vector and O.3llg EBO-pCD-Leu2 plasmid DNA (encoding Leu2, for selection 
with anti-CD8 beads) or pEGFP-Nl DNA (encoding EGFP, for selection with fluorescence) 
with 5.5J.lg Lipofectamine™ 2000 (Invitrogen). 
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2.5 Electrophysiology 
2.5.1 Xenopus laevis oocyte preparation 
Mature female Xenopus laevis frogs were obtained from Blades (UK) and killed by schedule 
1 methods; frogs were anaesthetised by immersion in 0.2% (w/v) tricaine for approximately 40 
minutes and killed by destruction of the spinal cord and brain. Ovarian lobes were removed and 
washed in sterile OR2 solution (see Table 2.2d). Connective tissue was removed by collagenase 
treatment on a gyro mixer for 40 minutes in 20ml OR2 solution and 2mg/ml type IA 
collagenase. The dissociated oocytes were washed in OR2 solution and stage V and VI oocytes 
were defolliculated with watchmaker's forceps (Dumont, size 5, Agar Scientific), and stored in 
OR2 until cRNA injection the same day. 
2.5.2 Preparation of cRNAfor microinjection 
Micropipettes were pulled from borosilicate glass (Drummond Scientific Company) using a 
Model P-87 FlaminglBrown micropipette puller (Sutter Instrument) and the tip manually broken 
using forceps. The micropipette was backfilled with mineral oil and mounted on a Drummond 
microinjection syringe on a Micro-instruments manipulator. The cRNA (l~l, l25ng/~1) was 
drawn up into the micropipette from a microscope slide covered with nescofilm (VWRI). 
Dumont stage V and VI oocytes were injected with cRNA (50nl, 5ng). After injection, oocytes 
were incubated at 19.6°C in 96 well culture plates containing Barth's solution (see Table 2.2d) 
with solution changes daily. Electrophysiological recordings of oocytes were carried out 3-4 
days after injection. 
2.5.3 Two-electrode voltage clamp 
Macroscopic currents were recorded using a GeneClamp 500 amplifier (Axon Instruments), 
filtered at 2kHz and sampled at 4kHz. CED analysis software was used to design protocols and 
aCED 1401 interface (Cambridge Electronic Design, UK) was used to supply command 
potentials to the amplifier and to record elicited currents. Microelectrodes were made with 
1.0mm x 0.58mm thin borosilicate glass (Harvard Apparatus), pulled by a custom-built vertical 
two-stage puller. The microelectrodes were filled with 3M KCI and mounted on the headstages 
(Axon Instruments) using a holder containing a silver-silver chloride wire. The head stages were 
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controlled using a Micro-instruments manipulator. The voltage microelectrodes showed 
resistances between 1.0 and 2.SMQ and the current microelectrode showed resistances between 
O.S and 1.0Mil. A silver-silver chloride wire or pellet was used for the bath electrode. 
Experiments were carried out at room temperature (20-22°C) in an oocyte chamber (Fig. 2.4) 
continuously perfused (2mllmin) with Frog Ringer's solution (Table 2.2d). Oocytes were 
impaled with both microelectrodes and allowed to stabilise for S minutes. The resting 
membrane potential was measured, to which the initial voltage clamp offset was set, and the 
amplifier was switched to voltage clamp mode. The gain and stability were increased during 
repetitive depolarising pulses (lOmV step at 0.1 Hz) of the oocyte membrane until the 
oscilloscope showed a square wave trace. The membrane potential was then held at -100mV, 
from which currents were elicited for 2Sms pulses with voltage steps from -90m V to +60m V in 
10m V increments in order to construct current-voltage (1- V) relationships. 
2.5.4 Preparation of trans fee ted mammalian cells 
Transfected cells were seeded on sterile 100mm diameter glass coverslips > 12 hours before 
use. For the selection of cells with CD8 beads, the beads (20/-11) were prepared by pelleting with 
a magnet and resuspending in PBS three times. The beads were then suspended in 2ml PBS and 
introduced to the PBS-washed cells, and incubated at 3TC (S% CO2) for 30 minutes. The 
unassociated beads were removed and the cells washed in PBS and allowed to recover at 3TC 
(S% CO2) for 30 minutes before use. 
2.5.5 Whole-cell patch clamp technique 
Transfection-positive cells were analysed 2-4 days after transfection and identified with 
immunobeads (anti-CD8 Dynabeads; Invitrogen) or green fluorescence using a Nikon super 
high pressure mercury lamp. Recordings of currents were obtained in the whole-cell 
configuration of the patch clamp technique (Fig. 2.5) at room temperature (20-22°C) on an air 
table using an Axopatch-1C or Axopatch 200B amplifier (Axon Instruments). Patch pipettes 
were fabricated from thin-walled borosilicate glass capillaries (GClSOTF-lO; Harvard 
Apparatus) using a Model P-87 or P-97 Flaming/Brown micropipette puller (Sutter Instrument) 
and usually fire polished using a Micro Forge (MF-830; Narishige). Patch pipettes were filled 
with internal solution (see Table 2.2d), which contains fluoride as in many previous studies of 
Nav 1.8 channel currents in cultured cells and TTX-resistant Na+ currents in DRG cells (John et 
ai., 2004; Leffler et ai., 2007; Zhao et aI., 2007; Elliott and Elliott, 1993; Choi et ai., 2006; 
Dekker et aI., 200S; Cardenas et aI., 2006). Patch pipettes were coated with Sigmacote (Sigma-
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Aldrich) and allowed to air dry. The patch pipette was inserted into an electrode holder 
containing a silver-silver chloride wire, which in turn was fixed into the head stage (CV-203 BU; 
Axon Instruments). The headstage was mounted and controlled with a coarse manipulator (TS-
5000-300; Burleigh), and also controlled remotely with a fine manipulator (PC-5000 series; 
Burleigh). A silver-silver chloride wire or pellet was used for the bath electrode. During 
experiments, cells were continuously perfused with an external solution (Table 2.2d) containing 
TTX (200nM, Tocris) in order to completely inhibit endogenous Na+ currents. Patch pipettes 
typically showed tip resistances of 1.5-2.5Mn, and while in solution « 1 minute) the pipette 
offset was used to zero the current at OmV. Using the coarse and fine manipulators the patch 
pipette tip was positioned against the cell membrane, negative pressure was applied until the 
resistance increased to > 1 GO ("cell-attached mode"), and pipette capacitance was compensated. 
The command voltage was changed to -40m V and further negative pressure was applied until 
the patched membrane was ruptured ("whole-cell mode"), and whole-cell capacitance was 
compensated. Series resistance was compensated by 80-85%. Cells were allowed to equilibrate 
for 10 minutes in the whole-cell configuration before voltage pulses were applied, and currents 
were filtered at 5kHz and sampled at 10kHz using pClamp8 or pClamp9 software (Clampex; 
Axon Instruments). Cells which showed an Imax of <200pA were discarded. Voltage pulses were 
adjusted by -8m V to correct for liquid junction potentials. The membrane potentials were then 
corrected offline +8mV accordingly. 
2.5.6 Application of drugs 
All compounds were prepared in dimethyl sulphoxide (DMSO) and x 100 stocks stored at-
20°C. The desired concentration in the external solution gave a final concentration of 1 % 
DMSO. Compounds were applied during a 3~ minute incubation period using a six-channel 
valve controller (VC-6; Warner Instruments) and rapid solution changer (SF-77B; Warner 
Instruments). The drug-free external control solution also contained 1 % DMSO in the drug 
experiments. 
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2.6 Electrophysiological protocols and analysis 
2.6.1 Software 
For offline data analysis, current traces were measured using Signal v2.05 (Cambridge 
Electronic Design, UK) for two-electrode voltage clamp recordings, or using Clampfit v9 or 10 
(Molecular Devices) for whole-cell patch clamp recordings. Data handling and statistical testing 
were done using Microsoft Excel, and Origin v5.0 (MicroCal Inc.) was used to present the data. 
2.6.2 Voltage-dependence of activation 
In order to construct current-voltage curves, test pulse voltages of -100mV to +60mV (Fig 
2.6) were used to elicit Na+ currents from a holding potential of -120 or -80mV. 
-80mVor 
-120 mV 
Figure 2.6. Voltage-dependence of activation pulse protocol. 
The peak current amplitude (INa) was measured and plotted against the test pulse voltage from 
which it was elicited. Conductance (G) was calculated from the peak sodium current (INa), using 
the equation: 
G= INa Eq.1 
V -E
rel • 
where V is the membrane potential and Ere\" is the reversal potential obtained from the 1-V curve 
for each cell. These curves were fitted with the Boltzmann equation: 
G Gmax 
= e'l ~-r') 
l+exp 
Eq.2 
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where Gmax is maximum conductance, Vi 2 is the voltage for half-maximal acti\ation, T' is the 
membrane potential and k is the slope factor. Conductance values were normalised to G
mas
. and 
plotted against the membrane potential. 
2.6.3 Voltage-dependence of steady-state inactivation 
In order to determine the voltage-dependence of steady-state inactivation, a 4 second 
conditioning pulse was used to inactivate channels and a test pulse to Om V was used to measure 
the proportion of non-inactivated channels. This protocol (Fig. 2.7) was carried out from 
holding potentials of -120mV or -80mV. 
-10 mV 
4-5 OmV 
-80mVor 
-120 mV 
Figure 2.7. Voltage-dependence of inactivation pulse protocol. 
Inactivation curves were fitted with the Boltzmann equation: 
B-A 
1= (V-V )+A \/2 
1 + exp k 
Eq.3 
where B is the maximum current and A is the amplitude of a non-inactivating component, V is 
the membrane potential, Vl!2 is the voltage of half-maximal inactivation and k is the slope factor. 
Current was normalised to the maximum current (B) and plotted against the membrane 
potential. 
2.6.4 Time course for inactivation 
In order to determine the inactivation time course, two approaches were used to measure the 
time constants. For the first approach, the decay phase of the current during the 15ms 
depolarising pulse was fitted with the exponential equation: 
Eq. -t 
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where 10 is the steady-state current asymptote, Ti is the time constant of the initial component 
with amplitude hand T2 is the time constant of the second component with amplitude 1~. 
However, since the kinetics were examined over relatively short ISms depolarising pulses, any 
slow component was generally too small in magnitude to be measured. Therefore, another 
approach was also employed to study the time course of development of inactivation, whereby 
the current amplitude was measured following a Om V control pulse of varying length and a 4ms 
recovery period (Fig. 2.8). 
Test 
...--.... OmV 
-120 mV 
4ms 
Figure 2.S. Development of inactivation pulse protocol. 
Development of inactivation showed two components. The current amplitude during the test 
pulse was fitted with the following exponential equation: 
I = I + I exp( ':, L expl r::',) 
o fasr slow Eq.S 
where 10 is the steady-state current asymptote, 1fast is the amplitude of the first component 
decaying with time constant Tfast, and 1slow is the amplitude of the second component decaying 
with time constant Tslow. 
2.6.5 Time course of recovery from inactivation 
Recovery from inactivation was investigated using a similar protocol as in Section 2.6.4 but 
with varying time between control pulse and test pulse (Fig. 2.9). 
50ms 
a mV r--.., _-.... OmV 
-120 mV -120 mV 
1-2000 ms 
Figure 2.9. Recovery from inactivation pulse protocol. 
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At least two components were shown for the recovery from inactivation time course. Where two 
components were observed, the curve was fitted with the equation: 
1=1 +1 exp[,:,L exp(r:~,) 
o fast slow Eq.6 
where 10 is the steady-state current asymptote, hast is the amplitude of the first component 
decaying with time constant Tfast, and I s10w is the amplitude of the second component decaying 
with time constant Tslow· However, when an additional third component was observed, the curve 
was fitted with the equation: 
1 = 1 + 1 exp[ ,:, L exp( r:~,.J + 1 exp( ~:) 
o fast slow 3 Eq.7 
where 10 is the steady-state current asymptote and Tfast, Tslow and T3 are the time constants of the 
first, second, and third components with their respective amplitudes Ifast, Islow and 13. 
2.6.6 Use-dependent current inhibition 
The effects of frequent depolarisation on the channels results in the accumulation of 
inactivated channels. This effect ("use-dependent current inhibition") was studied by measuring 
the peak current amplitude (INa) during a train of 10ms depolarising pulses to Om V from a 
holding potential of -120m V or -80m V (Fig 2.10). A train of 60 pulses at a range of frequencies 
(2-50Hz) was used. 
o mV 10 ms 
-80 m~'~rn -120~ L 
Figure 2.10. Use-dependent inhibition pulse protocol. 
2.6.7 Determination a/resting state dissociation constants 
Local anaesthetics and other drugs show a greater extent of block at more depolarised 
membrane potentials. Indeed, voltage-gated Na+ channels open and become inactivated at more 
depolarised potentials and these drugs show a significantly greater affmity for open/inactivated 
voltage-gated Na + channels compared to the resting channels. This finding is consistent with the 
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modulated-receptor hypothesis (Hille, 1977; Hondeghem and Katzung, 1977). Thus the 
simplified modulated-receptor model was proposed by Kuo and Bean (1994): 
(V) 
R~ 
RD~ID 
(V) 
Figure 2.11. Simplified modulated-receptor model 
where the transition between resting (R) and inactivated (1) channels is dependent on the voltage 
(V), and the association of drug (D) to either the resting channel or the inactivated channel gives 
drug bound (and blocked) states RD and ID respectively (Kuo and Bean, 1994). According to 
the modulated receptor hypothesis, the apparent dissociation constant (KD ) is the combination of 
the binding to resting and inactivated states: 
1 
KD = h I-h 
-+--
K,. Ki 
Eq.8 
where Kr and Ki are the dissociation constants for resting and inactivated channels respectively, 
and h is the proportion of resting channels (i.e. non-inactivated channels). Thus the Kr may be 
determined when h approaches 1; when virtually all channels are in the resting state at 
hyperpolarised potentials the apparent dissociation constant is equal to the resting state 
dissociation constant (Kr). The resting state dissociation constant may then be calculated using 
the equation: 
K = [R][D] 
,. [RD] 
Eq.9 
where [Xl represents the concentration of each state. Furthermore, the total channels (RT ) is 
given by: 
RT = [R] + [RD] Eq.IO 
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The Ki value may be calculated using the following equation: 
K; = f D] . (1- h) 
--1 
ID; 
Eq. 14 
where D is the drug concentration and IDi is the fraction of inactivated sodium channels not 
blocked by a drug (corrected for the effects on the inactivated current amplitude over time, see 
Section 5.2.3), where the fraction of non-inactivated sodium current following the 4 second 
depolarisation before drug application is h. 
2.6.9 Leak subtraction 
For two-electrode voltage clamp data, pulse protocols were followed by twenty 
hyperpolarising pulses at 2 second intervals to -110m V for subsequent leak and capacity 
subtraction. 
For whole-cell patch clamp data, for protocols using test pulses to various membrane 
potentials (voltage-dependence of activation and inactivation, Fig 2.6,2.7), leak and capacitance 
currents were minimised online using the P/4 protocol. In P/4 subtraction, four pulses at a 1/4 of 
value of the command potential are applied before each test pulse. The elicited currents are 
summated and subtracted from the data. For protocols that only used test pulses to OmV, since 
linear leak current would be practically equal between pulses and holding current is of small 
amplitude with a high-resistance seal (greater than 1 GO), leak subtraction was not carried out. 
2.6.10 Statistical analysis of data 
Data are presented as mean ± standard error, and Student's t test was used to determine the 
significance of changes in mean values. p values of less than 0.05 were considered statistically 
significant. 
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CHAPTER 3 
GENERATION OF MUTANT NavI.8 SODIUM 
CHANNELS 
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3.1. Introduction 
The size and instability of voltage-gated Na+ channel eDNA can make manipulation using 
standard techniques difficult. Furthermore, expression of the Nay 1.8 channel in Xenopus laevis 
oocytes or in mammalian cell lines has shown limited success. For these reasons structure-
function studies of the Nay 1.8 channel are rare. 
In this chapter, cRNA was prepared for the expression of the human Na\-l. 8 channel in 
Xenopus laevis oocytes. For the expression of Nay 1.8 channels in mammalian cells, eDNA 
encoding the rat Nay 1.8 channel was subcloned into the pFastBacMam 1 vector, to reduce any 
assumptions made during the comparison of human and rat channels since the human Na\-1.8 
was already in the pFastBacMaml vector. The pFastBacMaml vector also enables the 
generation ofbaculovirus particles for the transduction of mammalian cells, should the normal 
transfection methods be unsuccessful. In the pFastBacMaml vector, site-directed mutagenesis 
was used to substitute cDNA bases to encode alanine at seven positions in the S6 segments of 
the human and rat Nay 1.8 channels. Alanine is commonly located in a-helical transmembrane 
regions and due to its small side chain has little effect on the protein secondary structure 
(McPhee et aI., 1995). Therefore, alanine substitutions were used to alter the size and 
hydrophobicity of amino acids, without causing severe distortion of the molecular structure. The 
mutations of the S6 segments in the human Nay 1. 8 channel were at residue positions 1381, 
N390 in domain I, L14l0, V1414 in domain III and 11706, F171O, Y17l7 in domain IV, and the 
corresponding seven positions in the rat Nay 1.8 channel. The alanine mutations were chosen at 
these positions, as they correspond to positions found in other Nay channel subtypes that alter 
the functional properties and where a number of drugs have been found to act. 
3.2 Results 
3.2.1 Preparation of human Na rI8 cRNA 
The cDNA encoding the human Nay 1.8 channel was in the pSP64T Xenopus oocyte 
expression vector. The human Nay 1.8 channel sequence was flanked either side by globin gene 
sequences in the pSP64T vector, which has been shown to increase the stability of the injected 
cRNA (Krieg and Melton, 1984). A prominent band was observed by agarose gel 
electrophoresis of the pSP64T -hNay 1.8 plasmid DNA, corresponding to the supercoiled DNA 
(Fig. 3.1A, lane 2) The pSP64T-hNay1.8 plasmid DNA was linearised by cutting once in the 
vector sequence using the San enzyme. Agarose gel electrophoresis (Fig. 3.1A: lane 3) shows 
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the presence of a 9.7kb fragment corresponding to the linearised plasmid DNA. The linearised 
DNA was purified to RNA grade and human Nav I.S cRNA was synthesised in vitro using SP6 
polymerase (see Section 2.2.6). The presence of RNA can been seen from agarose gel 
electrophoresis (Fig. 3.lB, lane 2). The cRNA concentration was estimated from the band 
intensity as 125ng/~I, which is sufficient for injection in oocytes. 
3.2.2 Subcloning ofrNavl.8 into the pFastBacMaml vector 
Here the cDNA encoding the rat Nav 1.S channel was subcloned into the pFastBacMaml 
vector. This vector enables a number of possible means for expressing channels in a mammalian 
cell line. In addition to ampicillin and gentamicin antibiotic resistance genes, the 
pFastBacMaml vector (Condreay et aI., 1999) enables transient or stable expression ofNav1.S 
in mammalian cells or the generation of baculovirus for the transduction of mammalian cell 
lines. In addition, it is important that both the human and rat Nav I.S channels are in the same 
vector to reduce variation between experiments. 
The pFastBacMaml vector multiple cloning site contains single recognition site for XbaI and 
NotI restriction enzymes. The rNav1.S channel cDNA was subcloned into the pFastBacMaml 
vector using the procedure shown in Figure 2.2. The pFastBacMaml vector was first cut once 
using the XbaI enzyme and then purified. Agarose gel electrophoresis (Fig. 3.2A; lanes 2 and 3) 
shows the presence of a 7.4kb fragment corresponding to the linearised vector. The sticky ends 
were blunted with Pfu DNA polymerase, the DNA was purified and cut a second time with the 
NotI enzyme, and then the vector was dephosphorylated. In order to isolate the 7,4kb vector 
from the smalllSbp fragment, the DNA was visualised on an agarose gel (Fig. 3.2B; lane 3), 
and the large fragment was gel extracted. 
For the cDNA encoding the rNav I.S channel, the cDNA must first be removed from the 
pCIN5 vector. The pCIN5-rNav I.S construct contains single recognition sites for the HpaI and 
NotI enzymes flanking the 3' and 5' of the rNav1.S insert, respectively. The plasmid DNA was 
first restricted with the HpaI enzyme and then purified. The presence of a 1O.Skb band (Fig. 
3.2C; lanes 2 and 3) indicates that the pCIN5-rNav I.S plasmid DNA was linearised. Restriction 
enzyme NotI was used to cut the pCIN5-rNav I.S DNA a second time and the preparation was 
purified after restriction. The 5,9kb fragment corresponding to the rNay 1.S insert was gel 
extracted (Fig. 3.2D; lane 2). 
Following ligation of the insert and vector, the pFastBacMaml-rNad.S DNA was 
transformed into E. coli Stbl2 competent cells for the mini-prep for small-scale preparation of 
plasmid DNA. A subsequent large-scale grow up in duplicate achieved greater yields (200 to 
2000J.lg) after maxi-prep extraction. A prominent band was observed by agarose gel 
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electrophoresis, corresponding to the supercoiled DNA (Fig. 3.3B; lane 2). Restriction digest of 
the pFastBacMaml-rNav 1.8 plasmid DNA was carried out using EcoRl and KpnI or Sall and 
NotI. These restriction enzymes were chosen so that both the vector and insert were cut to give 
fragments with a range of sizes (see Figure 2.3B). The agarose gels for EcoRl and KpnI (Fig 
3.3; lanes 3, 7 and 9) gave bands of the expected sizes (7.4kb, 4.0kb and 1.9kb). Furthennore, 
restriction with Sall and NotI (Fig 3.3; lanes 4, 8 and 10) also gave bands of the expected sizes 
(9.4kb and 4.0kb). These restriction digests therefore indicate that the pFastBacMaml-rNad.8 
channel DNA has been inserted into the plasmid. In order to further confinn that there were no 
rearrangements or deletions in the cDNA encoding the rNav 1.8 channel, the entire insert was 
sequenced. The sequence correctly matched the known rNav 1.8 sequence, and the 5' end of the 
insert joined the vector with the predicted sequence (Fig. 3.4A,B), as did the 3' end of the insert 
(Fig. 3.4C,D). Therefore, the cDNA encoding the rNav 1.8 channel was successfully subcloned 
into the pFastBacMaml vector (Fig. 2.3). 
3.2.3 Generation of rat and human Nad. 8 channel mutations 
While the mutagenesis of sodium channels is nonnally carried out in a small DNA plasmid, 
and then subcloned back into the expression vector, here it was necessary to keep manipulations 
of the Nav1.8 channel DNA to a minimum. Thus, site-directed mutagenesis was carried out in 
the pFastBacMaml vector. However, due to the size of the plasmid DNA (l3kb), certain 
conditions were required. Site-directed mutagenesis was carried out with the PfuTurbo~ DNA 
polymerase, which has a lower error rate than Taq DNA polymerase, and requires shorter DNA 
extension times, fewer thennal cycles, and lower DNA template concentrations than Pfu DNA 
polymerase. The properties of the DNA polymerase reduce the potential for random mutations. 
For the mutagenic oligonucleotide primers it was expected that longer mutagenic primers would 
be necessary to prevent unspecific binding. However, they resulted in very few, if any viable 
colonies; thus, shorter (23-27 bases) mutagenic primers were used despite a reduced 
mutagenesis efficiency. For the transfonnation of the DNA it was important to use 
recombination-deficient competent cells (Stbl2 or XLIO-Gold cells), which show high 
transfonnation rates (~5xl09 cfu/j.lg). Finally, the competent cells were incubated at a reduced 
temperature of 28°C, in order to reduce the likelihood of recombination events. The mutated 
DNA was checked by restriction with at least two enzymes and visualised on an agarose gel, 
and when a sufficient volume of DNA had been prepared the entire rNavl.8 cDNA was 
sequenced. 
Following site-directed mutagenesis of human and rat Nav 1.8 channels, the plasmid DNA 
was extracted by mini-prep, and purified from 8 to 10 cultures of transfonned single E. coli 
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colonies. Sequencing of the mutated region with a single sequencing primer. showed a 
mutagenesis efficiency of approximately 50%. It is noteworthy that generation of the N 1411 
mutation in hNav 1.8 or the corresponding mutation in rNav 1.8 was not successful. For each 
successful mutation, two of the correct DNA preparations were extracted by maxi-prep, and 
visualised by agarose gel electrophoresis (for rNav 1.8, Figs. 3.5 and 3.6; for hNad.8, Figs. 3.7). 
The gels indicate that undigested DNA was of a sufficient concentration (200 to 500J.lg/J.ll), and 
supercoiled DNA showed a prominent band in all samples (for rNav 1.8, Figs. 3.5 and 3.6; not 
all shown for hNav 1.8). For rat Na\-1.8 mutant preparations, restriction of plasmid DNA with 
EcoRI and Kpnl showed 7.4kb, 4.1kb and 1.9kp bands for all mutations, as expected for the 
pFastBacMaml-rNav 1.8 channel (Fig. 2.3, Figs. 3.5 and 3.6). This was further supported by the 
restriction of a number of mutations I380A, N389A, Il707A, F1711A and Y1718A with EcoRI 
and Sadl enzymes, with 7.5kb, 4.0kb and 1.8kb bands (Fig 3.5). For human Nav1.8 mutant 
preparations, restriction of plasmid DNA with Smal and Sadl showed 6.0kb, 4.4kb and 2.9kb 
bands for mutation I381A as expected (Fig. 3.7A). Restriction by Xbal and NheI showed 7.7kb 
and 4.7kb bands for N390A, L1410A, V1414A, Il706A, F1710A and Y1717A preparations, as 
expected for the pFastBacMaml-hNav 1.8 channel (Fig. 2.3, Fig. 3.7). The XbaI and NheI 
restriction of L 141 OA (sample 1, lane 5) was incomplete. These results suggest that large 
rearrangements or deletions did not occur in the preparations corresponding to the mutated 
pFastBacMaml-rNav 1.8 and pFastBacMaml-hNav 1.8 channel DNA plasmids. Thus the DNA 
was ofa sufficient quality and quantity for sequencing of the entire human and rat Nad.8 
channel encoding sequence. 
Sequencing of the entire insert confirmed that the correct mutations in the human and rat 
Nav1.8 channel DNA were present (Figs. 3.8 to 3.11), while the remainder of the sequences 
were confirmed as identical to the wild type channel sequence. Indeed, the entire cDNAs 
encoding rat Nav1.8 mutations I380A sample 2, N389A sample 2, L1411A sample I, VI415A 
samples 1 and 2, Il707A samples 1 and 2, FI711A samples 1 and 2, and YI718A sample I 
were correct (the mutated region is shown in Figures 3.8 and 3.9). Furthermore, the entire 
cDNA encoding human Nav1.8 mutations I381A samples 1 and 2, N390A samples I and 2, 
L1410A sample 1 and 2, V1414A samples 1 and 2, Il706A sample 1, F1710A samples I and 2, 
and Y 1717 A samples 1 and 2 were correct (the mutated region is shown in Figures 3.10 and 
3.11). The translated protein sequence (Figs. 3.8 to 3.11) of the successful DNA preparations 
confirm that the seven key amino acid S6 residues were substituted to alanine in both human 
and rat Nav 1.8 channels. 


B 1 2 3 
bp 
12,000-
5,000-
2,000-
68 
A 1 2 3 
bp 
12,000-
5,000-
2,000-
1,000-
6,004 bp 
4,436 bp 
2,935 bp 
4 5 6 7 8 9 10 11 12 13 14 
7,654 bp 
4,671 bp 
Fig. 3.7. Restriction ofpFastBacMaml-hNav1.8 mutant plasmids. A) Lane 1 contains the 
Track-It 1 Kb Plus DNA ladder, lane 2 contains I381A sample 1 following double restriction with 
Sma I and Sadl and lane 3 contains I381A sample 2 following double restriction with Smal and 
SadI. The Smal and Sadl digests show 6004, 4436 and 2935bp fragments. B) Lane 1 contains the 
Track-It I Kb Plus DNA ladder and lane 2 contains an example pFastBacMaml-hNav 1. 8 mutant 
DNA preparation (V 1414A sample 1). The agarose gel shows samples following double 
restriction with Xbal and Nhel for N389A sample I (lane 3), N389A sample 2 (lane 4), LI410A 
sample 1 (lane 5), L1410A sample 2 (lane 6), V1414A sample 1 (lane 7), V1414A sample 2 (lane 
8), I 1706A sample I (lane 9), I 1706A sample 2 (lane 10), F 171 OA sample I (lane 11), F 171 OA 
sample 2 (lane 12), Y1717A sample 1 (lane 13), and Y1717A sample 2 (lane 14). TheXbal and 
Nhel digests show 7654 and 4671bp fragments (the 1050bp fragment is too faint to be seen). 
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Fig. 3.8. Sequencing of rNa,,1.8 mutant DNA. Electrophoretograms are shown for rNav l.8 
alanine mutations with the mutated codon indicated and alignment of mutant and wild type DNA 
sequences (the relevant codon indicated with a dotted line box). A) The I380A mutation (sample 
2) with the ATT codon changed to GCT. B) The N389A mutation (sample 2) with the AAT codon 
changed to GeT. C) The L1411A mutation (sample 1) with the eTG codon changed to GCG. D) 
The V14l5A mutation (sample 1) with the GTT codon changed to GCT. The amino acid residues 
are also shown. Sequences were aligned using ClustalW and visualised using BoxShade. 
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3.3 Discussion 
In this chapter, the human Nav 1.8 channel cRNA was prepared for Xenopus oocyte 
expression. For the expression ofNav 1.8 channels in mammalian cells, the rat Nav 1.8 channel 
cDNA was subcloned into the pFastBacMaml vector, and the codons encoding seven key S6 
segment amino acid residues of both cDNAs encoding human and rat Nav 1.8 channels were 
altered to encode alanine. 
The instability of cDNA for some ion channels can make manipulation using standard 
techniques difficult, and heterologous expression of some can also prove challenging. The 
cDNA encoding the rat Nav 1.8 channel was subcloned into the pFastBacMaml vector for 
consistency of experiments, since the human Nav 1.8 channel cDNA was already in the 
pFastBacMaml vector. The pFastBacMaml vector also enables baculovirus transduction of 
mammalian cells, if the normal transfection methods were shown to be unsuccessful. The 
rNav 1.8 channel cDNA was removed from the pCIN5 vector using HpaI and NotI restriction 
enzymes, and the vector was prepared by restriction with XbaI, Plu DNA polymerase blunting, 
and restriction with NotI. The rNav 1.8 insert was ligated to the dephosphorylated 
pFastBacMaml vector and the construct was checked for recombination or deletions. Multiple 
restriction digests showed that the plasmid DNA contained the expected band sizes for 
restriction of the pFastBacMaml-rNav1.8 construct. Furthermore, sequencing of the entire 
rNav 1.8 insert and the vector ends showed that the sequence matched the predicted sequence. 
Thus this strategy was successful in generating the pFastBacMaml-rNav 1.8 construct for 
expression of the rNav1.8 channel in mammalian cell lines. 
A number of S6 segment amino acid residues are known to play an important role in the 
functional and pharmacological properties of voltage-gated Na+ channels. Owing to the 
difficulties in manipulating and expressing the Nav 1.8 channel, the corresponding residues are 
yet to be investigated. In previous studies, site-directed mutagenesis of voltage-gated sodium 
channel cDNA was carried out in a small DNA plasmid, and the mutated cDNA is subsequently 
subcloned into the larger expression vector (Ragsdale et ai. 1994; Y arov-Yarovoy et aI., 2001; 
Yarov-Yarovoy et aI., 2002). However, in order to reduce the number of manipulations of 
Nav 1.8 channel cDNA, site-directed mutagenesis was carried out directly in the expression 
vector. Here site-directed mutagenesis was used to generate mutations I380A, N389A. L1411A, 
V14l5A Il707A F1711A and Y17l8A in the rat Nad.8 channel and the corresponding I381A, , , 
N390A, L1410A, V1414A, Il706A, F1710A and Y1717A mutations in the human Nad.8 
channel. Multiple restriction digests of both the human and rat Nav 1.8 channel mutant DNA 
showed bands of expected size for the 13kb plasmids cut at their respective restriction sites. 
Sequencing of the entire mutant cDNA confirmed that the mutagenesis was successful and the 
human and rat Na\·1.8 cDNAs did not contain random mutation. Therefore, the use of a high-
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fidelity DNA polymerase and low thermal cycle numbers, in combination with recombination-
deficient competent E. coli cells with high transformation efficiency propagated at reduced 
temperatures enabled the generation of point mutation in the Na\·1.8 channel eDNA. Overall. 
these results show seven key S6 segment mutations were successfully generated in the human 
and rat Nav 1.8 channel cDNAs, both in the pFastBacMaml vector. 
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CHAPTER 4 
FUNCTIONAL PROPERTIES OF HUMAN AND 
RAT NavI.8 SODIUM CHANNELS 
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4.1 Introduction 
The Nav1.8 channel has distinct functional properties compared to other voltage-gated Na-
channel subtypes. It shows slower gating kinetics, more depolarised voltage-dependent gating 
properties, more pronounced slow inactivation, and slower recovery from slow inactivation 
(Akopian et aI., 1996; Blair and Bean, 2003; Elliott and Elliott, 1993; Leffler et aI., 2007; 
Sangameswaran et aI., 1996). The human and rat forms of the Nav 1.8 channel are highly 
homologous; showing 83% identity (Fig. 4.1). Owing to difficulties with the expression of the 
Nav 1.8 channel, the comparison of the functional properties of the human and rat channel forms 
is not extensive and has only been carried out using the Xenopus laevis oocytes (Rabert et aI., 
1998). Moreover, a direct cross-species comparison of the electrophysiological properties of any 
voltage-gated Na+ channel subtype is yet to be carried out under the same experimental 
conditions in the same mammalian background. It can not be assumed that the functional 
properties and roles of closely related orthologues are conserved across species. Indeed, the 
expression of the human form of the N av 1. 8 channel has led to the speculation that the human 
and rat Nav 1.8 channels might differ in their inactivation properties (Akiba et aI., 2003). 
In this chapter, Nav 1. 8 channel currents were recorded from mammalian sensory-neuron 
derived ND7/23 cells using whole-cell patch clamp. Using this mammalian system, the 
activation and inactivation properties of human and rat Nav1.8 channels were analysed and 
compared in detail. Initial experiments were also carried out using Xenopus laevis oocytes 
expression system and two-electrode voltage clamp, although this did not prove to be a suitable 
expression system. 
4.2 Results 
4.2.1 Expression o/the human Nad.8 channel in Xenopus laevis oocytes 
The oocytes of the South African clawed frog,Xenopus laevis, are used extensively for the 
expression of recombinant ion channel proteins, due to the ease of manipulation and stability of 
two-electrode voltage clamp recordings. Following the injection of Xenopus laevis oocytes with 
hNav 1.8 cRNA, the human Nav 1.8 channel currents were examined using a test pulse to -90m V 
to +5OmV in lOmV increments from a holding potential of -lOOmV. Only very small Na~ 
currents were observed (Fig. 4.2A); the maximum current amplitude (lmaJ was -530±140nA at 
OmV. The peak Na+ current elicited at each membrane potential was measured in order to 
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Fig. 4.1. Amino acid sequence alignment of the hNay1.8 and rNay1.8 sodium channels. The 
SI-S6 segments for each domain (I-IV) are labelled. Sequences were aligned using ClustalW and 
visualised using BoxShade. 
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construct the 1-V relationships. Despite the small amplitudes, the currents were significantly 
larger than for control oocytes injected with water, suggesting that currents in cRNA-injected 
oocytes are mostly the result of the human Nav 1.8 channel (Fig. 4.2B). However, the expression 
of human Nav 1.8 channel varied greatly between oocytes, and only 5 out of 38 oocytes showed 
lrnax >200nA. Since currents were small and showed appreciable noise, detailed analysis was 
difficult. The current-voltage relationship (Fig. 4.2B) shows that the voltage for maximum 
current was at approximately OmV, and the reversal potential (Em) was 43±8mV (n=5). The 
conductance-voltage relationship for the human N av 1.8 channel expressed in oocytes showed a 
voltage for half-maximal activation (VI,2) of6±12mV, with a slope factor (k) of 19±3mV (n=5). 
The poor expression of this mammalian ion channel in an amphibian (oocyte) cell 
background may be due to the absence of regulatory, accessory or other factors, which are 
present in the native mammalian cell background. Thus all work in this chapter and thesis was 
carried out using mammalian ND7/23 cells. 
4.2.2 Expression of the human and rat Na vl.8 channels in mammalian ND7123 cells 
The ND7/23 cell line is derived from the fusion of rat DRG neurons with mouse N18Tg2 
neuroblastoma cells (Wood et aI., 1990). Figure 4.3 shows the morphology ofND7123 cells and 
the selection of a single cell by anti-CD8 beads or GFP fluorescence. Since the ND7/23 cell line 
is derived from sensory neurons it endogenously expresses TTX-sensitive Na+ currents (Fig. 
4.4A,B). Using whole-cell patch clamp, the maximum current amplitude (Jrna.'{) of endogenous 
current was -178±24pA/pF (n=8) for untransfected cells and -190±37pA/pF (n=7) for cells co-
transfected with both the pFastBacMaml vector and the GFP-expressing plasmid pEGFP-NI 
(for untransfected and transfected controls) (Fig. 4.5). However, in the presence ofTTX 
(200nM), the endogenous TTX-sensitive Na + currents were completely inhibited in both 
untransfected and transfected controls (Fig. 4.4B, Fig. 4.5). Following transient transfection of 
ND7/23 cells with TTX-resistant Nav 1.8 channels, large currents were observed in the presence 
of TTX (200nM). Cells transfected with the human Nav 1.8 channel showed a maximum current 
amplitude of -79± 7pA/pF (n=80) (Fig. 4.4C, Fig. 4.5), which was not significantly different to 
the rat Nav1.8 channel current (-74±9pA/pF, n=57) (Fig. 4.4D, Fig. 4.5). The native TTX-
resistant Na+ currents recorded by Elliott and Elliott (1993) are shown in Fig. 4.4F. Overall, 
these results show that transient transfection of the mammalian cell line, ND7/23, is sufficient 
for the expression of both human and rat Nav 1.8 channels after endogenous N a + currents are 
completely inhibited in the presence of TTX (200nM). Moreover, co-transfection with ~­
subunits is not necessary since the ND7/23 cell line endogenously expresses ~l and ~3 subunits 
(John et aI., 2004). 
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Fig. 4.4. Human and rat Nav1.8 channel current traces recorded from ND7/23 cells. A) An 
example current trace of endogenous Na+ currents recorded from ND7/23 cells in the absence of 
TTX. B) In the presence ofTTX (200nM), example current traces are shown recorded from 
ND7/23 cells. C) An example current trace recorded from ND7/23 cells transfected with hNay 1. 8 
channel cDNA in the presence of 200nM TTX. D) An example current trace recorded from 
ND7/23 cells transfected with rNa\.1.8 channel cDNA in the presence of200nM TTX. E) The 
pulse protocol used to elicit current in B-E, where steps to -100m V to +60m V in 10m V 
increments were used from a holding potential of -120mV. F) A current trace from Elliott and 
Elliott (1993) which shows TTX-resistant Na+ currents recorded from small cells of the rat dorsal 
root ganglia. Currents were elicited during -37, -32, -27, -23, -8, 7,22 and 36mV test pulses from 
a holding potential of -67mV. This current trace may include the TTX-resistant Nav l.9 channel 
current. 
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Fig. 4.5. Human and rat Navl.8 peak current amplitude recorded from ND7/23 cells. The bar 
diagram shows the peak current amplitude in cells which were untransfected, co-transfected with 
pFastBacMaml vector (pFBM) and pEGFP-Nl(GFP), co-transfected with pFastBacMaml-
hNav1.8 and pEGFP-Nl, or co-transfected with pFastBacMaml-rNay 1.8 and pEGFP-Nl. Control 
experiments were carried out in the absence and presence of TTX (200nM). The peak amplitude 
was determined from the current-voltage relationships recorded from holding potential of-
12OmV. The peak amplitude was normalised to the cell capacitance to take into account the size 
of the cell. 
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4.2.3 Voltage-dependence of activation for human and rat Nad.8 channels 
The voltage-dependence of activation for TTX-resistant human and rat Nay 1.8 channels and 
endogenous TTX-sensitive Na+ currents were compared in ND7/23 cells using test pulses to 
various potentials every 5 seconds, from a holding potential of -120m V or a more physiological 
potential of -80mV. For the current-voltage (I-V) relationships (Fig. 4.6A), the human and rat 
Nav 1.8 currents and TTX-sensitive Na + currents showed reversal potentials similar to the 
theoretical Erev (calculated as +56mV using the Nemst equation for the solutions used). 
For the TTX-sensitive Na+ currents, the I-V curve (Vh = -120mV) showed an Imax of 
approximately -12m V. In contrast, the 1-V curves for human and rat Na\·1.8 channels showed an 
Imax of approximately 10m V from both holding potentials of -120m V or -80m V, indicating that 
the human and rat Nav 1.8 channels activate with a similar dependence on the potential but at 
more depolarised potentials than for TTX-sensitive Na + channels. Indeed, when the 
conductance-voltage (G-V) curves were fitted (Fig. 4.6B), the voltage for half-maximal 
activation (Vu) was significantly depolarised (approx. 28mV more positive, Table 4.1) for the 
Nav 1.8 channel currents compared to the TTX -sensitive N a + currents. Furthermore, the VI ~ for 
activation was not significantly different between the human and rat Nav 1.8 channels from 
either holding potential (Fig. 4.6B, Table 4.1). A steeper slope was observed in the G- V curve 
for TTX-resistant Na + currents compared to both human and rat Nav 1.8 channels (Fig. 4.6B, 
Table 4.1). Indeed, compared to the TTX-sensitive Na + currents, the slope factor (k) was approx. 
8m V greater for the human Nav I. 8 channel and approx. 5m V greater for the rat channel, where 
there was a small but significant difference in k values (approx. 3mV) between the human and 
rat Nav1.8 channel curves from both holding potentials (Table 4.1). For the maximum 
conductance, human and rat Nav 1. 8 channels and TTX-sensitive Na + currents showed similar 
values (Table 4.1). Thus, overall the activation properties were essentially similar for the human 
and rat Nav 1.8 channels (irrespective ofthe holding potential), and they showed significantly 
more depolarised activation than for the TTX-sensitive Na + currents. 
TABLE 4.1 
Voltage-dependent activation and inactivation of human and rat Sa v1.8 sodium channels 
Holding Activation Inacti\'ation Navl.8 channel 
potential (mV) VI, (mV) k (mV) Gmax (nS) n VI/,(mY) k (my) B (nA) A(nA) n 
Human -120 -2.7 ± 0.8 14.7 ± 0.3 61.9 ± 4.6 79 79.9 ± 1.0 10.5 :t: 0.4 1.8 ±0.2 0.12±0.01 84 
Human -80 -4.0 ± 1.0 12.4 ± 0.3 47.9 ± 4.6 ~3 -76.3 ± 1.5 8.7 ± 0.4 3.1 ± 0.4 0.15 ±0.03 39 
Rat -120 -2.4 ± 0.8 11.7 ± 0.3 57.0 ± 5.8 57 --64.1 ± 1.2 8.0 ± 0.4 2.0 ± 0.3 0.08 ± om 51 
Rat -80 -1.6± 0.9 10.3 ± 0.3 61.2 ± 6.0 41 -57.9 ± 1.0 7.6 ± 0.2 2.3 ±0.2 0.03:t: 0.01 38 
TTX-sensitive Na + -120 -30.4± 0.8 6.7 ±O.I 51.2 ± 6.6 8 -76.2 ± 1.2 5.3 ± 0.2 2.9 ± 0.4 0.03 ± om 8 
Human+h~1 -80 ND -79.0± 4.5 9.0 ± 1.2 1.4 ± 0.5 0.08 = 0.02 5 
Human+h~3 -80 ND -75.3 ± 5.- 11.1±1.9 2.0 ± 0.2 0.07 ± 0.05 .. 
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Fig. 4.6. Voltage-dependence of activation for human and rat Nay1.8 channels. A) Current-
voltage (I-V) relationships are shown for the peak current for human (e) and rat (0) Nav l.8 
channels and TTX-sensitive Na+ channels (e) from a holding potential of -120mV, and also for 
human (_) and rat (D) Navl.8 channels from a holding potential of -80mV. Currents were 
normalised to the maximum current (lmaJ. B) Conductance-voltage curves are shown for human 
(e) and rat (0) Nav1.8 channels and TTX-sensitive Na~ channels (e) from a holding potential 
of -120mV, and also for human (_) and rat (D) Nav1.8 channels from a holding potential of-
80m V. The curves were fit with the Boltzmann equation and normalised to the maximum 
conductance (Gma,} The pulse protocol is shown in the inset ofB. The n numbers are given in 
Table 4.1. 
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4.2.4 Voltage-dependence o/inactivation/or human and rat NarI8 channels 
The voltage-dependence of steady-state inactivation for human and rat Nav 1.S channel 
currents was compared using a test pulse to Om V preceded by 4 second prepulses from a 
holding potential of -120mV or -SOmV (Fig. 4.7). The endogenous TTX-sensitive Na+ currents 
were also studied from a holding potential of -120mV. The steady-state inactivation curves for 
the human Nav I.S channel were more negative than for the rat Nav 1.S channel for both holding 
potentials (Fig. 4.7). Indeed, from a holding potential of -120mV, the VI '2 for inactivation was 
15.SmV more hyperpolarised for the human than for the rat Nav1.S channel (Table 4.1). In fact 
the inactivation curve for the human Nav I.S channel showed similar Vl2 values to the TTX-
sensitive Na + current (Fig. 4.7, Table 4.1). It is also noteworthy that from a holding potential of 
-SOmV, the human and rat Nav 1.S channels both showed a small depolarising shift in the 
steady-state inactivation curve. Compared to the TTX-sensitive Na+ currents, the slope factor (k) 
was approx. Sm V greater for the human Nav 1.S channel and approx. 5m V greater for the rat 
Nav I.S channel, where there was a very small difference in k values (approx. 3m V) between the 
human and rat Nav 1.S channel curves from both holding potentials. These results show that the 
human Nav 1.S channel inactivates at more hyperpolarised potentials than the rat Nav 1.8 
channel. 
The ND7/23 cell line has been shown to express ~l and ~3 subunits (John et aI., 2004), which 
are likely to be mouse or rat orthologues due to the origin of the cell line. Despite human, rat 
and mouse ~ subunits being near-identical in protein sequence, species-specific modulation of 
the Nav 1.S channel might nevertheless contribute to the differential voltage-dependence of 
inactivation observed between human and rat Nav 1.8 channels. In experiments co-expressing 
human ~l or ~3, the voltage-dependence of inactivation for human Nav 1.8 channel was 
unaltered, and indeed the Boltzmann curve parameters were not significantly different (Table 
4.1). Therefore, the presence of endogenous modulatory ~ subunits does not seem to explain the 
more hyperpolarised inactivation of the human Nav 1.8 channel compared to the rat channel. 
Overall the voltage-dependence of steady-state inactivation is different between human and 
rat Nav 1.8 channels. In order to determine whether other inactivation properties differed 
between human and rat Nav 1.8 channels, the time course for development of inactivation, and 
for recovery from inactivation, and use-dependent current inhibition will be compared 
(following sections). 
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Fig. 4.7. Voltage-dependence of steady-state inactivation for human and rat Nay 1.8 
channels. Curves are shown for steady-state voltage-dependence of inactivation for human (e) 
and rat (0) Nav1.8 channels and TTX-sensitive Na+ channels (e) from a holding potential of -
l20mV, and also for human (_) and rat (D) Nav1.8 channels from a holding potential of -80mV. 
Currents were normalised to the maximum current (parameter B, see Chapter 2). The pulse 
protocol and example currents elicited during the Om V test pulse are shown inset. The n numbers 
are given in Table 4.1. 
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4.2.5 Time course for development of inactivation for human and rat Nad.8 channels 
Inactivation from open states is responsible for the decay phase observed for yoltage-gated 
Na+ channel macroscopic current (Yarov-Yarovoy et aI., 2001). The example current traces 
shown in Figure 4.4 indicate the kinetics for inactivation are different for the human and rat 
Nav 1.8 channels. The mean time constants of inactivation fit to the time courses (Fig. 4.8) show 
that the rat Nav 1.8 channel showed significantly slower inactivation for all potentials examined 
than the human Nav 1.8 channel from a holding potential of -120m V. From a more physiological 
holding potential of -80mV, rat Nav1.8 was still slower than the human channel. It is also 
noteworthy that the rat channel was significantly slower from a holding potential of -80m V 
compared to -120mV, while the human channel showed near-identical time constants between 
the two holding potentials. Compared to the human and rat Nav 1.8 channel currents from a 
holding potential of -120mV, the TTX-sensitive Na+ currents were significantly faster for all 
potentials examined (Fig. 4.8). The time course for inactivation was examined over relatively 
short 15ms depolarising pulses, and although they fit well with two exponentials, any 
component with much slower time course was too small in magnitude to be measured. 
Therefore, another protocol was used to study the time course for development of inactivation. 
In this protocol, a control pulse to Om V of varying duration was preceded by a 4ms recovery 
period and a test pulse to Om V (protocol as in the inset of Fig. 4.9A). The test current amplitude 
was measured and normalised to the control current amplitude. The current was plotted as a 
function of the control pulse duration and fitted with two time constants, Tfast and Tslow. The time 
course shows that both time constants were significantly smaller for the human Nav 1.8 channel 
than for the rat channel (Fig 4.9B,C, Table 4.2). Therefore, both fast and slow components of 
inactivation appear to develop faster for human Nav 1.8 than for rat Nav 1.8 channels (Fig. 4.9). 
Furthermore, the magnitude of the fast component was significantly larger for the human 
Nav1.8 channel than the rat channel (and accordingly vice versa for the slow component). This 
indicates that the fast component of inactivation is more pronounced in the human Nav 1.8 
channel compared to the rat Nav 1.8 channel. The extent of inactivation at 4 seconds also 
appeared to be more pronounced for the human Nav 1.8 channel than the rat channel; the 
asymptote was significantly smaller for the human channel O.17±O.02 (n=5) than the rat channel 
O.28±O.04 (n=5) (Fig. 4.9). It is also noteworthy that since inactivation appears complete at 4 
seconds this time course confirms that inactivation is indeed steady-state following a 4 second , 
pulse. 
Therefore, these results suggest that the human and rat N a\·1.8 channels inactivate with at 
least two components. Both components of inactivation appear faster for the human Nay 1.8 
channel compared to the rat channel. Furthermore, the development of inactiyation is faster for 
the human and rat Nav 1.8 channel currents than for the TTX-sensitive NaT currents. 
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Fig. 4.8. Voltage-dependence of the inactivation time course for human and rat Na,,1.8 
channels. The time constant of inactivation, 7: i' is shown at each test potential, V, for human ( e) 
and rat (0) Na
v
l.8 channels and TTX-sensitive Na+ channels (e) from a holding potential of-
120mV, and also for human (_) and rat (0) Nav1.8 channels from a holding potential of -80mV 
The n numbers are given in Table 4.2. 
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Fig. 4.9. Development of inactivation for human and rat Nav1.8 channels. A) The figure 
shows the time course for the development of inactivation for human (e) and rat (0) Nav l.8 
channels and from a holding potential of -120m V. The pulse protocol is shown inset. The current 
amplitude during the test pulse was expressed as a fraction of the current amplitude during the 
control pulse, and plotted against the duration of the prepulse. The curves were fit with a double 
exponential equation. B) The bar diagrams of the fitted parameters are shown for the fast 
component, showing time constant r fast and its amplitude Ifast for human (filled bars) and rat 
(unfilled bars) N av 1. 8 channels. C) The bar diagrams of the fitted parameters are shown for the 
slow component, showing time constant r slow and its amplitude Islow for human (filled bars) and 
rat (unjilledbars) Nay 1.8 channels. The n numbers are given in Table 4.2. 
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TABLE 4.2 
Time cOllrse afinactivationfor human and rat Sa vI.8 channels 
Navl.S channel Holding 
potential (mY) 
Entry into inactivation 
Human 120 3.2 ± 0.2 56 6.5 ± 0.3 77 ... 1 635 ± 57 23 '" 1 5 
Human -SO 3.0 ± 0.2 36 ND 
Rat -120 4.2 ± 0.3 50 1l.4 ± O.S 57 ± 3 995 ± 71 43 ± 3 5 
Rat -SO 5.0 ± 0.3 30 ND 
TIX-sensitive Na- -120 0.32 ± 0.01 S ND 
The Ti shown is measured from test current elictited at OmV 
Recovery from inactivauon 
10.2=OA67±1 126±15 33=171 
~D 
5.9 ± 0.5 67 ± I 35~ ± 58 )3 = 1 55 
~D 
~J ±OJ 80±4 65 ± 9 20 2.2 6 
4.2.6 Time course of recovery from inactivation for human and rat Navl.8 channels 
In order to study the recovery from inactivation, a two-pulse protocol was used similarly to 
the latter part of Section 4.2.5, except the duration of the recovery periods between the control 
pulse and test pulse was varied (instead of the duration of the control pulse, Fig. 4.l0A inset). 
The current was plotted as a function of the duration of the recovery period and fitted with two 
time constants, 'fast and 'slow. Recovery from inactivation was compared between human and rat 
Nay 1.8 channels, and also compared with the TTX-sensitive Na + current, all from a holding 
potential of -120mV. The time course of recovery showed a Ziast in the order of tens of 
milliseconds and 'slow in the order of hundreds of milliseconds (Fig 4.l0B,C, Table 4.2). At 
short recovery periods (corresponding to the fast component of inactivation), recovery was 
slower for the human channel than for the rat Nav 1.8 channel (Fig. 4.1 OA), and indeed the 
initial time constant ('fast) was 1.6-fold slower for the human channel (Fig. 4.l0B, Table 4.2). 
Conversely, at longer recovery periods (corresponding to the slow component of inactivation), 
recovery was 2.8-fold faster for the human channel than the rat Nav 1.8 channel (Fig. 4.1 OA,C, 
Table 4.2). For the TTX-sensitive Na+ currents, recovery from inactivation was faster for both 
initial and later components compared to the human and rat Nav 1.8 channels. Furthermore, 
while the human Nav1.8 channel showed identical magnitudes of the fast (67%) and slow (33%) 
components to the rat Nav 1.8, for the TTX-sensitive Na+ current, there was a significantly 
(P<0.005) greater magnitude of the fast component, and accordingly, a smaller magnitude slow 
component (Table 4.2, Fig. 4.10). Therefore this suggests that compared to the TTX-sensitive 
Na + currents, the human and rat Nay 1.8 channels show a larger slow component of inactivation. 
Thus, overall these results show that Nay 1.8 channels show slower recovery from inactivation, 
with more favoured slow component of inactivation compared to TTX-sensitive Na+ currents. 
The human Nav 1.8 channel recovered from the initial component more slowly than the rat 
channel, and conversely, human Navl.8 recovered faster from the later component of 
inactivation than the rat channel. 
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Fig. 4.10. Recovery from inactivation for human and rat Nav1.8 channels. A) The time course 
for the recovery from inactivation is shown for human (e) and rat (0) Nayl.8 channels and 
TTX-sensitive Na+ channels (e) from a holding potential of -120mV. The pulse protocol is 
shown inset. The current amplitude during the test pulse was expressed as a fraction of the current 
amplitude during the control pulse, and plotted against the duration of the recovery period. The 
curve was fit with a double exponential equation. B) The bar diagrams of the fitted parameters are 
shown for the fast component, showing time constant r fast and its amplitude lfast for human (filled 
bars) and rat (unfilled bars) Nay 1.8 channels, and TTX-sensitive Na+ channels (grey bars) C) The 
bar diagrams of the fitted parameters are shown for the slow component, showing time constant 
r slow and its amplitude lslow for human (filled bars) and rat (unfilled bars) Nay 1.8 channels, and 
TTX-sensitive Na+ channels (grey bars). * indicates a statistically significant difference from 
human Nav 1.8 channels p<O.OS. The n numbers are given in Table 4.2. 
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4.2.7 Use-dependent current inhibition a/human and rat Nad.8 channels 
Frequent stimulation of voltage-gated Na+ channels in the absence of any drug results in the 
accumulation of inactivated channels until the rate development of inactivation reaches 
equilibrium with the rate of recovery from inactivation. This effect is known as use-dependent 
current inhibition, and is important for the study of the effects of specific stimulation 
frequencies on Nav channels, which may be related to action potential firing frequencies. 
The effect of frequent stimulation on human and rat Nav 1.8 channels was examined by 
applying a 10Hz train of 60 depolarising pulses to Om V (1 Oms in duration) from a holding 
potential of -120m V, or a more physiological holding potential of -80m V (Fig. 4.11). Example 
current traces recorded during the first and 60th pulses are shown for human (Fig. 4.11A) and rat 
(Fig. 4.l1B) Nav1.8 channels. For mean values taken at 10Hz stimulation, the current amplitude 
for human Nav 1.8 was reduced by 15±1 % (n= 121) at steady-state compared to the first pulse 
from a holding potential of -120mV, but reduced by 28±2% (n=26) from a holding potential of-
80mV (Fig. 4.l1C, Table 4.3). The more extensive use-dependent current inhibition at -80mV is 
the consequence of a greater probability of inactivated channels at a more depolarised holding 
potential. Indeed, this was also observed for the rat Nav 1.8 channel, where at 10Hz stimulation 
27±2% (n=86) inhibition was observed from a holding potential of -120mV, but 39±2% (n=32) 
from a holding potential of -80mV (Fig. 4.11C, Table 4.3). Interestingly, these results show that 
from holding potentials of both -120mV and -80mV, use-dependent current inhibition was 
significantly less pronounced for the human Nav 1.8 channel, compared to the rat Nav 1.8 
channel. 
TABLE 4.3 
Use-dependent current inhbition of human and rat Na v 1.8 channels 
Holding Use-dependent inhibition (lnoruJ Nav l.8 channel potential (mV) 5Hz n 10Hz n 20Hz n 
Human -120 0.89 ± 0.01 52 0.85 ± 0.01 121 0.74 ± 0.01 51 
Human -80 0.79 ± 0.02 33 0.72 ± 0.02 26 0.55 ± 0.03 26 
Rat -120 0.74 ± 0.02 40 0.73 ± 0.02 86 0.60 ± 0.02 39 
Rat -80 0.67 ± 0.02 32 0.61 ± 0.02 32 0.50 ± 0.02 32 
TTX-sensitive Na + 120 0.98 ± 0.01 8 0.95 ± 0.01 7 0.85 ± 0.01 7 
The TTX-sensitive Na+ current also showed use-dependent current inhibition at 10Hz (T'h= -
120m V), but this was significantly less pronounced than for both human and rat N av 1. 8 
channels (Fig. 4.11 C, Table 4.3). This suggests that relative to the rate of entry into inactivation, 
the rate of recovery from inactivation is fastest for TTX-sensitive Na+ current and slowest for 
the rat Na\·1.8 channel, with human Nav 1.8 channel intermediate. The extent of use-dependent 
inhibition correlates well with the time course of recovery from inactivation. Indeed, in Figure 
94 
4.12 depolarising trains at 20Hz show the greatest extent of inhibition, and at 5Hz show the 
least, where an equal dependence of the frequency of stimulation was observed for the htunan 
and rat Nav 1.8 channel currents and the TTX-sensitive Na+ currents (Fig. 4.12, Table 4.3). 
Furthermore, the 5Hz, 10Hz and 20Hz train all probe the slow component of the recovery from 
inactivation (with recovery periods of 190ms, 90ms and 40ms, respectively). In the previous 
section, the recovery from the slow component of inactivation was found to be faster for the 
TTX-sensitive Na+ current and slowest for the rat Nav1.8 channel, with human Nad.8 channel 
intermediate. 
Therefore, the extent of use-dependent current inhibition was more pronounced for rat 
Nav1.8 channels than for human Nav1.8 channels. The TTX-sensitive Na+ currents showed less 
pronounced use-dependent current inhibition than both human and rat Nav 1.8 channels. These 
findings correlate well with the extent of recovery from the slow component of inactivation. 
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Fig. 4.11. Use-dependent current inhibition of human and rat Nay 1.8 channels. A) Example 
human Nav l.8 channel currents are shown elicited by the fIrst and 60th depolarising test pulses (to 
OmV) of a 10Hz train. B) Example rat Nav1.8 channel currents are shown elicited by the first and 
last depolarising test pulses (to Om V) of a 10Hz train. C) The current amplitude elicited during a 
10Hz train of 60 test pulses to Om V (1 Oms in duration) was expressed as a fraction of the 
amplitude of the first pulse. The use-dependent current inhibition curves are shown for human 
(e) and rat (0) Nav1.8 channels and TTX-sensitive Na+ channels (e) from a holding potential 
of -120mV, and also for human (_) and rat (D) Nay 1.8 channels from a holding potential of-
80mV. The pulse protocol is shown inset. The n numbers are given in Table 4.3. 
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Fig. 4.12. Use-dependent current inhibition of human and rat Nay1.8 channels at different 
stimulation frequencies. The figure shows the current amplitude elicited at the end of a 5Hz, 
10Hz or 20Hz train of 60 test pulses to Om V (1 Oms in duration), which was expressed as a 
fraction of the amplitude of the first pulse. The extent of use-dependent inhibition is shown for 
human (e) and rat (0) Nav 1. 8 channels and TTX-sensitive Na+ channels (e) from a holding 
potential of -120mV, and also for human (.) and rat (D) Nav1.8 channels from a holding 
potential of -80mV. The pulse protocol is shown inset. The n numbers are given in Table 4.3. 
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4.3 Discussion 
4.3.1 Expression ofNad.8 channels 
In this study, the functional properties ofNav 1.S were examined. These experiments were 
carried out using the Xenopus laevis oocyte expression system and transient expression of the 
mammalian sensory-neuron derived ND7/23 cell line. Although the Xenopus laevis oocyte 
expression system has been previously used for the expression of both human and rat Na\-l.S 
channels (Akopian et aI., 1996; Rabert et aI., 1995; Sangameswaran et aI., 1996), here the 
human Nav I.S channel currents were observed in only 13% of examined oocytes. Despite ~­
globin sequences flanking either side of the human Nav 1.S channel sequence, channel currents 
were of small amplitude. The maximum current was similar here (approx. 500pA at OmV) to the 
previously reported values for human Nav I.S channels expressed in oocytes (approx. 700pA at 
lOmV, Rabert et aI., 1995). Furthermore, the latter authors reported an Erevof 45mV, which is 
similar to the value here (43m V). The voltage for half-maximal activation was shown here to be 
6mV, which is also consistent with the value of 12mV reported by Rabert et aI., (199S). 
Although it was possible to record human Nav1.S channels expressed in oocytes, it was difficult 
to carry out accurate analysis of such small amplitude currents. Therefore the oocyte expression 
system was shown here to unsuitable for the expression ofNav 1.S channels for these 
experiments. 
The mammalian ND7123 cell line was shown to be sufficient for the transient expression of 
human and rat Nav I.S channels. The Nav 1.S channel currents were recorded in the presence of 
TTX (200nM) in order to completely inhibit the endogenous TTX-sensitive Na+ current. 
4.3.2 Functional properties of human and rat Nad.8 channels 
A detailed comparison of the human and rat Nav I.S channels was carried out in ND7/23 cells 
under the same experimental conditions. In this thesis, the voltage-dependence of activation was 
found to be similar for the human and rat forms of the Navl.S channel, while the TTX-sensitive 
Na + currents were significantly more hyperpolarised. Indeed, in rat DRG cells the TTX-
sensitive Na+ currents are widely reported to be more hyperpolarised than the TTX-resistant 
currents (Catterall et aI., 2005; Elliott and Elliott, 1993), to a similar extent as shown in this 
chapter. 
The human Nav I.S channel was shown here to inactivate at more hyperpolarised potentials 
(V1/2 approx. -SOm V) than the rat Nav I.S channel (VI '2 approx. -64m V) from a holding potential 
98 
of -120mV. Indeed, the human Nav1.8 channel was shown to have a similar V
I2 
values as TTX-
sensitive Na + currents. This contrasts with the relatively more depolarised voltage-dependence 
of inactivation for Nav 1.8 that has been widely reported in studies of the rat Nav 1.8 channel 
(Akopian et aI., 1996; Sangameswaran et aI., 1996). From a more physiological holding 
potential of -80m V, a similar trend was observed for the human and rat Nav 1.8 channels. The 
VI '2 for inactivation observed here (-58m V) for rat Nav 1.8 channels (Vh = -80m V) was similar to 
the value reported for the same channel expressed in the same cell line ( -54m V) and also to the 
value reported for TTX-resistant Na+ currents recorded from rat DRG (-54mV) (John et aI., 
2004). 
Overall, these results suggest that at normal resting potentials for nociceptive neurons, where 
these channels are predominantly expressed, a larger proportion ofNav 1.8 channels will be 
inactivated in humans compared to rats. 
For both human and rat Nav 1.8 channels, the VI2 values for inactivation are generally more 
hyperpolarised here than compared to previously obtained values (Table 4.4). However, as 
noted above the VU2 value for rat Nav 1.8 (-58m V) from a holding potential of -80m V is 
consistent with John et al. (2004). The more hyperpolarised V1I2 value (-64mV) at -120mV 
holding potential, indicates the VlI2 values obtained at the less hyperpolarised holding potential 
may be distorted, as they already include partly inactivated channels. The strength of this 
present study is due to the fact that human and rat Nav 1.8 channels have been compared under 
the same experimental conditions, removing the effects of pulse protocols and other 
experimental conditions. Under these identical conditions, it is clear that the human Nav 1.8 
channel shows a more hyperpolarised voltage-dependence of inactivation than the rat Nav 1.8 
channel. 
TABLE 4.4 
Voltage-dependence o/inactivation/or human and rat Na 171.8 channels in the literature 
Nav 1.8 channel Holding Expression 
V11 for Reference 
potential (mY) system inactivation (mY) 
Human -120 ND7/23 -80 This thesis 
Human -80 ND7/23 -76 This thesis 
Human -100 Oocytes -54 Rabert et aI., 1998 
Human -100 CHO -63 Akiba et aI., 2003 
Human -100 HEK293 -50 Jarvis et aI., 2007 
Rat -120 ND7/23 -64 This thesis 
Rat -80 ND7/23 -58 This thesis 
Rat -100 Oocytes -48 Rabert et aI., 1998 
Rat -60 Oocytes -30 Akopian et aI., 1996 
Rat -100 Oocytes -53 Vijayaragaven et aI., 2004 
Rat -90 ND7!23 -54 John et al., 2004 
Rat -140 ND7/23 -47 Leffler et aI., 2007 
Rat -120 ND7/23 -41 Choi et al., 2004 
Rat -140 tsA201 -75, -34 Zhao et aI., 2007 
NB: While Fitzgerald et ai. (1999) and Sangameswaran et ai. (1996) also exami~ed the functional 
properties ofNav l.8 channels, the voltage-dependence of inactivation was not studied. 
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Although some previous studies have investigated properties of human and rat Nay 1.8 
channels (Table 4.4), only Rabert et aI., (1998) have carried out a direct comparison between 
human and rat channels in the same laboratory under the same experimental conditions, as 
described in this chapter. The comparison by the latter authors was done using oocyte 
expression system rather than the mammalian expression system used here. They were not able 
to discriminate clearly between the properties of human and rat channels, due to low numbers of 
recordings. However, the trend of the latter authors results for voltage-dependence of steady-
state inactivation were similar to those described in this chapter. Furthennore, Akiba et al. 
(2003) also noted that inactivation was more hyperpolarised for human Nav 1.8 channels 
expressed in eHO cells compared to values observed by Akopian et al. (1996) for the rat 
Nav 1.8 channel (Table 4.4). 
The hybrid cell line, ND7 123, is derived from rat and mouse cells and thus species-specific 
modulatory proteins may potentially contribute to differences in properties between the rat and 
human Nav 1.8 channels. However, species-specific modulation by endogenously expressed ~ 
subunits did not appear to explain the more depolarised voltage-dependence of inactivation 
observed for the human Nav 1.8 channel, since co-transfection with human ~ subunits did not 
significantly affect the inactivation curve parameters. However, it is not possible to rule out the 
possibility that the endogenously expressed ~ subunits are already at maximal levels, so that 
heterologous expression would have negligible effect. As noted above, previous studies have 
suggested that human Nav 1.8 channels inactivate at more hyperpolarised potentials compared to 
rat Nav1.8 channels (Akiba et aI., 2003; Rabert et aI., 1998). Thus, it seems unlikely that the use 
of ND7/23 cells contributed to the observed differences between human and rat Nav 1. 8 
channels. Furthermore, the results here are perhaps more relevant to physiological cases since a 
mammalian cell line was used. Thus, overall the results indicate that the ND7/23 cells did not 
contribute to the differences observed between human and rat Nav 1.8 channels. 
In order to determine whether other inactivation properties differed between human and rat 
Nav 1.8 channels, the time course for development of inactivation, and recovery from 
inactivation, and use-dependent current inhibition were studied. For the time course of 
inactivation during a single pulse, human Nav 1.8 channel kinetics decayed faster than for rat 
Nav 1.8 channels, but slower than TTX-sensitive Na + currents for all potentials examined. This 
was also supported by use of a two-pulse protocol. For the latter protocol the control pulse 
duration was varied, and the extent of inactivation at each control pulse period was plotted. 
There were two components to the time course, where the human Nav 1.8 channel showed faster 
development of both components of inactivation compared to the rat Nav 1.8 channel. 
Furthermore, the amplitude of the slow component was smaller for the human Nav 1.8 channel, 
than for the rat channel. For the recovery from inactivation, there were also two components to 
the time course, where human Nay 1.8 showed slower recovery from the fast component, and 
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faster recovery from the slow component compared to the rat Na\-1.8 channel. Furthermore, 
consistent with the literature, TTX-resistant Nav 1.8 channels showed slower recovery from 
inactivation with more favoured slow inactivation than TTX-sensitive Na+ current (Blair and 
Bean, 2003; Leffler et aI., 2007). 
In summary, for the fast component, inactivation of the human Nad.8 channel develops 
faster but recovers slower than the rat Nav 1.8 channel. For the slow component, the 
development of inactivation was faster for the human Nav 1.8 channel, but the recovery was also 
faster. The fast component of inactivation and slow component of inactivation appear to 
represent two kinetically distinct inactivation states; it seems likely that these states are perhaps 
the fast inactivation state and a slow inactivation state. Moreover, a greater proportion of rat 
Nav 1.8 channels enter the slow inactivation states than human Nav 1.8 channels. Thus the fast 
and slow components ofNav 1.8 inactivation appear to have a different mechanism. 
The slower recovery of the slow component of inactivation for the human Nav1.8 channel 
also explains its greater use-dependent current inhibition at 10Hz. As at this frequency, a 
recovery period would be present between depolarisations that would probe the slow component 
of the time course of recovery from inactivation. This is relevant physiologically because high 
frequency firing occurs in nociceptive C-fibres following neuropathy (approx. 10Hz), thus the 
human Nav 1.8 channel is capable of supporting high frequencies and more sustained action 
potential firing in these fibres (Akopian et aI., 1996; Elliott and Elliott, 1993; Jeftinija, 1994; 
Kajander and Bennett, 1992; Sangameswaran et aI., 1996; Schild and Kunze, 1997). Therefore 
because of the differences in the functional properties between human and rat Nav 1.8 channels, 
the use of rats to investigate nociceptive nerve transmission and excitability may not exactly 
reflect the situation in humans. 
The human Nav 1.8 channel shares 83% identity with the rat channel; 2% of differences 
occur in the transmembrane segments and 15% in the loop regions. However it is difficult to 
predict which regions might be particularly important for the differential functional properties of 
the two channels. The following list gives five examples that perhaps could be important for the 
different functional properties between the human and rat Nav 1.8 channels: 
1) Five serines of the I-II linker have been shown to be sites of cAMP-dependent kinase A 
(PKA) modification in rat Nav 1.8 channels (Fitzgerald et aI., 1999). The human Nav 1.8 
channel shares identity with only three of these sites. While the inactivation properties 
of the rat Nad.8 channel were not affected by PKA in oocytes (Vijayaragavan et aI., 
2004a), the effects of PKA on the human Nav 1.8 channel I-II linker are yet to be 
investigated. 
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2) A single amino acid difference between the human (FI465) and rat (Y1466) Navl.8 
channels is present in the DIll-IV linker which comprises the fast inactivation gate. 
Although the role of this residue in inactivation has not been investigated in the Na\.1.8 
channel, the additional hydroxyl group might perhaps reduce interactions leading to the 
slower inactivation kinetics for the rat Nav 1.8 channel compared to the human channel. 
3) The N-terminus of the rat Nav 1.4 channel has also been demonstrated to interact with 
the C-terminus through a 22 amino acid residue region overlapping the calmodulin IQ 
motif (Choi et al., 2006; Zhang et al., 2000), which differs by two residues between 
human and rat Nav1.8 channels. While the role of the interaction between the N- and C-
termini is unknown, the interaction between the C-terminus and calmodulin was shown 
to be involved in the extent of use-dependent current inhibition (Choi et al., 2006). 
Perhaps the differences in the amino acid sequence lead to reduced interactions between 
the N-terminus and the C-terminus, the C-terminus and calmodulin, or both. 
4) The rapid recovery from fast inactivation of the rat Nav 1.8 channel has been attributed 
to a tetrapeptide (serine-leucine-glutamic acid-asparagine) in the IVS3/S4linker (Dib-
Hajj et al., 1997). However, the corresponding tetrapeptide differs in the human Nav 1.8 
channel (glutamine-serine-glutamic acid-asparagine). Perhaps this difference 
contributes to the different recovery inactivation between human and rat Nav 1.8 
channels. 
5) In addition to the intracellular linkers, the transmembrane segments and P-Ioops have 
also been shown to be involved in inactivation (Ulbricht, 2005). It is possible that these 
regions may also be involved in the different inactivation properties observed between 
the human and rat Nav 1.8 channels. 
In conclusion transient transfection of mammalian ND7/23 cells is sufficient for recording , 
human and rat Nav1.8 channel currents. While the voltage-dependence of activation was similar 
between human and rat Nav 1.8 channels, the human Nav 1.8 channel showed different 
inactivation properties; the voltage-dependence of inactivation was more hyperpolarised, 
development of inactivation was faster, and recovery from the first component of inactivation 
was slower, and vice versa, recovery from the second component of inactivation was faster. 
Therefore these results suggest that under physiological conditions, there would be a greater 
proportion of Nav 1. 8 channels inactivated in humans compared to rats (except at very 
depolarised potentials), and higher action potential firing frequencies may be achieved for 
humans. 
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CHAPTERS 
PHARMACOLOGICAL PROPERTIES OF 
HUMAN AND RAT Navl.8 SODIUM 
CHANNELS 
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5.1 Introduction 
The Nay 1.8 channel is known to play an important role in pain signalling. Agents which 
block Nay l.8 channels have been shown to be anti-hyperalgesic and anti-allodynic in 
inflammatory and neuropathic pain animal models. Many drugs (such as local anaesthetics), act 
on voltage-gated Na+ channels mainly by their preferential action on the inactivated state of the 
channel (Hille, 1977). The selectivity for inactivated channels results in a voltage- and use-
dependent action leading to greatly augmented drug block during repetitive firing or sustained 
depolarisation, as may occur, during pain signalling (Blair and Bean, 2002; Renganathan et aI., 
2001). 
In the previous chapter it was shown that the e1ectrophysiological properties differ between 
human and rat Nav 1.8 channels. In this chapter, electrophysiologica1 measurements using 
whole-cell patch clamp were used to analyse and compare the pharmacological actions of a 
range of drugs on human and rat Nay 1.8 channels expressed in ND7123 cells. The tonic and use-
dependent actions of the local anaesthetic tetracaine, the a-aminoamide derivative ralfinamide 
(which shows analgesic properties, Stummann et al. 2005), the lamotrigine derivative 227c89 
(which also shows analgesic properties, Liu et ai. 2003), the potent anticonvulsant VI02862 
(which has the potential utility as an analgesic, Ilyin et al. 2005), and the potent and highly 
selective Nay l.8 channel inhibitor A-803467 (which also has analgesic properties, Jarvis et al. 
2007). These five known sodium channel blockers (Fig. 5.1) were chosen to further understand 
their action on the Nav 1.8 channel, which is known to be involved in pain signalling. 
5.2 Results 
5.2.1 The effect of dmg application on Nav1.8 channel currents over time 
In order to study the effects of drugs on resting and inactivated channels, it is first necessary 
to determine the most appropriate method for drug application. The length of time required for 
the effects of drug application on Nay 1.8 channel currents to reach steady-state was addressed 
for each drug in preliminary experiments using a test pulse to OmV every 20 seconds. Currents 
for all five drugs reached steady-state before 4 minutes. For instance, application of tetracaine 
(1 J.lM) to human Nay 1.8 channels (Vh= -80m V, therefore approx. 50% inactivated) showed that 
steady-state drug block ofNa\OI.8 channel currents was reached at approximately 2 minutes (Fig 
5.2). The time required for drug block is the result of the solution changer system delay, the 
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227c89 Ralfinamide 
Tetracaine 
V102862 A-803467 
Fig. 5.1. Chemical structures of test compounds. The structures for 227c89, ralfinamide, 
tetracaine, VI02862 and A-803467 are shown. These structures were created using ChemSketch 
11.0 (ACD). 
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time for the diffusion of drug across the cell membrane, and the time for onset of drug onto 
channels. Application of a drug-free solution to remove drug also showed a delay apparently for 
the same reasons. 
Many mammalian cell lines show a hyperpolarised shift in the inactivation curve over time 
, 
although the reason for this is presently unknown (Catterall, 2002). Indeed, both human and rat 
Nav 1.8 channels showed a shift in the inactivation curve to more hyperpolarised potentials after 
15 minutes between inactivation protocols (Fig. 5.3). This suggests that the effects of drug 
application on the inactivation curve, and the shift in the inactivation curve over time would be 
difficult to separate. Therefore, in order to reduce the shift in the inactivation curve over time 
, 
generally only one drug concentration was applied to each cell. The dissociation constants were 
determined from the effects of a single drug concentration on the Nav 1.8 channel currents, as 
carried out in previous studies for other voltage-gated Na + channels (Ilyin et aI., 2005; Li et aI., 
1999; Liu et aI., 2003; Yarov-Yarovoy et aI., 2001; Yarov-Yarovoy et aI., 2002). The procedure 
for the determination of dissociation constants is described for resting channels in the next 
section and inactivated channels in the section after, and the theory was described in Chapter 2. 
The resting and inactivated state dissociation constants were determined using pulse protocols 
at the same time point between cells, always immediately before drug application, and 
immediately after drug application. This reduced the time period between untreated and treated 
Nav 1.8 channel currents. To reduce any differences between cells untreated and treated 
experiments were carried out in the same cell and the data was paired. 
5.2.2 Resting state affinity of drugs for human and rat Na rI8 channels 
The state-dependent properties of voltage-gated sodium channel blocking drugs are 
important for their mechanism of action. The known drugs preferentially act on inactivated 
channels rather than resting channels. Therefore the extent of block is greatly increased during 
periods of repetitive firing (use-dependent block) or sustained depolarisation (tonic block), 
when inactivated channels are more prevalent. The extent that the inactivated state affinity is 
greater than the resting state affinity indicates how selective the drug is for neurons that are 
more depolarised than others. Here the resting state affinity (more precisely, the resting state 
dissociation constant, K r, see Section 2.6.7) for Nav 1.8 channels was studied from a holding 
potential of -120mV, at which virtually all channels are in the resting state (Chapter 4). The 
peak current amplitude during a test pulse (lOms in duration to OmV, Fig. 5.4A) was measured 
in the presence and absence of a test compound and the ratio of these currents, IDr, was 
determined as described in Chapter 2. The resting dissociation constants were calculated from 
the values of lOr and drug concentration. The drug concentration used, D, was chosen to produce 
appreciable resting state inhibition, with 10% to 60% resting state block. For example, the 
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Fig. 5.2. The time course of the effect of drug on hN a,,1.8 channels. The graph shows the 
effect of the application of tetracaine (111M) on human Nav 1.S channels from a holding potential 
of -SOmV (where channels are half-inactivated). The peak current amplitude was measured at a 
OmV test pulse every 20 seconds (n=4). The effect of tetracaine was removed following perfusion 
of the paired cells with a drug-free solution. 
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Fig. 5.3. Shift in the voltage-dependence of inactivation over time for human and rat Nay 1.8 
channels. Curves for steady-state voltage-dependence of inactivation are shown for human (., 
n=8) and rat (0, n=4) Nav l.8 channels after 12 minutes, and for human (.) and rat (b.) Na\1.8 
channels after 27 minutes, of entering the whole-cell configuration in paired cells. The currents 
shown were elicited from a holding potential of -120m V and expressed as a fraction of the 
maximum current (parameter B, see Chapter 2). 
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current traces in Figure 5.4B show the test current is dramatically reduced after the application 
of tetracaine (1 O~M). The values for %resting block and IDr at the respectiYe drug 
concentrations are given in Table 5.1 together with the calculated resting state dissociation 
constants for human and rat Nav 1.8 channels. The resting state dissociation constants are also 
shown graphically in Fig. 5.4C. 
Compound A-803467 had the highest resting state affinity (i.e. lowest dissociation constant, 
Kr approx. l50nM), while compound 227c89 and ralfinamide showed the lowest resting state 
affinities of the drugs studied with similar affmities (Kr approx. 10011M). Tetracaine and 
compound VI 02862 had intermediate affinities (Kr approx. 20l1M and 111M, respectively) (Fig. 
5.4C, Table 5.1). While the resting state affmity for 227c89, ralfinamide and A-803467 was 
similar between human and rat Nav 1.8 channels, the resting state affmity for tetracaine and 
V102862 was greater for human Nav1.8 channels than for rat Nav1.8 channels (2.7-fold and 
2.9-fold, respectively). 
TABLE 5.1 
Dissociation constants for block of resting Na v 1.8 channels 
NavL8 channel Drug Concentration % Resting IDr Kr(j.!M) n (flM) block 
Human 227c89 10 13 ± 2 0.87 ± 0.02 81.3 ± 19.4 5 
Rat 227c89 10 9±3 0.91 ± 0.03 118 ± 34 3 
Human Ra1finamide 50 31 ± 8 0.69 ± 0.08 129 ± 36 3 
Rat Ra1finamide 50 30± 3 0.70 ± 0.03 126 ± 21 5 
Human Tetracaine 10 56 ± 7 0.44 ± 0.07 10.3 ± 3.9 6 
Rat Tetracaine 10 27 ±3 0.73 ± 0.03 27.3 ± 4.0 3 
Human V102862 58 ± 2 0.42 ± 0.02 0.73 ± 0.06 6 
Rat V102862 33 ± 2 0.67 ± 0.02 2.l ± 0.2 5 
Human A-803467 0.1 49± 9 0.51 ± 0.09 0.13 ± 0.03 5 
Rat A-803467 0.1 36± 2 0.64 ± 0.02 0.18 ± 0.02 5 
5.2.3 Inactivated state affinity of drugs for human and rat Navl. 8 channels. 
In order to calculate the inactivated state affinity (the inactivated state dissociation constant, 
KJ for each drug, a two-pulse protocol (Fig. 5.5A) was used before and after the application of 
drug. Here a 4 second depolarisation was used give 60 to 80% inactivation before the test pulse 
(see Section 2.6.8). In the absence of drug, the test current amplitude expressed as a fraction of 
control current amplitude was used to determine the amount of non-inactivated channels h 
(Table 5.2). The test current amplitude in the presence of drug, expressed as a fraction of the 
current amplitude before drug application, is the parameter IDi (see Section 2.6.8). Since the 
Nay 1.8 channels showed altered voltage-dependent gating over time, control experiments 
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Fig. 5.4. Dissociation constants for each drug for resting Nav1.8 channels. A) The pulse 
protocol shown was used in the absence and presence of drug to determine resting state 
dissociation constants (KJ B) Example current traces are shown elicited by the pulse protocol in 
A, where current in bold was elicited in the absence of drug and the fine trace was elicited in the 
presence of drug. C) Bar diagrams are shown representing the ~ values for test compounds 
227c89, ralfinamide, tetracaine, V102862 and A-803467, for human (filled bars) and rat (unfilled 
bars) Nav1.8 channels. The concentrations (chosen to give 10-60% resting state block) and n 
numbers are shown in Table 5.1. 
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showed that after a 4 minute incubation period, the test pulse current amplitude increased by 
11 % (n=6) for the human Na\·1.8 channel and 5% (n=6) for the rat Nav 1.8 channel. Therefore 
the IDi parameter was corrected by these values for the determination of the inactivated state 
dissociation constants. The inactivated state dissociation constants were calculated from h and 
I Di , and the drug concentrations (Table 5.2). The calculated inactivated state dissociation 
constants are also shown graphically in Fig. 5.5C. 
TABLE 5.2 
Dissociation constants for block of inactivated Na v 1.8 channels 
Nav1.8 channel Drug Concentration IDi (flM) h Ki ().lM) n 
Human 227c89 10 0.61 ± 0.05 0.32 ± 0.03 12.1 ± 2.4 5 
Rat 227c89 ND 
Human Ralfmamide 10 0.60 ± 0.08 0.31 ± 0.04 15.4±5.0 5 
Rat Ralfmarnide 10 0.56 ± 0.04 0.24± 0.01 10.2 ± 1.8 4 
Human Tetracaine 1 0.62 ± 0.05 0.28 ± 0.05 1.12 ± 0.31 7 
Rat Tetracaine 1 0.59 ± 0.09 0.31 ± 0.05 1.61 ± 0.35 8 
Human VI02862 1 0.16 ± 0.03 0.28 ± 0.03 0.15 ± 0.03 6 
Rat V 102862 0.15 ± 0.02 0.36 ± 0.04 0.11 ± 0.01 5 
Human A-803467 0.01 0.63 ± 0.06 0.34 ± 0.03 0.015 ± 0.004 7 
Rat A-803467 0.01 0.83 ± 0.06 0.35 ± 0.04 0.043 ± 0.015 .3 
Compounds 227c89 and ralfinamide showed the lowest inactivated state affinities of the 
drugs studied with similar dissociation constants (Ki approx. l2J.1M), and compound A-803467 
had the highest resting state affinity (Ki approx. 30nM). Tetracaine and compound V102862 had 
intermediate dissociation constants (Ki approx. I~M and 120nM, respectively) (Fig. 5.5C, Table 
5.2). The order of affinity of drugs for the inactivated state was the same as for the resting state. 
While the inactivated state affinities were not significant different between human and rat 
Nav 1.8 channels for most compounds studied here, compound A-803467 showed a 2.9-fold 
greater affinity for the human channel. Importantly, these dissociation constants were all 
significantly greater for the resting state than for the inactivated state (i.e. greater affmity for the 
inactivated state). Indeed, the example current traces in Figure 5.5B, show that while tetracaine 
(1 )lM) has little effect on the resting channels, a marked effect was observed for inactivated 
channels. The ratio of the inactivated state affinity to the resting state affmity is a measure of the 
preferential inactivated state block. Compared to the resting state affinity, the human Nav 1.8 
channel showed an inactivated state affmity that was 7-fold greater for 227c89. 8-fold greater 
for ralfinamide, 9-fold greater for tetracaine, 5-fold greater for V102862 and 8-fold greater for 
A-803467. However, for the rat Nav 1.8 channel this ratio was lower for A-803467 (4-fold), 
greater for 227c89 (9-fold) and ralfinamide (l2-fold) and greater still for tetracaine (l7-fold) 
and compound VI02862 (l9-fold) (Tables 5.1 and 5.2). Therefore, these results suggest that all 
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Fig. 5.5. Dissociation constants for each drug for the inactivated Na,,1.8 channels. A) The 
pulse protocol shown was used in the absence and presence of a drug to determine inactivated 
state dissociation constants (K), where the 4 second pulse indicated was taken at membrane 
potentials of -50 to -80 mY, such that 60% to 80% inactivation occurred. B) Example current 
traces are shown using the pulse protocol in A, where currents in bold are in absence of drug and 
the fine traces are in the presence of drug; the currents larger in magnitude correspond to the 
control pulses and currents smaller in magnitude correspond to the test pulse. C) Bar diagrams are 
shown representing the Kj values for test compounds 227c89, ralfinamide, tetracaine, VI02862 
and A-803467, for human (filled bars) and rat (unfilled bars) Nayl.8 channels. The concentrations 
used and n numbers are shown in Table 5.2. 
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the drugs examined here preferentially bind to the inactivated state. The resting state affInity for 
tetracaine and V102867, and the inactivated state affinity for A-803467 were greater for human 
Nav 1.8 channels than for rat Nav 1.8 channels. The human and rat forms of the Nay 1.8 channel 
also differed in terms of the preference of the five drugs for the inactivated state over the resting 
state. 
5.2.4 Use-dependent drug block of human and rat NaTI 8 channels 
Use-dependent block underlies an important pharmacological property of voltage-gated Na+ 
channel blocking drugs, where neuronal excitability determines the level of drug block. As it 
was noted above (Section 4.2.7), frequent stimulation of channels results in channel opening and 
subsequent inactivation, such that, in the absence of drug, use-dependent current inhibition 
depends on the rate of development of inactivation during each depolarising pulse as well as the 
recovery from inactivation during the period between pulses. In the presence of a drug that 
preferentially binds to open/inactivated channels, this use-dependent effect is more pronounced. 
Therefore, in addition to the kinetics of drug binding and dissociation, the presence of drug 
alters the rates for development of inactivation and recovery from inactivation. Indeed, the 
states induced by frequent stimulation are usually stabilised by the drug and the recovery from 
inactivation is slowed, resulting in more pronounced inhibition (termed "use-dependent block" 
for treated cells, to distinguish from "use-dependent current inhibition" for untreated cells). 
In order to investigate the use-dependent block of human and rat Na\-1.8 channels in the 
presence of drugs, a 5Hz or 10Hz train of 60 depolarising pulses (1 Oms duration, to Om V from a 
holding potential -120m V) was used in the absence of drug and during the continual application 
of drug (drugs were applied before and during the train). Currents elicited in the absence and 
presence of drug in paired cells were first expressed as a function of the peak current amplitude 
recorded during the first pulse of the train (Fig. 5.6). The peak current amplitude recorded in the 
presence of drug were then expressed as a function of the peak current amplitude recorded in the 
absence of drug (Fig. 5.6). Thus the use-dependent block shown in Figures 5.7 to 5.9 (and Table 
5.3) take into account the use-dependent current inhibition in the absence of drug, and show the 
effect of the drug only. The mean currents recorded during trains at 10Hz are shown in Fig. 5.7 
for compound 227c89 and ralfinamide, Fig. 5.8 for tetracaine and V102862, and Fig. 5.9 for A-
803467. The current amplitude of inhibition at steady-state (i.e. the 60th pulse) following 5Hz 
and 10Hz trains is shown as a fraction of the current amplitude of the first pulse in the train 
(Fig. 5.10). Overall, a range of use-dependent properties were observed for the different drugs 
studied here. Compound 227c89 (Fig. 5.7A; 10f.lM), showed moderate onset of use-dependent 
block and significant (P<0.005) inhibition was observed at the end of the 10Hz train for both 
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Fig. 5.6. Overview of the method used to normalise the currents recorded during repetitive 
stimulation in the absence and presence of drug. For purposes of clarity, these data points are not 
real recordings from cells. 
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Fig. 5.7. Use-dependent effects of 227c89 and ralfmamide. A) The nonnalised current is shown 
plotted against pulse number during stimulation at 10Hz (pulses to Om V of lOms duration from a 
holding potential of -120m V) in the continual presence of 227c89 (lOJlM). Curves are for human 
(e) and rat (0) Navl.8 channels. B) Nonnalised current is shown plotted against pulse number 
during stimulation at 10Hz (pulses to Om V of 10ms duration) in the continual presence of 
ralfinamide (50J-lM). Curves are for human (e) and rat (0) Nav 1.8 channels. Currents were 
nonnalised as shown in Figure 5.6. The n numbers are shown in Table 5.3. 
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Fig. 5.8. Use-dependent effects of tetracaine and VI02862. A) Normalised current is shown 
plotted against pulse number during stimulation at 10Hz (pulses to Om V of 10ms duration from a 
holding potential of -120m V) in the continual presence of tetracaine (111M). Curves are for human 
(e) and rat (0) Nay1.8 channels. B) Normalised current is shown plotted against pulse number 
during stimulation (pulses to Om V of lOms duration) in the continual presence of ralfinamide 
(50IlM) for human (e) and rat (0) Nay 1. 8 channels at 10Hz, and for human (.) and rat (6) 
Nay1.8 channels at 5Hz. Currents were normalised as shown in Figure 5.6. The n numbers are 
shown in Table 5.3. 
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A-803467 (lOOnM) 
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Fig. 5.9. Use-dependent effects of A-803467. Normalised current is shown plotted against pulse 
number during stimulation at 10Hz (pulses to Om V of lOms duration from a holding potential of -
12OmV) in the continual presence of A-803467 (lOOnM). Curves are for human (e) and rat (0) 
Nayl.8 channels. Currents were normalised as shown in Figure 5.6. The n numbers are shown in 
Table 5.3. 
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* 
227c89 RalfinamideTetracaine V102862 A-803467 
* 
227 c89 Ralfinamide Tetracaine V102862 A-803467 
Fig. 5.10. Use-dependent properties of each compound. A) Currents are shown for the 60th 
pulse ofa 10Hz train for 227c89, ralfinarnide, tetracaine, V102862 and A-803467 for human 
(filled bars) and rat (unfilled bars) Navl.8 channels. B) Currents are shown for the 60th pulse of a 
5Hz train for each drug for human (filled bars) and rat (unfilled bars) Nay l.8 channels. * p<O.05, 
compared to the first pulse. Currents were normalised as shown in Figure 5.6. The n numbers are 
shown in Table 5.3. 
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human and rat Nav 1.8 channels. The main feature at 5Hz generally was a decrease in the effect 
of the compound (Table 5.3). For ralfinamide (50/-lM), little use-dependent block was observed 
at both stimulation frequencies at a holding potential of -120mV. Tetracaine (l/-lM) showed the 
slowest onset of use-dependent block, and significant (P<0.05) use-dependent block was 
observed from 10Hz stimulation frequencies for both human and rat forms of the Nad.8 
channel (Figs. 5.8A and 5.10A, Table 5.3). The effect of tetracaine was reduced at 5Hz for both 
human and rat Nav1.8 channels (Fig. 5.10B, Table 5.3). Compound V102862 showed 
significant (P<0.005) block at 10Hz with the fastest onset of the drugs studied. Interestingly, a 
5Hz stimulation frequency showed a significantly reduced extent ofV102862 block at the end 
of the train (Figs. 5.8B and 5.l0, Table 5.3). For compound A-803467, use-dependent block was 
not observed for rat N av 1. 8 from both 5Hz and 10Hz stimulation frequencies (Fig. 5.9). For 
human Nav 1.8 the presence of compound A-803467 increased the current rather than showing 
use-dependent block (effectively increasing the current) by approximately 17% at 10Hz (Figs. 
5.9 and 5.l0, Table 5.3). 
Overall, compound 227c89, tetracaine and compound V102862 showed the greatest extent of 
inhibition at the end of a 10Hz train. A similar trend was also observed for use-dependent 
current inhibition at 5Hz, but to a lesser extent (most notably for compound V102862). 
TABLE 5.3 
Effects of drugs on use-dependent block 
Nav1.8 Concentration Use-dependent block 
channel 
Drug (J.1M) 5Hz 10Hz n n 
Human 227c89 10 0.87 ± 0.03 4 0.75 ± 0.05 4 
Rat 227c89 10 0.94 ± 0.03 5 0.84 ± 0.02 5 
Human Ralfinamide 50 1.10 ± 0.09 3 0.95 ± 0.05 7 
Rat Ralfinamide 50 0.86±0.15 3 0.87 ± 0.08 8 
Human Tetracaine 0.86 ± 0.02 10 0.79 ± 0.02 20 
Rat Tetracaine 0.92 ± 0.04 6 0.85 ± 0.05 10 
Human VI02862 1 0.92 ± 0.03 5 0.73 ± 0.01 11 
Rat V102862 1 0.93 ± 0.04 5 0.78 ± 0.03 12 
Human A-803467 0.1 1.20 ± 0.06 6 1.17 ± 0.07 11 
Rat A-803467 0.1 1.11 ±0.10 4 0.98 ± 0.09 4 
5.2.5 Effects of drug block on the recovery from inactivation 
In order to further understand the use-dependent properties of compounds 227c89, 
ralfinamide, tetracaine, V102862 and A-803467, their effects on recovery from inactivation was 
studied. In these experiments, the same protocol as in Fig. 4.l0 (also shown in Fig. 5.11A) was 
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used before and after the application of test compound, in order to study the effect of the drug 
on the time course of recovery from inactivation. 
As discussed above in Chapter 4, the time course of recovery from inactivation for both 
human and rat Nav l.8 channels showed an initial fast component (time constant approx. lOms) 
followed by a slower component (time constant approx. 150ms). Compound 227c89 (lOJ.1M) did 
not affect recovery from inactivation (Fig. 5.IIA); the values for the fast and slow components 
of recovery were similar to those of the untreated cells (Figs. 5.l4 and 5.15, and Table 5.4). In 
contrast, ralfinamide (50JlM) and tetracaine (l0J.1M, Figs. 5.lIB and 5.l2A) slowed both the fast 
and slow time constants (Figs. 5.l4 and 5.l5 and Table 5.4), suggesting that these drugs 
stabilise both components of inactivation. Furthermore, ralfinamide and tetracaine decreased the 
fast component amplitude while they increased the amplitude of the slow component (Figs. 5.l4 
and 5.15 and Table 5.4). 
Compound Vl02862 (lJlM, Fig. 5.l2B), showed an additional slow component of recovery 
with increased current for human Nav 1.8, but not for rat Nav 1.8. Therefore, for the human 
Nav l.8 channel the curve was fitted with three exponential time constants (see Section 2.6.5). 
This increase in current is most likely due to a removal of drug block by stimulation, since the 
experiments were carried out in the continual presence of drug and the data includes resting 
channel block (58±2%; Table 5.l). The first exponential component was of small amplitude and 
the second component of recovery was slower and of greater amplitude in the presence of drug 
(Fig. 5.l2B and Figs. 5.l4,5.l5). The third component (due to the increased current) had 
amplitude 13 (see Section 2.6.5) of29.9±7.3% (taking the fully recovered total current as 100%) 
and a slow decay time constant of 1.1±O.2 seconds (Table 5.4). The increase in current 
amplitude above the control value may be a result of the removal of resting block from the 
channel, and the time course represents a slow reinstatement of resting block. 
Similarly to compound Vl02862, compound A-803467 (lOOnM, Fig. 5.l3) also showed a 
marked increase in current above the control value for the time course of recovery from 
inactivation. Indeed, the time course of recovery also required a three-exponential fit following 
the application of compound A-803467. For the first component, there was a small increase in 
the amplitude, while the time constant was unaltered by the drug (Fig. 5.l4). The second 
component showed little change in either amplitude or the time constant (Fig. 5.15). The third 
component showed an amplitude 13 of22.1±3.2% and time constant of 1.7±0.2 seconds. For A-
803467 (lOOnM), 49±9% of resting channels were blocked (Table 5.1), again indicating that the 
increased current may be due to an appreciable removal of the resting component, and its 
consequent time course is due to resting block returning. 
The removal of drug block observed following frequent stimulation and recovery from 
inactivation is an unexpected result and has not previously been observed for voltage-gated Na + 
channel blocking drugs. The term "disinhibition" will be used to describe this effect. 
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Fig. 5.11. The effects of 227c89 and ralfinamide on the time course of recovery from 
inactivation. A) Time courses are shown for human (e) and rat (0) Nay 1.8 channels in the 
absence of drug, and for human (A) and rat (~) Nayl.8 channels after the application of 227c89 
(l0flM) in paired cells. B) Time courses are shown for human (e) and rat (0) Nay 1.8 channels 
in the absence of drug, and for human (A) and rat (~) Nay 1.8 channels after the application of 
ralfinamide (50flM) in paired cells. The current amplitude during the test pulse was expressed as a 
fraction of the current amplitude during the control pulse, and plotted against the duration of the 
recovery period. The pulse protocol is shown in the inset of A. The curves were fit with a double 
exponential equation. The n numbers are shown in Table 5.3. 
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Fig. 5.12. The effects of tetracaine and VI02862 on the time course of recover)" from 
inactivation. A) Time courses are shown for human (e) and rat (0) Na\,1.8 channels in the 
absence of drug, and for human ( .. ) and rat (~) Nav 1.8 channels after the application of 
tetracaine (lOIlM) in paired cells. B) Time courses are shown for human (e) and rat (0) Nay l.8 
channels in the absence of drug, and for human ( .. ) and rat (~) Na\.l. 8 channels after the 
application of V 1 02862 (111M) in paired cells. The current amplitude during the test pulse was 
normalised as a fraction of the current amplitude during the control pulse, and plotted against the 
duration of the recovery period. The curves were fit with a two exponential components, except 
for the hNay1.8 channel in the presence ofV102862, \vhich was fit with three. The n numbers are 
shown in Table 5.3. 
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A-803467 (lOOnM) 
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Fig. 5.13. The effect of A-803467 on the time course of recovery from inactivation. Time 
courses are shown for human (e) and rat (0) Nay 1.8 channels in the absence of drug, and for 
human (A) and rat (.6.) Nay 1.8 channels after the application of A-803467 (lOOnM) in paired 
cells. The current amplitude during the test pulse was normalised as a fraction of the current 
amplitude during the control pulse, and plotted against the duration of the recovery period. The 
curves were fit with a two exponential components, except for the hNay1.8 channel in the 
presence of A-803467, which was fit with three. The n numbers are shown in Table 5.3. 
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RalfinamideTetracaine V102862 A-803467 
227c89 Ralfinamide Tetracaine V102862 A-803467 
Fig. 5.15. The effects of each drug on the parameters of the slow component of recovery. A) 
The bar diagram shows the fitted parameters for the slow component time constant, r slow'. for 
human (jilledbars) and rat (unfilled bars) Nay 1.8 channels. The parameters shown for each drug 
were normalised to the paired values before drug application. B) The bar diagram shows the fitted 
parameters for the slow component amplitude, 1510\\' for human (jilled bars) and rat (unfilled bars) 
Nay I. 8 channels. The parameters shown for each drug were normalised to the paired yalues 
before drug application. r slow is not shown for tetracaine (rat Na\.1.8 channel) in A due to large 
experimental errors. * p<O.05. The n numbers are shown in Table 5.3. 
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Fig. 5.14. The effects of each drug on the parameters of the fast component of recovery. A) 
The bar diagram shows the fitted parameters for the fast component time constant, r fast'. for 
human (jilledbars) and rat (unfilled bars) Nav 1.8 channels. The parameters shown for each drug 
were nonnalised to the paired values before drug application. B) The bar diagram shows the fitted 
parameters for the fast component amplitude, Ifast ' for human (filled bars) and rat (unfilled bars) 
Na\.1.8 channels. The parameters shown for each drug were nonnalised to the paired \"alues 
before drug application. * p<O.05. The n numbers are shown in Table 5.3. 
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TABLE 5.4 
Effects of dmgs on recovery from inactiration 
Nav1.8 Drug 
Concentration Recoyery from inactivation 
channel (1lM) !filst norm 1f3st norm !,Iow norm 1,Iow norm t3 (ms) I, lO 0) n 
Human 227c89 10 1.12 ± 0.25 1.00 ± 0.13 0.87 ± 0.48 1.06 ± 0.23 5 
Rat 227c89 10 0.76 ± 0.24 0.87 ± 0.07 0.82 ± 0.46 1.50 ± 0.49 3 
Human Ralfinarnide 50 2.14 ± 0.42 0.79 ± 0.05 0.99 ± 0.46 1.32 ± 0.28 5 
Rat Ralfinarnide 50 2.90 ± 0.86 0.82 ± 0.13 1.34 ± 1.06 1.29 ± 0.20 ~ 
Human Tetracaine 10 1.74 ± 0.20 0.90± 0.07 5.46 ± 1.80 1.24 ± 0.20 6 
Rat Tetracaine 10 1.89 ± 0.29 0.53 ± 0.06 15.9 ± 9.3 2.40 ± 0.27 3 
Human VI02862 -0.29 ± 0.04 1.21 ± 0.46 4.64 ± 0.66 1073 ± 232 29.9 ± 7.3 5 
Rat VI02862 0.1l± 0.24 3.63 ± 3.60 2.91 ± 0.52 6 
Human A-803467 0.1 0.90 ± 0.20 1.06 ± 0.11 0.50 ± 0.27 1.92 ± 0.41 1668 ± 183 22.1±3.2 5 
Rat A-803467 0.1 0.91 ± 0.51 1.20 ± 0.11 0.25 ± 0.26 1.12 ± 0.34 ~ 
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5.3 Discussion 
5.3.1 Tonic block a/resting and inactivated NarI8 channels 
In this chapter the properties of compounds 227c89, A-803467, ralfinamide, tetracaine and 
VI02862 were compared between human and rat N av 1. 8 channels. Experiments were carried 
out such that protocols were as short as possible, to reduce effects of whole-cell patch clamp 
holding time on the functional properties of the Nav1.8 channels. For the resting state, the 
compounds tested showed drug affinities in the order ralfinamide < 227c89 < tetracaine < 
V I 02862 < A-803467 for both human and rat Nav 1.8 channels, although tetracaine and 
V102862 showed an approximately 2-fold greater affinity for resting human Nav 1.8 channel 
compared to the rat Nav 1.8 channel. The binding affmity for inactivated channels was higher 
than for resting channels for all drugs studied, suggesting they all preferentially act on 
inactivated channels. Affinities for the inactivated state showed the same drug order as for 
resting channels for both human and rat Nav 1.8 channels. Compound A-803467 showed an 
approximately 3-fold greater affmity for the inactivated human Nav 1.8 channel than for the 
inactivated rat Nav 1.8 channel. The affinity for the inactivated human Nav 1.8 channel was 5- to 
9-fold greater than for the resting channel, whereas the affinity for the inactivated rat Nav 1.8 
channels was 4- to 18-fold greater than for the resting channel. These results suggest differences 
in the state-dependent properties of these drugs acting on the human and rat Nav 1.8 channels, 
where a wider range of drug selectivity for the inactivated state over the resting state was shown 
for rat Nav 1.8 compared to human Nav 1.8. For instance, a much greater differential between 
block of resting and inactivated channels was shown for rat Nav 1.8 for tetracaine (l7-fold) and 
V102862 (19-fold) compared to the human channel for tetracaine (9-fold) and VI 02862 (5-
fold). Conversely, compound A-803467 showed a smaller differential between block of resting 
and inactivated channels for the rat Nav 1.8 channel (4-fold) compared to the human Nav 1.8 
channel (8-fold). Following the stable expression of rat Nav 1. 8 in ND7/23 cells, John et al. 
(2004) determined the concentration for half-maximal inhibition (lC50) of tetracaine for resting 
states (holding potential -90m V) as 13 ~M, which is comparable to the value determined in this 
chapter (27~M) for the resting rat Nav1.8 channel. 
Dekker et al. (2005) showed that tetracaine is 16-fold more potent for human Nav 1.8 
channels than for rat Nav 1.8 channels stably expressed in SH-SY5Y cells. At first sight this 
would appear to contradict the results of this chapter (a 2-fold difference in the affinity for 
resting human and rat Nav 1.8 channels, and near-identical affmities for the inactivated Nav 1.8 
channels). However, in the membrane potential fluorescence assay used by Dekker et ai., the 
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cells are not voltage clamped and are at resting membrane potentials of the neuroblastoma SH-
SY5Y cells. Since human Nav 1.8 displays a significantly more depolarised inactivation curve 
compared to rat Nav 1.8 channels (Chapter 4), at resting membrane potentials human Nav 1.8 
will be substantially more inactivated and able to bind tetracaine with higher affinity compared 
to rat Nav 1.8. This would explain the apparent higher selectivity for human Nav 1.8 observed by 
Dekker et aI., since many channels would be inactivated at these resting membrane potentials. 
Moreover, the latter authors also reported an IC50 value of 10JlM for ralfinamide. This value is 
also consistent with the substantial inactivation of human Nav 1.8 compared to rat Nad.8 since 
it was similar to the human Nav1.8 inactivated state dissociation constant (l5J.1M), but not the 
resting dissociation constant (l25JlM). Similarly, the IC50 value for ralfinamide binding to the 
rat Nav 1.8 channel determined by Dekker et al. (55JlM) is intermediate between resting 
(127 J.1M) and inactivated (1 0J.1M) dissociation constants, consistent with less inactivation of the 
rat channel at the membrane potentials used. Therefore these results indicate that the 
measurements made by Dekker et al. using a membrane potential fluorescence assay largely 
represent binding to the substantially inactivated human Nav 1.8 channel as compared with the 
rat Nav 1.8 channel. Furthermore, in agreement with the value for ralfinamide binding to 
inactivated rat Nav 1.8 channels determined in this chapter (1 0J.1M), Stummann et al. (2005) 
reported an IC50 value of 10JlM for ralfinamide binding to inactivated rat TTX-resistant 
channels. These findings are consistent with the findings here and exemplify the necessity to 
control the membrane potential for the investigation of voltage-dependent blocking drugs. 
It is also interesting to compare the inactivated state binding affinity data for Nav 1. 8 
channels with data in the literature for other Nav channel subtypes. Compared to the inactivated 
state binding affinity of tetracaine for the rNav1.3 channel (Ki 6.3 JlM; Li et aI., 1999), the 
human Nav 1.8 channel showed a 6-fold greater affinity and the rat Nav 1.8 channel showed 4-
fold greater affmity. Subtype-selectivity was also observed for compound V102862, where both 
human and rat Nav 1.8 channels showed a 4-fold greater inactivated state affinity than for 
rNav 1.2 channels (Ki 0.4J.1M; Ilyin et aI., 2005). Furthermore, the affinity of compound A-
803467 for human Nav 1.8 was similar to the IC50 reported by Jarvis et al. (2007) for the same 
channel. The latter authors showed an approximate 100-fold greater affinity for human Nav 1.8 
than for hNav 1.2, hNav 1.3, hNav 1.5 and hNav 1.7. Consistent with the results described here, 
Jarvis et al. also reported a greater inactivated state affinity of A-803467 for human Nav 1.8 
channels, as compared with rat TTX-resistant Na+ currents. The results here for ralfinamide are 
also consistent with those of Stummann et al. (2005), and suggest a 2-fold greater affinity for 
Nav1.8 channels as compared with TTX-sensitive Na+ channels. In contrast, compound 227c89 
showed an inactivated state binding affinity for rat Nav 1. 2 channels (Ki 17.3 j.1M; Liu et aI., 
2003), similar to the value shown for human and rat Nav 1.8 channels. 
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The binding affinity of a compound depends on the relative strengths of interaction with 
accessible amino acid residues in the binding site. The drugs studied here are expected to 
interact with previously identified amino acid residues of the pore-lining S6 segments (Catterall. 
2002~ Nau and Wang, 2004). However, the greater affinity of tetracaine, V102862, A-803467 
and ralfinamide for Nav 1.8 over other channel subtypes indicates differences in relatiye 
strengths of binding to these residues. Despite the near identity of these residues in the S6 
segments, interactions must somehow differ between Nav subtypes, and indeed between human 
and rat Nav 1.8 channels. It is also possible that because the properties of the first and second 
components of recovery from inactivation are also different between human and rat Na\-1.8 
channels (first component slower for human and vice versa, second component faster for 
human, see Chapter 4) the relative drug binding affinity to the kinetically distinct inactivation 
states may be different. It has been reported that there can be differences in drug affmity (and 
hence drug action) between slow and fast inactivated channels (Cardenas et aI., 2006). For 
example, lacosamide appears to interact with slow (rather than fast) inactivation states ofTTX-
sensitive Nav currents (Errington et aI., 2008). Furthermore, the more pronounced frequency-
dependent block for Nav 1.8 channels by lidocaine compared to TTX-sensitive channels was 
explained by the greater tendency for Nav 1.8 to enter slow inactivation states (Leffler et at, 
2007). 
In summary, the block of inactivated channels was greater than for resting channels for all 
drugs studied, and differences in the drug binding affinities were observed between human and 
rat Nav 1.8 channels, and also between Nav 1.8 and other subtypes in the literature. 
5.3.2 The effect of drugs on Nad.8 channel recovery from inactivation 
In the continual presence of compounds 227c89, tetracaine and ralfinarnide, the recovery 
from inactivation was fitted with two exponential components. While 227c89 did not appear to 
affect the recovery from inactivation, both tetracaine and ralfinamide slowed the fast and slow 
components of inactivation and increased the amplitude of the latter. These results suggest that 
tetracaine and ralfmarnide stabilise the inactivation states of human and rat Nay 1.8 channels. 
Following the application of compound V102862 or A-803467 a striking and unexpected 
effect was observed for the human Nav 1.8 channel during recovery from inactivation. Recovery 
involved not simply the removal of inactivation, but also a period where resting drug block was 
apparently removed, and the current amplitude of the test pulse became greater than control, 
termed "disinhibition". The time course of recovery from inactivation was fitted with an 
additional slow component representing this disinhibitory component. The compounds that 
showed this effect for the human Nay 1.8 channel (V 1 02862 and A-803467) were also the most 
potent Nav 1.8 channel blockers studied. For rat Nay 1.8 channels, the effect was not obseryed in 
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the presence ofV102862, and only to a small extent in the presence of A-803467. Furthermore, 
this phenomenon has never been reported for any Nav blocking drugs acting on any Nav 
channel subtype, for example it was not observed for rat Nav 1.2 channels in the presence of 
compound VI02862 (Ilyin et aI., 2005). 
Since disinhibition by compounds A-803467 and V 102862 was not observed for rat Nay 1.8, 
but was observed for human Nav1.8 channels, this suggests that the binding of these compounds 
is different between the two channels under these conditions. The reason for the difference is 
unclear, but both compounds A-803467 and V102862 have differential drug binding affinities 
between the two channels for the inactivated and resting states respectively. 
5.3.3 The effect of drugs on repetitive stimulation 
Lamotrigine derivative 227c89 was found here to show marked use-dependent block at 
10Hz. The extent of227c89 (lOJlM) block at the end ofa 10Hz train observed here (approx. 
20%) is similar to the extent described for the much greater concentration of227c89 (300JlM) 
acting on the rat Nav 1.2 channel during a 10Hz train (approx. 20%). Although it is difficult to 
compare results where different experimental conditions have been used, these obsevations 
suggest that use-dependent block by 227c89 is more pronounced for Nav 1.8 channels than for 
Nav 1.2 channels. It would be interesting to test whether use-dependent block by 227c89 is 
indeed greater for Nav 1.8 channels than for Nav 1.2 channels, and whether this underlies the 
basis for the analgesic properties of compound 227c89. 
In the presence of ralfinamide the human and rat Nav 1.8 channels showed very little use-
dependent block during 5Hz or 10Hz stimulation. This finding is in contrast with the marked 
use-dependent inhibition reported for the same concentration of ralfmarnide at 5Hz stimulation 
in rat TTX-resistant Na+ currents (Stummann et aI., 2005). However, the latter authors used 
40ms test pulses (rather than the 10ms test pulses used here), which may allow more drug to 
bind during the depolarisation. 
Tetracaine showed marked use-dependent block for both human and rat Nay 1.8 channels at 
10Hz with relatively slow onset. Compared to the results here, the extent of use-dependent 
block of the rat Nav 1.8 channel by tetracaine was more pronounced in a previous study (John et 
aI., 2004). This may be explained by the use of a higher (3-fold) concentration of tetracaine. 
Compound A-803467 is a potent and highly selective blocker ofNav 1.8 channels and has 
been shown to reduce pain in certain rat models of hyperalgesia and allodynia (Jarvis et al., 
2007). Use-dependent inhibition was not observed here for compound A-S03467 at 10Hz for rat 
Na\.I.S channels (as also found for rat TTX-resistant Na+ currents, Jarvis et aI., 2007), this 
suggests that the physiological action of A-803467 is by tonic rather than use-dependent block; 
Nav 1.S channels in sensory neurons would not be inhibited based on their excitability (use-
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dependent block) but rather in sensory neurons that are more depolarised (tonic block). 
However, for the human Nav 1.8 channel in the presence of A-803467, the observed 
disinhibition during the recovery from inactivation would be expected to also increase the 
current following frequent stimulation. Indeed, at 10Hz stimulation a "reverse use-dependence" 
was observed as an increase in current above the control values. This is consistent with a 
supplementary data of a previous report, which suggests a small increase in current (Jarvis et al. 
2007). This suggests that when physiological frequencies are of this order (Kajander and 
Bennett, 1992), compound A-803467 would show disinhibition, and thus may be less effective 
than anticipated for humans. 
For compound V102862, although recovery from inactivation showed a disinhibition of 
current for human Nav 1.8, no increase in current over the control value was observed during 
5Hz or 10Hz stimulation frequencies. The absence of "reverse use-dependence" may be 
explained by the observation that disinhibition in the presence ofVI02862 is prevalent at longer 
periods of recovery than in the presence of A-803467. For instance, a 10Hz train of IOms 
depolarising pulses includes a 90rns recovery period between pulses, at which the component of 
disinhibition is too small, indeed only inhibition was observed at 10Hz (Fig. 5.8). However, a 
5Hz stimulation frequency (including a 190ms recovery period between pulses); there was an 
apparent component of disinhibition that partially compensated the background inhibition 
leading to almost no inhibition. Thus the magnitude of the disinhibitory component determines 
the extent of the use-dependent block for compound V102862, and explains the pronounced 
use-dependent block observed at 10Hz and apparent absence of use-dependent block observed 
at 5Hz. Therefore when action potential firing frequencies are in the higher range during pain 
conditions (Kajander and Bennett, 1992), this property is likely to be important for the 
frequency-dependent inhibition of excitable sensory neurons. One highly interesting prediction 
may be that at lower stimulation frequencies (perhaps 2Hz), current disinhibition would be 
observed for V102862, as for the longer periods of recovery. Indeed, disinhibition of resting 
block at low firing frequencies, but pronounced use-dependent block at higher frequency firing 
nerve fibres would be highly desirable for an effective drug for use in the treatment of pain 
arising from hyperexcitability. 
5.3.4 Mechanisms for the current disinhibition effect 
In cases where disinhibition occurs, the initial control value in the experiments carried out 
here includes a component of resting channel drug block. The observed increase in current at 
certain periods of recovery from inactivation is likely due to the removal of drug block from 
resting channels. Indeed, the current amplitude of disinhibited current did not exceed the current 
amplitude of channels before resting block. Although the mechanism for this phenomenon is not 
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clear, it seems likely that in the presence of certain drugs, recovery involves dissociation of drug 
from the resting state and/or shift in equilibrium toward the unblocked resting state. While at 
first glance this might seem to contradict the finding that both V102862 and A-803467 have 
higher affinities for the inactivated state than the resting state, the disinhibitory state may occur 
just after recovery from the inactivated states, and seemingly not while the channels are in the 
same higher affinity state. This model would suggest the additional slow component during 
recovery represents the reinstatement of resting block after the initial depolarisation in the 
presence of drug. An alternative mechanism for this effect might be that the presence of drug 
causes the induction of new states, with a greater single channel conductance or open 
probability, explaining the increase in current amplitude. Thus, there appears to be at least two 
possible mechanisms to explain the increase in current amplitude during recovery from 
inactivation in the presence of certain drugs: the dissociation of drug from resting channels, or 
perhaps less likely, the modification of single channel conductance. The study of single Nav 1.8 
channels would provide more understanding of the mechanism leading to disinhibition. 
In summary, all drugs studied here showed a greater affinity for the inactivated state than for 
the resting state, suggesting preferential tonic block of inactivated channels. Compounds A-
803467 and VI02862 were the most potent, and the inactivated state affinity of A-803476 was 
greater for human Nav1.8 than for rat Nav1.8 channels. Furthermore, tetracaine, V102862, 
ralfinamide and A-803467 block of inactivated Nav 1.8 channel appears more potent than for 
TTX-sensitive subtypes in the literature. Unexpectedly, the time course of recovery from 
inactivation showed an increase in current in the presence ofV102862 and A-803467, perhaps 
due to disinhibition of resting block. For A-803467, this led to an increase in current during 
high frequency repetitive stimulation. For VI02862, while low frequency stimulation showed 
no inhibition, high frequency stimulation showed marked inhibition. This supports the 
suggestion that VI02862, rather than A-803467, may be useful as an analgesic where 
physiological firing frequencies are higher. Indeed, despite 83% identity and highly homologous 
S6 segments (Fig. 4.1), the human and rat Nav 1.8 channels show differences in the tonic block 
of resting and inactivated channel states, and use-dependent block with a range of anti-
nociceptive agents. The structural determinants for drug block will be studied in the next two 
chapters. 
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CHAPTER 6 
FUNCTIONAL PROPERTIES OF S6 SEGMENTS 
MUTATIONS OF NavI.8 SODIUM CHANNELS 
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6.1 Introduction 
The generation and propagation of action potentials in excitable cells is largely influenced by 
the voltage-dependent gating mechanisms of voltage-gated Na+ channels. The pore-lining S6 
segments are thought to be involved in conformational changes leading to channel opening and 
inactivation (Jiang et aI., 2002; Nau and Wang, 2004; Perozo et aI., 1999; Yellen, 1998). 
Compared to other voltage-gated Na+ channel subtypes, the Nav 1.8 channel has distinct 
activation and inactivation properties, contributing to its role in action potential electrogenesis 
III sensory neurons. 
While the role of the S6 transmembrane segments in the functional properties and drug 
action is well established for other voltage-gated Na + channel subtypes, and the key residues in 
the S6 segments for drug action have been identified (see Chapter 1), the corresponding 
residues for the Nav 1.8 channel subtype have not been addressed (Fig. 6.1 and 6.2). In this 
chapter, the activation and inactivation properties of mutant human and rat Nay 1.8 channels 
containing alanine substitutions at the corresponding key positions in the S6 segments were 
investigated. As in previous chapters, N av 1.8 channels were expressed in ND7/23 cells and the 
functional properties were examined using whole-cell patch clamp. 
6.2 Results 
6.2.1 Effects on the voltage-dependence of activation by Nad.8 channel mutations in 
the S6 segments 
Using site-directed mutagenesis, seven key S6 segment amino acid residues of the human and 
rat Navl.8 channels were mutated to alanine (Chapter 3) and expressed in ND7/23 cells. 
Whole-cell currents were recorded in the presence of TTX (200nM), and currents were elicited 
using test pulses from a holding potential of -120mV for human Nav1.8, and a holding potential 
of -80m V for rat Nav 1.8. To examine the effects of alanine mutations on the functional 
properties of rat Nav 1.8 mutations, a holding potential of -80m V was used to study 
physiologically relevant closed and inactivation states. However, due to the relatively 
hyperpolarised inactivation of human Nav1.8 channels, the human Nad.8 mutations were 
recorded from a holding potential of -120mV. The macroscopic currents for human Nad.8 
channel mutations I38lA, N390A, L1410A, V1414A, 11706A, F1710A and Y17l7A, and for 
rat Navl. 8 channel mutations I380A, N389A, L14l1A, V1415A, 11707 A, Fl711A and Y1718A 
are shown in Figures 6.3 and 6.4. 
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Fig. 6.2. Positions of mutated residues of S6 segments in domains I, III and IV. The S6 
segment residues of domain I, III and IV are shown, with the mutated residues in red. 
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For both human and rat N av 1. 8 channel mutations, the 1-V curves showed similar reyersal 
potentials to wild type channels, showing that the ion selectivity was not altered by the 
substitution of amino acid to alanine (Fig. 6.5). However, the voltage for the maximum current 
(lrnax) appeared to be different for a number of mutations of the human and rat Nav 1.8 channels. 
Accordingly, the G-V curves show both hyperpolarising and depolarising shifts for mutant 
human Nav 1.8 channels compared to the wild type human Nav 1.8 channel, while mutant rat 
Nav 1.8 channels showed only depolarising shifts compared to the wild type channel (Fig. 6.6). 
These effects were studied in detail by comparing the Boltzmann parameters for activation. For 
the human N av 1. 8 channel, a 9m V shift to more depolarised potentials was observed for 
mutations N390A and V1414A, while mutations I381A and F1710A showed hyperpolarised 
shifts by 5mV and 7mV respectively (Fig. 6.7A, Table 6.l). In contrast, the VI2 for activation 
was unaffected by human Nav 1.8 mutations L1410A, I1706A and Y1717A. For the rat Nav1.8 
channel, mutations 11707 A and Y 1718A showed depolarised shifts in the activation curve (8m V 
and 7mV respectively), and even greater depo1arising shifts were observed for mutations 
N389A, L1411A and V1415A (20mV, 21mV and 15mV respectively, Fig 6.7B, Table 6.1). 
However, the VI2 for activation was unaffected by mutations I380A and F 1711A. The slope of 
the activation was slightly steeper for human Nav1.8 channel mutations N390A and F1710A, as 
shown by a small (but significant) decrease in the kvalues (2 and 1mV, respectively) (Figs. 
6.6A and 6.7A, Table 6.1). The rat Nav1.8 mutations L1411A and Il707A also slightly affected 
the slope, showing a small increase (2 and 3mV respectively) in the kvalue (Figs. 6.6B and 
6.7B, Table 6.1). The maximum conductance (Gma,) was significantly decreased by human 
Nav1.8 channel mutations I381A, L1410A, Il706A, F1710A and Y1717A, and increased by 
mutation N390A, (Fig. 6.7 A, Table 6.1). F or rat Nav l. 8, only mutation F 1711 A altered the Gmax, 
showing a significant decrease in its value (Fig. 6.7B, Table 6.1). It is not possible to explain 
these changes in the Gmax without recording from single channels. 
TABLE 6.1 
Voltage-dependent activation and inactivation of human and rat Sa v 1. 8 sodium channel S6 mutations 
Activation Inactivation 
Nay1.8 channel 
Vl/o (mV) k (mV) Gmax(nS) ylo (mY) k (mV) B (nA) A(nA) n n 
hNav1.8 WT -2.7 ± 0.8 14.7 ± 0.3 61.9 ± 4.6 79 -79.9± 1.0 10.5 ± 0.4 1.8 ± 0.2 0.12±0.01 84 
hNav1.8I381A -8.0± 1.1 14.2 ± 0.4 34.6 ± 2.5 50 -94.0± 1.1 9.6 ± 0.5 1.3 ± 0.2 0.07 ± 0.01 13 
hNav1.8 N390A 5.8 ± 0.9 12.7±0.2 89.4± 10.2 52 -87.2 ± 1.0 9.7 ± 0.3 2.0 ± 0.5 0.10 ± 0.01 1~ 
hNav1.8 Ll410A -0.2 ± 1.7 14.5 ± 0.6 27.2 ± 2.1 31 -95.7 ± 2.2 6.4 ± 0.4 0.9 ± 0.2 0.08 ± 0.02 6 
hNav1.8 V1414A 6.0 ± 1.0 14.8 ± 0.3 57.6 ± 4.9 58 -86.4± 1.3 9.7 ± 0.7 1.5 ± 0.2 0.09 ± 0.01 25 
hNav 1.811706A -1.4 ± 1.4 15.2 ± 0.4 27.3 ± 2.4 38 -89.5 ± 2.8 9.9 ± 0.9 0.9 ± 0.2 0.09 ± 0.02 12 
hNa..,.1.8 Fl710A 
-9.3 ±0.9 13.7 ± 0.3 43.1 ± 3.8 45 -77.9± 1.7 10.1 ± 0.8 1.5 ± 0.3 0.17±0.04 18 
hNay1.8 Y1717A -0.5 ± 1.3 15.5 ± 0.4 36.4 ± 2.8 54 -104±3 15.6 ± 1.2 1.2 ± 0.2 0.20 ± 0.05 I~ 
rNa..,. 1. 8 WT -1.6 ± 0.9 10.3 ± 0.3 61.2 ± 6.0 41 -5-.9± 1.0 7.6 ± 0.2 2.3 ± 0.2 0.03 ± 0.01 38 
rNay1.8I380A 1.4 ± 1.6 9.9 ± 1.0 62.2 ± 14.1 8 -6c.5 ± 2.8 8.1 ± 0.2 2.9 ± 0.3 0.12±0.05 5 
rNav1.8 N389A 18A ± 1.3 10.0 ± 0.6 66.5 ± 10.5 10 -58.2±.U 8.5 ± 0.6 0.- ± 0.2 ~ 
rNa..,. 1. 8 Ll411A 18.9 ± 2.2 12.7 ± 1.1 39.1 ± 14.8 5 -67.6 ± 0.9 7.2 ±OA 0.6 ± 0.2 0.03 ± 0.01 ~ 
rNa..,. 1. 8 V1415A 13.5 ± 1.9 11.6 ± 0.8 57.7 ± 12.3 9 -57.5 ± 2.3 6.9±0.4 0.9 ± 0.2 0.03 ± 0.02 7 
rNav 1.811707A 6.6 ± 2.5 12.5 ± 0.5 44.7±1O.3 6 -65.2 ± 1.6 6.6 ± 0.9 1.1 ± 0.3 0.06 ± 0.02 4 
rNa..,.1.8 Fl711A 0.6 ± 1.9 11.5 ± 0.6 28.9 ± 6.5 15 -53.7 ± 3.1 8.3 ± 0.3 1.1 ± 0.4 6 
rNay1.8 YI718A 5.3 ± 1.5 10.8 ± 0.6 49.3 ± 10.4 12 70.3 ± 2.6 10.8 ± 0.9 'A± 0.6 8 
Wild type hNav 1.8 
lnAL 
2ms 
Mutant N390A hNav1.8 
200pAL 
2ms 
Mutant V1414A hNav 1.8 
200pAL 
2ms 
Mutant F1710A hNav 1.8 
lnAL 
2ms 
137 
Mutant I381A hNav 1.8 
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Mutant I1706A hNav l.8 
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Mutant Y1717A hNav1.8 
200pAL 
2ms 
Fig. 6.3. Mutant human Na,,1.8 channel current traces recorded from ND7/23 cells. Example 
current trace are shown for ND7/23 cells transfected with wild type or mutant hNav 1.8 channel 
cDNA in the presence of 200nM TTX. Currents were elicited for voltage steps to -100m V to 
+6OmV (in 10mV increments) from a holding potential of -120mV. 
Wild type rNay1.8 
500pAL 
2ms 
Mutant N389A rNay l.8 
500pA L 
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Mutant V1415A rNay 1.8 
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Mutant L1411A rNay l.8 
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Mutant Y1718A rNay1.8 
200pA L.-
2ms 
Fig. 6.4. Mutant rat Nay1.8 channel current traces recorded from ND7/23 cells. Example 
current trace are shown for ND7/23 cells transfected with wild type or mutant rNav 1.8 channel 
cDNA in the presence of 200nM TTX. Currents were elicited for voltage steps to -100m V to 
+60mV (in IOmV increments) from a holding potential of -80mV. 
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Fig. 6.5. Current-voltage relationships for human and rat Nay 1.8 channel mutations. A) 
Current-voltage relationships are shown for the peak current for human Nav l.8 channels 
normalised to the maximum current, Imax. The Imax was obtained separately from the current-
voltage relationship recorded from each cell. Relationships are shown for wild type (.), and 
mutations I381A (e), N390A (~), L1410A (~), V1414A (D), Il706A (0), F1710A (~) and 
Y1717A C\7). B) For rat Nav1.8 channels, relationships are shown for wild type (.), and 
mutations I380A (e), N389A (~), L1411A (~), V1415A (D), Il707A (0), F1711A (~) and 
Y1718A (\7). The n numbers are given in Table 6.1. 
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Fig. 6.6. Conductance-voltage relationships for human and rat Nav1.8 channel mutations. A) 
The conductance-voltage curves are shown for human Nav1.8 channels; wild type (_), and 
mutations 1381A (e), N390A (.), L1410A C~), V1414A (D), Il706A (0), F1710A (~) and 
Y1717A (\7). B) Conductance-voltage curves are shown for rat Nay1.8 channels; wild type (_), 
and mutations 1380A (e), N389A (.), L1411A C~), V1415A (D), Il707A (0). F1711A (~) 
and Y1718A (\7). The n numbers are given in Table 6.1. 
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Fig. 6.7. The effects of mutations on the Boltzmann parameters for activation. Bar diagrams 
show the voltage for half-maximal activation (VI 2)' the slope factor (k) and maximum 
conductance (G
max
) for mutations of human (A) and rat (B) Nav1.8 channels. * indicates a 
statistically significant difference from wild type channels p<O.05. The n numbers are given in 
Table 6.1. 
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6.2.2 Effects on the voltage-dependence o/inactivation by Navl.8 channel mutations ill 
the S6 segments 
The inactivation properties of the alanine mutations were firstly studied by examining the 
voltage-dependence of inactivation. The current amplitude was measured during a test pulse 
using the protocol shown in the inset of Fig. 6.8, from a holding potential of -120mV for human 
Nav 1.8, and -80m V for rat Nav 1.8. The steady-state inactivation curves show that a number of 
human and rat Nav 1.8 mutations gave strong hyperpolarising shifts (Fig. 6.8). Human Nav 1.8 
mutations N390A, V1414A and Il706A showed significant hyperpolarising shifts (7 to lOmV), 
and even greater hyperpolarising shifts were observed for human Nay 1. 8 mutations I38lA, 
L14l0A and Y17l7 A (14 to 24mV) (Figs. 6.8A and 6.9A, Table 6.1). For the rat Nay 1.8 
channel, mutations I380A, L141lA, Il707A and Y1718A showed hyperpolarising shifts in the 
range of7 to 12mV (Figs. 6.8B and 6.9B, Table 6.1). 
Most ofthe mutants did not affect the slope parameter, k (Fig. 6.9, Table 6.1). However, 
human Nay1.8 mutation L1410A gave a steeper slope (4mV decrease in the kvalue), and 
mutation Y1717 A showed a less steep slope (5mV increase in the k value) (Figs. 6.8A and 
6.9A, Table 6.1). Rat Nav 1.8 mutation Y 17l8A also showed a less steep slope (3m V increase in 
the k value) (Figs. 6.8B and 6.9B, Table 6.1). 
F or human Nay 1. 8, mutations II 706A, F 1 71 OA and Y 1717 A (all located in the IVS6 
segment) showed less inactivation at positive potentials compared with the wild type channel 
(inactivation curve parameter, A, see Section 2.6.3). In the human Nay 1.8 channel the fraction of 
non-inactivated current remaining during strong depolarisation (parameter AlB, see Chapfer 2) 
was 1.7-fold greater for mutation Il706A and F1710A and 2.3-fold greater for Y1717A 
compared to the wild type channel (Fig. 6.9). The remaining human Nay 1.8 channel mutations 
(I38lA, N390A, L1410A and V1414A) did not affect the fraction of non-inactivated current. 
For the rat Nay 1.8 channel, although there were some increases in the fraction of non-
inactivated current, they were not statistically significant. 
Taken together, these results suggest that in addition to their role in voltage-dependent 
activation, residues of the S6 segments also appear to be important for the voltage-dependent 
inactivation ofNa\·1.8. 
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Fig. 6.S. Voltage-dependence of inactivation for human and rat Navl.S channel mutations. 
A) Curves are shown for the peak current for human Na\.1.8 channels; wild type (_), and 
mutations 1381A (e), N390A (~), L1410A (T), Vl414A (0), Il706A (0), F1710A (.~) and 
Y1717 A ('\7). The pulse protocol is shown inset. For a number mutations, voltage steps to more 
hyperpolarising potentials were required. B) Curves are shown for the peak current for rat N av 1.8 
channels; wild type (_), and mutations 1380A (e), N389A (A), L1411A (T), V1415A (0), 
Il707A (0), F1711A (~) and Y1718A Cv). Currents were normalised to the maximum current 
(parameter B, see Chapter 2). The n numbers are given in Table 6.1. 
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Fig. 6.9. The effects of mutations on the Boltzmann parameters for inactivation. Bar 
diagrams show the voltage for half-maximal activation (VI J, the slope factor (k) and the 
amplitude of the non-inactivated component normalised to the maximum current (AI B) of human 
(A) and rat (B) Na\J.8 channels. The AlB ratio for mutations I380A, N389A, F1711A and 
Y 1718A was too small to be measured accurately. * indicates a statistically significant difference 
from wild type channels p<O.05. The n numbers are given in Table 6.l. 
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6.2.3 Effects on the entry into open-inactivated states by Nar1.8 channel mutations in 
the S6 segments 
The example current traces shown in Figures 6.3 and 6.4 suggest that the rate of inactivation 
is faster for most Nav1.8 mutations compared to the wild type channels. Therefore the current 
decay phase was fitted with an exponential equation in order to determine the time constant for 
inactivation (fJ The current elicited at Om V decayed with a significantly smaller r
1 
indicating 
faster inactivation for most human and rat Na\·1.8 mutations studied compared to the wild type 
channels (Figs. 6.10 and 6.11, Table 6.2). For human Nav1.8, mutations I381A, L141OA, 
V1414A, Il706A F1710A and Y1717A showed ri values that indicate faster inactivation 
compared to the wild type channel (2.0-, 2.6-, 2.2-, 2.0-, 1.6- and l.4-fold faster inactivation 
respectively). Furthennore, while human Nav 1.8 mutation N390A did not show a significant 
difference in the fi value at Om V, at 10m V it showed faster inactivation. For rat Na\·1.8, 
mutations N390A, 11707 A and Y 1 718A showed fj values, which indicate 1.3- and 1.9-fold 
faster inactivation respectively. The N390A mutation in rat Nav 1.8 showed a 1.8-fold larger r1 
value at OmV. These results suggest that human Nav1.8 S6 segment mutations I381A, L141OA, 
V1414A, Il706A, F1710A and Y1717A and rat Nav1.8 mutations Il707A and Y17l7A studied 
here enter inactivated states from open states faster than the wild type Na\·1.8 channels, while 
rat Nav 1.8 mutation N389A appeared to slow this transition. 
6.2.4 Effects on the recovery from inactivation by human Nav1.8 channel mutations in 
the S6 segments 
The time course of recovery from inactivation for the mutant human Nav 1.8 channel were 
detennined as described for the wild type channel in Chapter 4. The recovery from inactivation 
time courses were fitted with two exponential components and the mean curves for wild type 
human Nav 1.8 and the L1410A mutant are shown in Figure 6.12. The parameters of the fits are 
shown for all human Nav 1. 8 mutations in Figure 6.13. For wild type, the initial component 
showed a time constant (ffast) of 10ms and a later component (rslow) of l30ms (Figs. 6.12 and 
6.13). For the initial component, ffast was unaltered for human Nav 1.8 mutations N390A, 
V1414A and F1710A (Fig. 6.13A, Table 6.2). However, ffast was significantly larger for 
mutations I381A, L1410A, Il706A and Y1717A (Fig. 6.13A). For the slow component, all 
mutations showed a similar time constant, fslow, with the exception of a larger value for mutation 
Il706A (Fig. 6.l3B, Table 6.2). 
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Fig. 6.10. Voltage-dependence of the inactivation time course for human and rat Nay1.8 
mutations. The time constant of inactivation, 7: j, is shown at each test potential, T '. A) Curves are 
shown for human Nav1.8 channels; wild type (_), and mutations I381A (e), N390A (.). 
Ll410A (~), V1414A (D), 11706A (0), F1710A (.6.) and Y1717A ('\7). B) Curves are shown 
for rat Nav1.8 channels; wild type (_), and mutations I380A (e), N389A (.). L1411A (T). 
V1415A (0),11707 A (0), F 1711A (.6.) and Y1718A ('\7). The n numbers are given in Table 
6.2. 
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Fig. 6.11. The effects of mutations on the inactivation time constant. Bar diagrams show the 
time constant for inactivation of currents elicited with a step to Om V for mutations of human (A) 
and rat (B) Na
v 
1.8 channels. * indicates a statistically significant difference from wild type 
channels p<O.05. The n numbers are given in Table 6.2, and the values shown here are from the 
same data as in Fig. 6.10. 
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Fig. 6.12. Recovery from inactivation for wild type and L1410A human Nav1.8 channels. 
Time course for the recovery from inactivation for wild type (e) and L1410A (0) human Na\"1.8 
channels is shown. The pulse protocol is shown inset. The curve was fit with a double exponential 
equation. The n numbers are given in Table 6.2. 
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Fig. 6.13. The effects of mutations on the recovery from inactivation. A) Bar diagrams are 
shown for the fitted parameters for the fast component, showing time constant, r fast' and its 
amplitude, lfast, for wild type and mutant Navl.8 channels. B) Bar diagrams are shown for the 
fitted parameters for the slow component, showing time constant, r slow' and its amplitude, 1.,low, 
for wild type and mutant Nay l.8 channels. * indicates a statistically significant difference from 
wild type channels p<O.05. The n numbers are given in Table 6.2. 
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6.2.5 Effects on the use-dependent current inhibition by NarI8 channel mutations in the 
S6 segments 
Experiments were carried out with repetitive stimulation at 10Hz to investigate use-
dependent current inhibition of the mutant human Nad.8 channel currents. While mutations 
N390A and L1410A showed slightly more pronounced (4-5%) current inhibition than for wild 
type channel, less current inhibition was observed for mutations V1414A and F1710A (also 4-
5%, Fig. 6.14, Table 6.2). The other mutants did not significantly alter the extent of use-
dependent current inhibition at the 60th pulse (Fig. 6.14, Table 6.2). Since these are only small 
effects on the use-dependent current inhibition it is difficult to attribute the changes in the rate 
of development of inactivation and the rate of recovery from inactivation to these effects. 
TABLE 6.2 
Time course o/inactivation/or human and rat Na v 1.8 channel 56 mutations 
Entry into inactivation Recovery from inactivation UD inhibition 
Nav 1.8 channel 
'j (ms) 'fast (ms) Ifast (%) 'slow (ms) I slow (%) Inann n n n 
hNav1.8 WT 3.2 ± 0.2 56 10.2 ± 0.4 67 ± 1 126 ± 15 33 ± 1 71 0.85 ± 0.01 121 
hNav1.8I381A 1.6 ± 0.2 35 12.8±1.370±5 142 ±29 30 ± 5 13 0.85 ± 0.01 43 
hNav1.8 N390A 2.9 ± 0.2 34 11.8 ± 1.6 62 ± 3 102 ± 18 38 ± 3 13 0.79 ± 0.01 50 
hNav1.8 L1410A 1.2 ± 0.2 32 27.5 ± 7.5 66 ± 9 177 ± 52 34 ±9 12 0.81 ± 0.0l 28 
hNav1.8 V1414A 1.5 ± 0.1 36 9.1 ± 1.6 61 ± 5 101 ± 47 39 ± 5 11 0.89 ± 0.01 38 
hNav1.8 II706A 1.6 ± 0.2 32 13.1±7.867±7 299 ± 135 33 ± 7 7 0.84 ± 0.01 37 
hNav1.8 F1710A 2.0 ± 0.2 37 8.4 ± 1.5 68 ± 5 95 ± 32 32± 5 12 0.90 ± 0.01 56 
hNav1.8 Y1717A 2.4 ± 0.2 38 15.2±3.2 69±4 171 ±79 31 ±4 7 0.82 ± 0.02 43 
rNav1.8 WT 5.0± 0.3 30 5.9 ± 0.5 66 ± 1 354 ± 58 33 ± 1 55 0.73 ± 0.02 86 
rNav1.8I380A 3.9 ± 0.3 6 ND ND 
rNav1.8 N389A 9.0 ± 0.3 9 ND ND 
rNav1.8 L1411A 3.3 ± 0.3 4 ND ND 
rNav1.8 V1415A 3.7 ± 0.3 9 ND ND 
rNav 1.8 II 707 A 3.0 ± 0.3 5 ND ND 
rNav1.8 F1711A 5.2 ± 0.3 11 ND ND 
rNav1.8 Y1718A 2.6 ± 0.3 10 ND ND 
In summary, the IS6, I1IS6 and IVS6 segment residues studied here appear to be important 
for the voltage-dependence of activation, and also inactivation properties; the voltage-
dependence of inactivation, time course for entry into inactivation and recovery from 
inactivation, and indeed, the use-dependent current inhibition ofNa\·1.8 channels were all 
affected by alanine mutation. Furthermore the effect of amino acid residues in activation and 
inactivation of the Nav 1.8 channel were often different between the human and rat orthologues. 
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Fig. 6.14. Use-dependent current inhibition of mutant human Na,,1.8 channels. A) Current 
amplitudes are shown elicited during a 10Hz train of 60 test pulses to Om V (1 Oms in duration) for 
wild type (_), N390A (e) and F1710A (.) hNa\" 1. 8 channels. Only currents from two 
mutations are shown for clarity. Currents were normalised to the amplitude of the first pulse. B) 
The bar diagram shows the current at the 60th pulse expressed as a fraction of the current at the 1 st 
pulse ofa 10Hz train. * p<0.05, compared to the first pulse. The n numbers are given in Table 6.2. 
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6.3 Discussion 
In addition to their role in the local anaesthetic binding site, the pore-lining S6 segments of 
the Nav 1.8 channel are also proposed to play an important role in the activation and inactivation 
gating processes of many voltage-gated Na+ channels. Here the role of seven key S6 segment 
amino acid residues in activation and inactivation properties were studied in human and rat 
Nav 1.8 channels. 
6.3.1 Effects on the voltage-dependence of activation by Nad. 8 channel mutations in 
the S6 segments 
For the activation curve, human Nav1.8 mutations I381A and F1710A gave strong 
hyperpolarising shifts. The corresponding mutations of the rat Nav 1.8 channel (I380A and 
F1711A) were the only not to show a shift in the activation curve. Hyperpolarising shifts in the 
activation curve suggest that the native residues are involved in interactions that reduced open 
states or stabilise closed states, since the probability of channel activation is decreased at any 
one membrane potential. Thus the native residues at these positions are important for 
destabi1ising open states or stabilising closed states for human Nav 1.8, but not for rat Nav 1.8. In 
contrast, the rat Nav1.8 channel mutations N389A, L1411A, V1415A, Il707A and Y171SA 
shifted the activation curve to significantly more depolarised potentials. For human Nav I.S, 
only the N390A and V1414A mutations showed depolarised shifts. Therefore, the native 
asparagine and valine residues at these positions are important for stabilising open states or 
destabilising closed states for human and rat Nav 1.8. Consistent with this fmding, a molecular 
model of the open human Nav1.8 channel (based on homology with the rat Kv1.2 channel 
structure by Long et aI., 2005) carried out by Frank Blaney (GlaxoSmithKline, Harlow) 
suggests that residues N390 and V1414 form interactions with adjacent helices. The N390 
residue in domain I appears to hydrogen bond with T250 in S5 of domain I and N 1724 in S6 of 
domain IV (Fig 6.15A). The V1414 residue in domain III appears to make hydrophobic 
interactions with L889 and F893 on S6 of domain II (Fig. 6.15B). These residues appear to be 
located in the cytoplasmic side of the transmembrane bundle in the open state (Fig. 1.9B), so 
that these residues may indeed stabilise open states. Furthermore, the corresponding mutations 
at these positions (390 and 1414 in human Nav 1.8) showed similar positive shifts in rNav 1.2 
and rNad.4 (Nau et aI., 1999; Wang and Wang, 1997; Yarov-Yarovoy et aI., 2002). The valine 
residue is an isoleucine residue in all other known Nav subtypes, which shows similar 
hydrophobicity . 
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Electrophysiological recordings also showed that the hyperpolan'sl'ng sh·ft· h . . 1 In t e aCtl\atlOn 
curve observed for human Nav1.8 mutations 1381A and F1710A was not observed forthe 
corresponding mutations in rat Nav 1.8 channel. The corresponding mutations in th t N .1'" era a\._ 
channel also did not show hyperpolarising shifts in previous studies (McPhee et aI., 1995: 
Yarov-Yarovoy et aI., 2002). Furthermore, in contrast to the lack of shifts for human Nav1.8 
mutations L 141 OA and Il706A, the homologous rat Nav 1.8 mutations showed positive shifts 
here, as did the corresponding rat Nav 1.2 mutations in previous work (Y arov-Y arovoy et aI., 
2001). 
Therefore, almost all of the rat N av 1. 8 mutations showed shifts in the activation curve 
similar to rNav1.2, whereas, in contrast to these channels, the human Nad.8 mutations I381A 
and F 171 OA showed hyperpolarising shifts, and mutation L 141 OA and I 1706A did not show 
shifts. Thus, the S6 segment residues play an important role in stabilisation and/or 
destabilisation of states during the activation process and this role for some of the residues 
appears to be different for the human Nav 1.8 channel than other subtypes. 
The involvement of native residues in the activation process may also be considered from the 
effect of the point mutations on the activation curve slope. The altered slope can be taken to 
indicate that changes in the electric field induce movement in an altered relative valence of 
charges. An altered slope factor suggests that the mutated residue may also be involved in the 
activation process. However, only a small decrease in the slope factor (steeper slope) was 
observed for human Nav 1.8 mutations N390A and F 171 OA, and a small increase in the slope 
factor (less steep slope) was shown for rat Nav1.8 mutations L1411A and Il707A. 
Complex subtype-specific effects on the slope of the activation curve have been described in 
the literature for the corresponding S6 segment mutations. For example, the steeper slope for 
human Nav1.8 mutation N390A described here was also described for the corresponding 
mutation in rat Nav 1.2 in previous work (Yarov-Yarovoy et aI., 2002), but contrasts with the 
corresponding mutation in rat N av 1.4 (Wang and Wang, 1997) and also the result here for rat 
Nav 1.8. Further, the steeper slope observed for human Nav 1.8 mutation F 171 OA was not 
described for rat Nav 1.2 (McPhee et aI., 1995) or here for rat Nav 1.8, while the homologous 
mutation of human Nav 1.5 also gave a steeper slope (Carboni et aI., 2005). 
6.3.2 Effects on the inactivation properties by Nav1. 8 channel mutations in the 56 
segments 
For the voltage-dependence of steady-state inactivation, almost all human Nav 1.8 mutations 
and some of the rat Nav1.8 mutations showed strong hyperpolarised shifts in the curve. For 
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example, human Nav1.8 mutations I38IA, N390A, L141OA, V1414A, I1706A and Y1717A. 
and rat Nav 1.8 mutations I380A, L1411A, I1707A and Y1718A all exhibited more 
hyperpolarised inactivation compared to the wild type channels The Shl'ftS' th' . . 
. In e mact!yatIon 
curve might possibly be explained by the shifts in the activation cun·es. However, the voltage-
dependence of inactivation does not appear to be simply coupled to the voltage-dependence of 
activation since Nav 1.8 activation showed both negative and positive shifts depending on the 
mutation studied, as already noted for Nav 1.4 (Kondratiev and Tomaselli, 2003). Since the 
steady-state inactivation curves studied here were obtained over potentials where yery little 
activation occurred, these curves represent mainly inactivation from closed states (Yarov-
Yarovoy et aI., 2001). All of the human Nav 1.8 mutations (except F 171 OA) and most of the rat 
Nav 1.8 mutations (I380A, L 1411A, 11707 A and Y 1718A) shifted the inactivation to more 
hyperpolarising potentials, indicating the amount of closed-state inactivation is greater than for 
the wild type channel. The human Nav1.8 mutations N390A and Vl414A both showed a 
depolarising shift in the activation curve and a hyperpolarised shift in the inactivation curve, and 
a similar effect was also observed for the rat Nav 1.8 mutations L 1411A, 11707 A and Y 171SA. 
This suggests that the native residues at these positions may playa role in coupling activation to 
channel opening, enabling closed-state inactivation but not channel opening. Interestingly, 
human Nav 1.8 mutation F 1 71 OA only showed a hyperpolarising shift in the activation curve and 
human Nav 1.8 mutations L 141 OA, I 1706A and Y 1717 A only showed hyperpolarising shifts in 
the inactivation curve. Therefore, it is possible that these residues (L 141 0, 11706, F 1 710 and 
Y1717) are involved in the coupling of the activation to the inactivation process, and residue 
F1710 favours closed-state inactivation while residues L141O, I1706 and Y1717 do not favour 
closed-state inactivation. For rat Nav1.S, mutations N389A and V1415A showed a depolarising 
shift in the activation curve, while the inactivation curve was unaffected, suggesting the native 
residues at these positions perhaps do not favour closed-state inactivation and are involved in 
the coupling of the activation to the inactivation process. Thus, many of the native residues at 
these positions appear to play different roles in the voltage-dependent gating processes between 
the human and rat Nav 1.8 channels. 
It is also of interest to compare the effects of mutations on inactivation for Nav I.S channels 
with data in the literature for the corresponding alanine mutations in other Nay channel 
subtypes. The inactivation curve for human and rat Nav 1.S mutations L 141 OA and I 1706A was 
shifted to a similar extent by the corresponding mutations ofrNad.2. In contrast, the lack ofa 
shift in the VI,2 for inactivation by the F 171 OA mutation in both human and rat Nav 1.S channels 
here contrasts with the appreciable shift described for Nad.2 and Nad.5 (Carboni et aI., ::!005; 
McPhee et aI., 1995). The Y 1717 A mutation showed depolarising shifts greater in magnitude 
for human and rat Na\·l.S channels than for both Nay 1.2 and Nay 1.4 channels (McPhee et al., 
1995; O'Reilly et aI., 2000). Furthermore, the human Navl.S channel mutation N390A showed a 
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similar strong negative shift to the corresponding mutation in the Na 1 4 hie 11 . 
v . c anne 10 owmg a 
long prepulse inactivation (Nau et aI., 1999' Wang and Wang 1997) Ho th I 
' ,. wever, e atter 
mutation in the rat Nav 1.8 channel did not significantly alter the inactivation curve, and the 
corresponding mutation in the Nav 1.2 channel showed a small positive shift (Y arov-Yarovoy et 
aI., 2002). This residue has been shown to be essential for slow inactivation in Nay 1.4 channels 
(Wang and Wang, 1997). The human Nav1.8 channel1381A and V1414A mutations showed 
hyperpolarising shifts, which contrast with the depolarising shifts reported for the corresponding 
mutations of the rat Nav 1.2 channel (Yarov-Yarovoy et aI., 2001; Yarov-Yarovoy et aI., 2002). 
For the rat Nav 1. 8 channel, mutation of the corresponding 1381 residue also showed a 
hyperpolarising shift, while the corresponding V1415A mutation showed a similar inactivation 
curve to the wild type channel. These results suggest that the phenylalanine (corresponding to 
F17l0 in human Nav1.8 channel) residue plays a lesser role in the voltage-dependence of 
inactivation of human and rat Nav 1.8 channels. Moreover, human Nav 1.8 residues 1381, N390, 
V1414 and Y1717, and rat Nav1.8 residues 1380 and Y1718 favour more depolarised 
inactivation than other Nav subtypes. 
For human Nav1.8, mutations Il706A, F1710A and Y1717A showed a significant increase 
in the non-inactivating current component during strong depolarisation. The residues at these 
positions are all located in the fourth domain, and this effect was the most pronounced for 
Y 1717 A, which is proposed to be located near the intracellular mouth of the pore (11 706A and 
F1710A are located in the middle of the S6 segment) (Fig. 6.2). The intracellularly located fast 
inactivation gate (DIll-IV linker) is thought to interact with a receptor site within or close to the 
intracellular mouth of the pore. Mutation of these residues to alanine decreases the extent of 
inactivation, suggesting these mutations are somehow involved in the fast inactivation gate 
mechanism. Consistent with the results shown here, significantly more sustained currents at the 
end of a 30ms depolarising pulse were reported for the alanine mutations of the corresponding 
F 171 OA and Y1717 A mutations in rNav 1.2 (McPhee et aI., 1995). However, in contrast to the 
results for human and rat Nav 1.8 channels, incomplete inactivation was also exhibited by 
rNav1.4 glutamate mutation ofN434 (corresponding to human Navl.8 residue N390) (Nau et 
aI., 2003). 
The time course for open-state inactivation at Om V was significantly faster for almost all 
human Nav 1.8 mutations; indeed only mutation N390A showed an unaltered time constant at 
OmV. For rat Nav1.8, mutations Il707A and Y1718A also showed significantly faster 
inactivation. Thus the reduced time to inactivate from open states suggests that the native 
residues at these positions do not favour inactivation from open states. Conversely, rat Nay 1.8 
mutation N389A showed slower inactivation, indicating the native residue favours inacti\ation 
from open states. 
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Comparing the results here with the corresponding mutations of other Nay subtypes in the 
literature, the effects on the time course for inactivation appear to be subtype-specific. For 
example, compared to Nav 1.4, the corresponding Il706A and Y1717 A mutations did not affect 
the rate of inactivation, while the corresponding F 171 OA mutation showed a longer time to 
inactivate (Kimura et aI., 2000). Furthermore, corresponding mutations of Nay 1.2 did not alter 
the rate of inactivation. The underlying reason for these differences is not understood, but may 
be related to the slower inactivation characteristic for Nav 1.8 channels compared to other Nay 
subtypes. 
In this thesis, the recovery from inactivation was only studied in the human form of the 
Nav1.8 channel. The S6 segment mutations 1381A, L1410A, Il706Aand Y1717Amainly 
affected the first component of recovery, increasing the time constant. For the second 
component, only Il706A increased the time constant. Therefore these results suggest that 
perhaps the fast inactivation state is more favoured for the native residues at these positions. 
Taken together, the results described in this chapter support the involvement of the S6 
segment residues in both activation and inactivation gating mechanisms, and the coupling of 
activation to channel opening. It appears that the native S6 segment residues play an important 
role in producing the slower inactivation kinetics characteristic for the Nav 1.8 channel. Indeed, 
a number of key S6 residues are involved in the voltage-dependent inactivation properties of 
human and rat Nav 1.8 channels in a distinct manner to other voltage-gated Na + channel 
subtypes. 
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CHAPTER 7 
STRUCTURAL DETERMINANTS OF DRUGS 
ACTING ON THE NavI.8 SODIUM CHANNEL 
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7.1 Introduction 
The S6 segments of the Nav1.8 channel and other voltage-gated Na+ channel subtypes are 
highly homologous. However, differences in drug action between subtypes have been reported 
(see Chapter 5). For instance, inactivated state block by compound A-803467 is more than 100-
fold more selective for Nav 1.8 than for several other Nav channel subtypes (Jarvis et aI., 2007). 
These properties have led to the speculation that compound A-803467 might bind elsewhere on 
the channel rather than the usual local anaesthetic binding site (Cummins and Rush, 2007). 
Furthermore, compound A-803467 showed an unusual removal of resting block 
("disinhibition") for the human Nav 1.8 channel during repetitive stimulation or recovery from 
inactivation (Chapter 5), an effect which had never been previously described for yoltage-gated 
Na + channel blocking drugs. 
The role of S6 transmembrane segments in voltage-gated Na + channel functional properties 
and drug action is well established for other subtypes. The functional properties of human 
Nav 1.8 channel S6 segment mutations were studied for the first time in Chapter 6. Here in this 
chapter, the effect of the human Nav 1.8 channel mutations on the action of highly selective 
compound A-803467 was examined, and compared with the action of local anaesthetic 
tetracaine. This was carried out in order to understand the action of A-803467 as a selective 
blocker acting on a promising therapeutic target for anti-nociceptive drugs, Nav 1.8. 
7.2 Results 
7.2.1 Affinity of tetracaine and A-803467 for resting and inactivated mutant NarI8 
channels 
Tetracaine and compound A-803467 were shown to preferentially bind to inactivated rather 
than resting Nav 1.8 channels in Chapter 5. In Chapter 6 the effects of S6 mutations on the 
functional properties of the Nav1.8 channel were studied. In order to determine the effects of the 
same human Nav1.8 channel S6 segment amino acid substitutions on tetracaine and A-803467 
block, the resting and inactivated state affinities were first examined. 
The affmity for the resting state (calculated as the dissociation constant, Kr) was obtained as 
. . . I db.c e and after the application of drug m Chapter 5, where a depolansmg test pu se was use elor ~ 
from a holding potential of -120mV (Fig. 7.lA). All human Nav1.8 channel mutations (except 
. . . ld' . I (Ch pter 6) and the reduction in Y 1717 A) were m the restmg state at thIS ho mg potentIa a , 
.. ffi·.c t' hannels (Chapter 2). Howeyer, 
current amphtude gIves a measure of the a llllty lor res lllg c 
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since mutation Y 1717 A showed a very strong hyperpolarising Shl·ft· th' . . 
m e mact!yatlOn curye 
(see Chapter 6), it was partially inactivated at -120m V and consequently the resting state 
affinity was not calculated. Furthermore, somewhat surprisingly, the mutation Ll410A showed 
a complete block of test pulse current at very low concentrations of tetracaine or A-803467, and 
thus the unusual effects of drugs on mutant L 141 OA will be considered separately in the next 
section. 
For tetracaine, mutations 1381A and F17l0A both gave a significant reduction in the affinity 
(2.4- and 2.7-fold increases in the Kr, respectively), while mutations N390A, Vl414A and 
Il706A did not significantly alter the affinity for resting channels (Fig. 7.lB, Table 7.l). For 
compound A -803467, mutation F 171 OA showed a significant reduction in the affinity for 
resting states (6.2-fold increase in the Kr; Fig. 7.lC, Table 7.l), while the affinity of compound 
A-803467 for the remaining mutations was comparable to the wild type Nay 1.8 channel. 
Therefore, these results suggest that residues 1381 and F1710 are involved in the resting state 
binding of tetracaine to Nav 1.8 channels, while only residue F 171 0 is involved in resting state 
binding of compound A-803467. 
The affinity for the inactivated state (calculated as the dissociation constant, KD was obtained 
as in Chapter 5, where channels were inactivated by 60-80% with a 4 second prepulse and the 
effect of the drug on a following test pulse before and after drug application was studied (Fig. 
7.2A). The potential to be used for the 4 second conditioning pulse was chosen knowing the 
effect of each mutation on steady-state inactivation (Chapter 6, as to produce 60-80% 
inactivation). In the case of mutation Y1717 A, since some inactivation is already present at the -
120mV holding potential this was taken into account with the h value. The h value was 
calculated by determining the extent of inactivation at -120m V from the steady state 
inactivation curves (23.1±2.4%), which was used to adjust the control pulse current amplitude in 
the absence of drug. The Nav1.8 channel mutations I381A, F1710A and Yl717A significantly 
reduced the inactivated state affinity for tetracaine, showing increases in the Ki value by 6-, 6-
and 3-fold, respectively (Fig. 7.2B, Table 7.2). Mutations N390A, V1414A and Il706A did not 
alter the affinity for tetracaine. For compound A-803467, only mutation F1710A reduced the 
affinity, showing a 6-fold increase in the Kj • The other Nav 1.8 mutations examined here gave a 
similar inactivated state affinity for compound A-803467 as for the wild type channel (Fig. 
7.2C, Table 7.2). These results indicate that the F1710 residue in an important molecular 
determinant for the inactivated state affinity of tetracaine and compound A-803467, in addition, 
residues 1381 and Y17l7 are important for tetracaine but not for A-803467. 
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Fig. 7.1. Dissociation constants for resting state oftetracaine and A-803467 for mutant 
human Navl.8 channels. A) The pulse protocol shown was used in the absence and presence of 
drug to detennine resting state dissociation constants (KJ B) The bar diagram shown represents 
the Kr values for tetracaine for wild type and mutant hNa\.1.8 channels. C) The bar diagram 
shown represents the ~ values for A-803467 for wild type and mutant hNav l.8 channels. The 
concentrations used and n numbers are shown in Table 7.l. 
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Fig. 7.2. Dissociation constants for inactivated states of tetracaine and A-803467 for mutant 
human Nav1.8 channels. A) The pulse protocol shown was used in the absence and presence of a 
drug to determine inactivated state dissociation constants (K), where the 4 second pulse indicated 
was taken at membrane potentials such that 60% to 80% inactivation occurred. B) The bar 
diagram shown represents the Kj values for tetracaine for human wild type and mutant Nay 1. 8 
channels. C) The bar diagram shown represents the Kj values for A-803467 for human wild type 
and mutant Navl.8 channels. The concentrations used and n numbers are shown in Table 7.2. 
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TABLE 7.1 
Dissociation constants for block of resting Na J 8 h I S6 . v . c anne mutatIOns 
Nay1.8 channel Drug Concentration IDr (IlM) ~(JlM) n 
hNay 1.8 WT Tetracaine 10 0.44 ± 0.07 10.3 :d.9 6 
hNay1.8I381A Tetracaine 10 0.71 ± 0.02 24.9:t: 2.2 7 
hNay1.8 N390A Tetracaine 10 0.62 ± 0.05 15.8 ± 2.5 S 
hNay1.8 L1410A Tetracaine 
hNay 1.8 V1414A Tetracaine 10 0.35 ± 0.02 5.34 ± 0.37 5 
hNay 1. 8 Il706A Tetracaine 10 0.34 ± 0.10 10.9 ± 7.7 6 
hNay1.8 F1710A Tetracaine 10 0.72 ± 0.04 27.7±6.3 4 
hNay1.8 Y1717A Tetracaine 
hNay1.8 WT A-803467 0.1 0.51 ±0.09 0.13 ± 0.03 5 
hNay1.8I381A A-S03467 0.1 0.47 ± 0.04 0.091 ± 0.012 4 
hNay1.8 N390A A-803467 0.1 0.48 ± 0.03 0.097 ± 0.010 9 
hNay1.8 L1410A A-803467 
hNay 1.8 V1414A A-803467 0.1 0.48 ± 0.04 0.102 ± 0.020 6 
hNay1.8Il706A A-803467 0.1 0.42 ± 0.13 O.OSl ± 0.039 2 
hNay1.8 F1710A A-803467 0.1 O.Sl ±0.03 0.77 ± 0.35 7 
hNay1.8 Y1717A A-803467 
TABLE 7.2 
Dissociation constants for block of inactivated Na r J. 8 channel S6 mutations 
Nay 1. 8 channel Drug Concentration IDi h (1lM) K; (JlM) n 
hNay1.8 WT Tetracaine 0.62 ± 0.05 0.28 ± 0.05 1.12 ± 0.31 7 
hNay1.8I381A Tetracaine 0.78 ± 0.07 0.34 ± 0.02 5.69 ± 2.29 6 
hNay1.8 N390A Tetracaine 0.62 ± 0.04 0.27 ± 0.04 l.27 ± 0.19 6 
hNay l.8 L1410A Tetracaine 
hNay1.8 V1414A Tetracaine 0.76 ± 0.04 0.39 ± 0.03 2.42 ± 0.64 6 
hNay 1. 8 Il706A Tetracaine 0.59 ± 0.06 0.37 ± 0.03 0.71 ± 0.08 5 
hNay1.8 F1710A Tetracaine 10 0.56 ± 0.03 0.35 ± 0.03 8.59 ± 0.92 4 
hNay1.8 Y1717 A Tetracaine 1 0.83 ± 0.03 0.37 ± 0.02 4.00± 0.S3 7 
hNay l.8 WT A-803467 0.01 0.63 ± 0.06 0.34 ± 0.03 0.015 ± 0.004 7 
hNay 1.8 I381A A-803467 0.01 0.62 ± 0.06 0.34 ± 0.03 0.011 ± 0.003 6 
hNay1.8 N390A A-803467 0.01 0.73 ± 0.03 0.35 ± 0.05 0.019 ± 0.003 7 
hNay 1. 8 Ll410A A-803467 
hNay1.8 V1414A A-803467 0.01 0.68 ± O.OS 0.40 ± 0.03 0.0105 ± 0.0025 5 
hNay1.8 Il706A A-803467 0.01 0.64± 0.08 0.37 ± 0.02 0.020 ± 0.0086 6 
hNay1.8 F1710A A-803467 0.1 0.65 ± 0.03 0.31 ± 0.01 0.141 ± 0.025 7 
hNay1.8 YI717A A-803467 0.01 0.42 ± 0.03 0.28 ± 0.01 0.0056 ± 0.0009 7 
7.2.2 Tetracaine and A-803467 drug block/or Nad.8 mutation L1410A 
While mutation L 141 OA did not show any unusual functional properties (Chapter 6), 
complete inhibition of test pulse current was obsenoed following the application of tetracaine or 
A-803467 at concentrations even 1000 times smaller than used in the preyious section to 
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measure resting block (i.e. 10nM tetracaine or 100pM A-803467) SI·nce c 
. urrents were not 
observed in the presence of drug, the resting and inactivated dissociation constants could not be 
readily determined for mutation L 141 OA using the above protocols. 
Since virtually all L 141 OA channels are in the resting state at a holding potential of -120m V 
(Chapter 6), the complete inhibition by these drugs suggests the affinity for resting states is 
much larger than for wild type human Nav1.8 channels. If the resting state affinity ofL14lOA 
channels is greater than the affinity for the open or inactivated state, depolarisation will cause 
drug dissociation. Indeed, as can be seen from Figure 7.3A, in the continual presence of 
tetracaine (l0nM) or A-803467 (lOOpM), trains of depolarising pulses at 10Hz led to a marked 
increase in the current amplitude from very low values to 70% of the current amplitude before 
drug application. Furthermore, in comparison with intermediate stimulation frequencies (10-
20Hz), the amplitude of the final pulse in the train was less at relatively lower (2Hz) and higher 
(50Hz) stimulation frequencies for both tetracaine and compound A-803467 (Fig. 7.3B). These 
findings show that the extensive resting block of this mutant was removed by repetitive 
depolarisation in a frequency-dependent manner. Indeed, it was previously shown in Chapter 5 
that in the presence of compound A-803467 (using a concentration of 100nM which gave 49% 
inhibition of resting channels) a train of depolarising pulses at 10Hz causes a "disinhibition" of 
wild type human Nav1.8 channel current, which was proposed to be the result of removal of 
resting block. For human Nav1.8 mutation L141OA, the removal of high-affinity block of A-
803467 and also tetracaine appears to be a similar disinhibitory effect, with removal of resting 
block. 
In order to determine whether the high-affinity resting block of mutant L 141 OA channels is 
removed by the induction of inactivated states, sustained depolarisation was used to inactivate 
channels. Using a 600ms conditioning depolarising pulse (the sum of 60, 10ms pulses used 
above for use-dependent inhibition) to inactivate channels and a lOOms recovery period (to 
allow inactivated channels to recover from inactivation), the current amplitude at a test pulse to 
Om V was measured (Fig. 7.3C). Comparing the test current amplitude before and after the 
application of the same low concentrations of tetracaine (lOnM) and A-803467 (lOOpM), 
practically complete removal of resting block was observed by this protocol. Thus it appears 
that sustained depolarisation removes the extensive block of resting channels, in fact even more 
effectively than repetitive stimulation. 
Overall, these results suggest mutation of residue L 141 0 causes a dramatic increase in resting 
state block, and frequent stimulation and sustained depolarisation reduce this block. 
Furthermore, these data support the hypothesis that this disinhibition occurs by the removal of 
resting block. 
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Fig. 7.3. Disinhibition of resting block for human Nay1.8 mutation L1410A. A) Currents, 
Inorm' for mutant L1410A are shown during a 10Hz train of pulses (lOms duration to OmV from a 
holding potential of -120m V), plotted against pulse number and normalised to the first pulse of the 
untreated cell. The currents are shown before the application of tetracaine (_, n=6) or A-803467 
(e, n=8) and after tetracaine (lOnM, D) or A-803467 (lOOpM, 0) in paired cells. B) The current 
amplitude elicited at the end of different frequency trains is shown for current normalised to the 
first pulse of the train. C) The pulse protocol shown was used in the absence and presence of drug 
to determine the effect sustained depolarisation on L1410A currents. D) The bar diagram shows 
the effect of sustained depolarisation on L1410A currents before (filled bars) and after (unfilled 
bars) the application of tetracaine (lOnM, n=5) or compound A-803467 (lOOpM, n=6) in paired 
cells. The protocol in C was used to obtain the test current value shown. 
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7.2.3 The effect of A-803467 and tetracaine on the recovelyfrom' t' . (S mac IvatlOll 0 6 
segment mutations 
The recovery from inactivation was studied using the protocol shown inset in Fig. 7.4A 
before and after the application of drug In Figure 7 4 and 7 5 the currents durl' 
. '. , ng recovery are 
expressed as a fraction of the control pulse amplitude in the absence of the compound. It can be 
seen that in the absence of drug the human Nav 1.8 channel current eventually recovers to 
similar values to the control pulse amplitude. As shown in Chapter 5, resting wild type human 
Nav 1.8 channel currents were reduced approximately 50% in the continual presence of 
compound A-803467 (lOOnM), and the time course of recovery from inactivation showed an 
increase in current above the control pulse amplitude (disinhibition). This can be seen in Figure 
7.4A, in the presence of A-803467 the human Nav 1.8 channel current tends towards the level of 
resting block at longer recovery periods (approximately 50%, indicated with a dotted line). The 
increase in current above the control value in the presence of A-803467 was proposed to be the 
result of a partial removal of resting block, where the additional slow component of recovery 
represents the reinstatement of the resting block (Chapter 5). The extent for which the currents 
increase above the resting block level can be measured by expressing the amplitude of the 
additional slow component (/3) as a fraction of resting block; termed the amplitude of 
disinhibition, I dis. For the human Nav 1. 8 channel the additional slow component was 26% of the 
magnitude of the resting block by A-803467. Therefore the amplitude of disinhibition (ldis) is 
26%, which may be seen from Figure 7.4A. 
For the mutations in the S6 segments examined here, quite unexpectedly, hs was 
significantly larger for all mutations than for the wild type channel in the presence of A-803467 
(Fig. 7.6A). Only small effects were apparent on the first and second components of recovery 
from inactivation (Table 7.3). The time courses for recovery from inactivation are shown in 
Figures 7.4 and 7.5, and the fit parameters are shown in Table 7.3. For mutation L141OA, there 
was complete resting block following the application of A-803467 (lOOpM) (Fig. 7.4D). For 
this mutant, marked disinhibition was observed during the time course of recovery from 
inactivation, corresponding to the removal of the high-affinity resting block during 
depolarisation (Fig. 7.4D). Mutations I38IA, N390A, V14l4A and Il706A all showed a similar 
extent of resting A-803467 block to wild type human Nav1.8 channels (Fig 7.1C), but showed 
larger dis inhibitory components (Figs. 7.4-7.6). For mutation F171OA, the resting block was 
reduced (Fig. 7.IC), but the dis inhibitory component expressed as a fraction of the resting block 
(ldis), is larger than for wild type channels (Fig. 7.6A). For mutation Y1717A, currents were too 
small to be measured accurately in the presence of 100nM A-803467. however even at 100M 
(Fig. 7.5D), A-803467 caused a larger disinhibitory component (35.2± 7.4%, n=5) compared to 
the very small disinhibitory component observed for wild type at the same concentration (n=9). 
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The time constant of recovery for the dis inhibitory component was similar for all mutations 
studied here, except for I 1706A, as compared to the wild type human Nav 1.8 channel (F ig. 
7.6B). These results suggest that relative to the resting state, disinhibition of compound A-
803467 is generally markedly increased by mutation of the S6 segment residues. 
However, in contrast to compound A-803467, the time course ofrecO\·ery from inactivation 
for tetracaine did not show disinhibition for wild type human Nav 1.8 channels (see Chapter 5). 
Unexpectedly, in the presence of tetracaine disinhibition was observed for all studied mutations, 
except I381A (Fig. 7.7-7.9). For these mutations, the recovery from inactivation was fitted with 
three components. The values for the fits are shown in Table 7.3. For mutation L141OA, the 
additional slow component expressed as a fraction of the resting block (hs) by tetracaine was 
68% (Figs. 7.7D and 7.9A). For mutation F171OA, a striking disinhibition of tetracaine was also 
observed (Fig. 7.8C), particularly when the disinhibitory component was expressed as a fraction 
of resting block (Fig. 7.9A). While the L1410A and F1710A mutations showed striking 
disinhibitory components, the other mutations showed a disinhibitory component that was small 
relative to the extent of resting block (Fig. 7.9A). Following the application of tetracaine, the 
time constants of the additional slow component are shown in Figure 7.9B. These time 
constants for the human N av 1. 8 channel mutations could not be compared to the wild type 
channel since it did not show this additional component in the presence of tetracaine. 
Overall these results suggest that mutation of the S6 segment residues L 1410 and F 1710 
induced marked disinhibition by tetracaine, and mutation of all residues studied here led to 
pronounced disinhibition by A-803467. 
Navl.8 channel 
hNavl.8 WT 
hNavl.8I381A 
hNavl.8 N390A 
hNavl.8 LI410A 
hNavl.8 Y1414A 
hNavl.8I1706A 
hNavl.8 F1710A 
hNavl.8YI7I7A 
hNavl.8 WT 
hNav l.8I381A 
hNavl.8 N390A 
hNavl.8 LI410A 
hNavl.8 \'1414A 
hNav1.8I1706A 
TABLE 7.3 
Effects of dntgs on recovery from inactivation and use.dependent block ofhNa vI.S channel S6 mllTations 
Drug 
Tetracaine 
Tetracaine 
Tetracaine 
Tetracaine 
Tetracaine 
Tetracaine 
Tetracaine 
Tetracaine 
A·803467 
A·803467 
A·803467 
A·803467 
A·803467 
A·803467 
Concentration Recovery from inactivation 
(fiM) ' .. " nonn 4." nonn ',low nonn I~ow nonn '3 <IDS) 
10 
10 
10 
0.01 
10 
10 
10 
10 
0.1 
0.1 
0.1 
0.0001 
0.1 
0.1 
1.74 ± 0.20 0.90 ± 0.07 5.46 ± 1.80 1.24 ± 0.20 6 
1.84 ± 0.40 1.02 ± 0.10 4.62 ± 1.48 0.96 ± 0.21 6 
1.23±0.31 0.87±0.09 1.15±0.09 1.12±0.10 2639±740 26.6± 16.6 4 
1.10 ± 0.19 0.96 ± 0.11 1.16 ± 0.50 1.20 ± 0.57 1801 ± 361 67.7 ± 3.7 7 
1.73 ± 0.32 0.82 ± 0.21 4.38 ± 2.50 1.38 ± 0.57 1032 ± 575 16.2 ± 6.6 3 
4.27 ± 2. 7 0.68 ± 0.50 1.55 ± 1.38 1.51 ± 0.88 1523 ± 767 3.2 ± 1.0 
1.91±0.56 112±0.23 239±1.24 0.74±0.39 2175±962 63.7±28.1 4 
0.65 ± 0.30 0.55 ± 0.19 0.41 ± 0.21 2.09 ± 0.56 4858 ± 536 18.9 ± 3.9 6 
0.90 ± 0.20 1.06 ± 0.11 0.50 ± 0.27 1.92 ± 0.41 1668 ± 183 25.6 ± 3.9 5 
1.13 ± 0.3 
1.21±0.3 
0.04 ± 0.02 
0.85 ± 0.17 0.29 ± 0.09 1.39 ± 0.58 1479 ± 143 62.7 ± 8.9 7 
0.99 ± 0.16 1.71 ± 0.76 1.01 ± 0.25 134" ± 173 46.0 ± 12.0 7 
0.30 ± 0.19 2.03 ± 0.55 
2.34 ± 0.81 1.00 ± 0.00 
0.71 ± 0.58 0.57 ± 0.23 0.09 ± 0.04 3.72 ± 2.15 
1658 ± 60 58.8 ± 5.0 
1628 ± 64 66.6 ± 9.0 6 
751 ± 150 70.3 ± 265 2 
UD block 
10Hz n 
0.75 ± O.OS 20 
0.75±0.OS II 
0.75 ± O.OS 10 
0.75 ± O.OS 4 
0.75 ± 0.05 5 
0.75±0.05 16 
0.75 ± 0.05 13 
0.7S±005 12 
0.75 ± 0.05 7 
0.75 ± 0.05 7 
0.75 ± 0.05 
0.75 ± OOS 6 
0.75 ± 0.05 2 
1" 73· ± I~ 9 7 0.75 I 0.05 7 O• 0 18 028 ± 0 13 089 ± 0 36 1687 ± -_.' .~ .. hNav1.8f1710A A·803467 0.1 I.24±0.36 I.)±. . . . . . 
. . . th resence of A·80~467 as this component was too small For UO block is use·dependent block. NB: The I ... , could not be obtamed for mutatIon LI410A m e p . 
. ' fA 803467 this component was also too small. mutation \. I 4 I 4A the The I >low could not be obtamed m the presence o· as 
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Fig. 7.4. The effects of A-803467 on the time course of recovery from inactivation for mutant 
human NavI.8 channels. Time courses of recovery from inactivation are shown for wild type 
(A), 1381A (B), N390A (C) and L1410A (D) Nay 1.8 channels, before (_) and after (e) the 
application of A-803467 in paired cells. The curves for were fit with three exponential 
components. The pulse protocol is shown in the inset of A. The dotted line represents the extent of 
resting block. The resting block and the amplitude of the addition slow component (/3) are 
illustrated with arrows in A. The concentrations used and n numbers are shown in Table 7.3. 
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Fig. 7.5. The effects of A-803467 on the time course of recovery from inactivation for mutant 
human Na,.1.8 channels. Time courses of recovery from inactivation are shown for V1414A (A), 
I1706A (B), F1710A (C) and Y1717A (D) Navl.8 channels, before (-) and after (e) the 
application of A-803467 in paired cells. The pulse protocol is shown in the inset of A. The curves 
fwere fit with three exponential components. The doffed line represents the extent of resting block. 
The concentrations used and n numbers are shown in Table 7.3. 
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Fig. 7.6. The effects of A-803467 on the parameters of the disinhibitory component of 
recovery. A) The bar diagram shows the amplitude (ldis' which is 13 expressed as a fraction of the 
resting channel block) of the disinhibitory component from the time course of recovery from 
inactivation for wild type, and mutant Nav 1.8 channels. B) The bar diagram shows the time 
constant, r, of the disinhibitory component for wild type, and mutant Nav l.8 channels. The n 
numbers are shown in Table 7.3. 
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Fig. 7.7. The effects of tetracaine on the time course of recovery from inactivation for 
mutant human Na,,1.8 channels. Time courses of recovery from inactivation are shown for \vild 
type (A), I381A (B), N390A (C) and L1410A (D) Nay 1.8 channels, before (_) and after (e) the 
application of tetracaine in paired cells. The pulse protocol is shown in the inset of A. The cUr\'es 
for wild type and I381A were fit with two exponential components, while the curves for N390A 
and L 141 OA were fit with three. The dotted line represents the extent of resting block. The 
concentrations used and n numbers are shown in Table 7.3. 
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Fig. 7.8. The effects of tetracaine on the time course of recovery from inactivation for 
mutant human Nav1.8 channels. Time courses are for V1414A (A), Il706A (B), F1710A (C) 
and Y1717A CD) Nav1.8 channels, before (_) and after (e) the application of tetracaine in paired 
cells. The pulse protocol is shown in the inset of A. The curves for were fit with three exponential 
components. The dotted line represents the extent of resting block. The concentrations used and n 
numbers are shown in Table 7.3. 
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Fig. 7.9. The effects of tetracaine on the parameters of the disinhibitory component of 
recovery. A) The bar diagram shows the amplitude (lilis' which is I~ expressed as a fraction of the 
resting channel block) of the disinhibitory component from the time course of recovery from 
inactivation for wild type, and mutant Nay 1. 8 channels. B) The bar diagram shows the time 
constant, r, of the disinhibitory component for wild type, and mutant Na\.1.8 channels. The n 
numbers are shown in Table 7.3. 
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7.2.4 The effect 0/S6 segment mutations on use-dependent block of A-803467 and 
tetracaine 
Since most of the S6 mutations showed an altered time course of recovery from inactivation 
time course in the presence of drug, it would be expected that this property would also be 
observed during trains of depolarising pulses. Indeed, use-dependent block of 1 ~M tetracaine at 
10Hz (example mean currents are shown in Fig. 7.1 OA) was no longer observed for mutations 
I381A, N390A, V14l4A or F1710A (Fig. 7.1OA,B). Furthermore, mutant Y1717A showed the 
disinhibition of tetracaine (Fig. 7.1 OB). In contrast, mutation Il706A showed a similar extent of 
use-dependent block compared to wild type human Nav1.8 channels (Fig. 7. lOB). 
For compound A-803467 (1 0nM), 10Hz stimulation showed a greater extent of disinhibition 
(example mean currents are shown in Fig. 7.l0C) for mutations I381A, N390A, V1414A, 
Il706A and Y1717A compared to wild type channels (Fig. 7.l0C,D). Only mutation F1710A 
did not alter the extent of use-dependent disinhibition (Fig. 7.l0D). 
Taken together, the results show that mutations of the S6 segments induced disinhibitory 
components for both tetracaine and A-803467. 
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Fig. 7.10. Effect of mutant human Nav1.8 channels on the use-dependent block by tetracaine 
and A-803467. A) Normalised mean currents are shown plotted against pulse number during 
stimulation at 10Hz (pulses to Om V of 10ms duration from a holding potential of -1 ~Om V) in the 
continual presence of tetracaine (l J..lM). Curves are for wild type (_), V1414A (e), F 1710A 
(.), and Y1717A ('~). B) The bar diagram shows the extent of use-dependent block by 
tetracaine at the 60th pulse of a 10Hz train for wild type and mutant hNavl.8 channels. C) 
Normalised example mean currents are shown plotted against pulse number during stimulation at 
10Hz in the continual presence of A-803467 (lOnM). Curves are for wild type (_), V1414A (e), 
Fl710A (.), and Y1717A ("'). D) The bar diagram shows the extent of use-dependent block by 
A-803467 at the 60th pulse ofa 10Hz train for wild type and mutant hNav 1.8 channels. In A-D, 
currents were first expressed as a fraction of the first pulse and then expressed as a fraction of 
their respective control pulses before the application of drug, as shown in Figure 5.6. * p<O.05. 
compared to the first pulse. The n numbers are shown in Table 7.3. 
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7.3 Discussion 
7.3.1 Effects of S6 segment mutations on the tonic block of tetracaine and A -803467 
In this chapter, the effects ofNav 1.8 channel S6 segment mutations on the action of local 
anaesthetic, tetracaine, and the highly Nav 1.8-selective compound, A-803467, were studied. 
These mutations have all been shown to affect the tonic and/or use-dependent properties of a 
number of drugs for other Nav channel subtypes (see Chapter 1). The effect of the mutations on 
block by tetracaine and A-803467 was first investigated by examining the affmity for both the 
resting and inactivated states. For tetracaine, the affinity for the resting channel was reduced by 
I38lA and F1710A, with 2-fold and 3-fold increases in Kr respectively (the resting state affinity 
was not calculated for Y1717 A). The affinity for the inactivated channel was reduced by I381A, 
F17lOA and Y1717 A, with 6-fold, 6-fold and 3-fold increases in Kr respectively. For compound 
A-803467, mutation of the F17lO residue reduced the resting state affinity (Kr increased 6-fold), 
and the affinity for the inactivated channel was also reduced (Ki also increased 6-fold). In 
contrast to the effects of the other mutations, mutation L 141 OA showed a surprising increase in 
resting block, as currents were completely inhibited even by lOOO-fold lower concentrations of 
tetracaine or A-803467, suggesting a greater than lOOO-fold increase in affinity for resting 
states. These results suggest that while the role of L 141 0 is unknown, residues 13 81, F 1 710 and 
Y 1717 are important for the action of tetracaine, but only residue F 1 710 for the action of A-
803467. Thus the F1710 residue is important for the action of both tetracaine and compound A-
803467, but in contrast to tetracaine, mutations I381A and Y1717A do not appear to be 
important for the affinity of compound A-803467 for resting or inactivated channels. 
Previously, mutagenesis of the drug binding sites on Nav 1.8 sodium channels has not been 
carried out. It was not understood where compound A-803467 bound in the Nav 1.8 channel; 
indeed, it was speculated that it might not bind to the local anaesthetic site (Cummins and Rush, 
2007). However, these results suggest it binds to a site within the pore, which partially overlaps 
the local anaesthetic binding site. 
As discussed in Chapter 1, the residue corresponding to F 1 710 has been found to be the most 
important in determining the action of voltage-dependent pore-blocking drugs; indeed, no drug 
tested has been shown to be unaffected by the mutation F 1 71 OA. This residue is also important 
for the preference of drugs for the inactivated state over the resting state (Li et aI., 1999). For 
tetracaine mutation F 171 OA reduced the affmity for inactivated states more than for resting 
, 
states, in Nav 1.3 channels (Li et aI., 1999) and in Nav 1.8 channels in this chapter, indicating 
tetracaine interacts with F 171 0 more effectively when the Nay 1.8 channel is inactivated. This 
. ' f' c. th' ti 'ated channe I rather than the property likely underlies the preference 0 tetracame lor e mac " 
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resting channel. In contrast, mutation F 171 OA showed a practicall 1 fii 0 y equa e ect on the restmg 
and inactivated state binding of compound A-803467 Theretlore whol F1710 
. ,1 e appears to be 
important for the binding of A-803467, it does not appear to contribute to the preferential 
inactivated state binding of this compound A more extensive study of t t· th 
. mu a IOns at 0 er 
positions would be necessary to understand the selectivity of A 803467 c th 0 • d 
- lor e InactIvate state 
over the resting state in Nav 1.8, and also for the Nav 1.8 channel subtype over other Nay channel 
subtypes. 
7.3.2 Effects of A-803467 and tetracaine on the recovery from inactivation 0/S6 
segment mutations 
The effect of disinhibition, first observed in Chapter 5, involves the partial removal of A-
803467 resting block during recovery from inactivation. The extent of disinhibition of A-
803467 was more pronounced than the wild type channel for all the human Na\OI.8 channel S6 
segment mutations examined in this chapter. A striking example of this was for mutation 
L1410A, where resting channels were completely inhibited in the presence of tetracaine and A-
803467, but a marked disinhibition of resting block was observed during recovery from 
inactivation. For the other mutations, relative to the extent of resting block, the extent of A-
803467 disinhibition was more pronounced for all the mutations studied than for wild type 
channels. Thus the native residues at all these positions appear to be involved in the 
dis inhibitory phenomenon. 
While tetracaine did not show the disinhibitory effect for wild type human N av I. 8 channels, 
the appearance of a disinhibitory component was observed for mutations during recovery from 
inactivation. The time course of recovery from inactivation showed disinhibition by tetracaine 
of varying extents for mutations N390A, L141OA, V1414A, Il706A, FI710A and Y1717A, but 
not I381A. Although small effects were observed for N390A, V 1414A, Il706A and Y 1717 A, 
the most marked disinhibition was shown for L1410A and F1710A. As with compound A-
803467, tetracaine blocked resting L1410A mutant channels with high-affinity, and marked 
disinhibition of tetracaine was shown during stimulation. For mutation F 1 71 OA, tetracaine 
blocked resting channels with a lower affmity than wild type, but a large proportion of the 
blocked channels were also disinhibited by stimulation. These findings suggest that the native 
residues L 1410 and F 1710 contribute to the mechanism underlying the main disinhibitory effect 
on human Nav1.8 channels for tetracaine. 
The residues considered here have been shown to be important determinants for the action of 
a number of drugs in Nad .2, Nav 1.3, Nad.4 and Nav 1.5 channels (see Chapfer 1). The effect 
of corresponding mutations on the action of tetracaine has so far only been studied in Nay 1.3, 
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and the effects were similar to those here in the present chapter. For Nav 1.2 channels, the 
inactivated state affinity of etidocaine was significantly reduced by corresponding mutations 
I381A (Ki increased 6-fold), L1410A (Ki increased 6-fold), V1414A (Ki increased 7-fold), 
F1710A (Ki increased 130-fold) and Y1717A (Ki increased 35-fo1d) (Ragdale et aI., 1994; 
Y arov-Yarovoy et aI., 2001; Yarov-Yarovoy et aI., 2002). For all drugs studied to date, the 
corresponding F 171 0 residue appears to be the principal determinant for drug action in a 
number ofNav channel subtypes, and is proposed to directly bind to local anaesthetics by a ]!_ 
cation interaction (Ahem et aI., 2008). For the human Nav 1.8 channel, the F 1710 residue was 
shown in this chapter to be important for the action of both local anaesthetic tetracaine and 
Nav1.8-selective compound A-803467. For V1414A, tetracaine does not appear'to make 
interactions with the Nav 1.8 channel that were found to be important for etidocaine binding in 
the Nav 1.2 channel. For L 141 OA, high-affinity drug block of resting channels was not observed 
in the corresponding mutations ofNav 1.2 or Nav 1.4 (Wang et aI., 2004; Wang et aI., 2000: 
Y arov-Y arovoy et aI., 2001), or indeed any mutation of aN av channel. 
While it is possible that the substitution of the leucine to an alanine residue at position 1410 
might cause the marked increase in resting block by direct interactions, the notable magnitude 
of this effect suggests that this is unlikely. The hydrophobic pathway (see Section 1.3.3) has 
been suggested to exist at the interface between the IIIS6 and IVS6 segments (Bruhova et aI., 
2008), and since the L1410 residue is located on the IIIS6 segment perhaps its mutation alters 
this pathway. Perhaps the drugs become trapped in the resting state, although it is difficult to 
understand how mutation to a smaller alanine residue might enhance trapping. The mutation did 
not show unusual functional properties in the absence of drug (Chapter 5), thus it is unlikely 
that the mutation caused severe distortion of the molecular structure. 
7.3.3 Effects of mutations ofS6 segments on the use-dependent block of tetracaine and 
A-803467 
It was observed in Chapter 5, that the disinhibition observed during frequent stimulation 
correlated with the effects on the time course of recovery from inactivation. As expected from 
the time course of recovery from inactivation showing marked disinhibition by tetracaine, 
mutations N390A, V1414A, F17IOA and YI717 A caused a reduction in use-dependent block 
by tetracaine. For tetracaine acting on Nav 1,8, the N390A mutation showed a similar effect for 
etidocaine acting on the corresponding mutation of rNav 1.2: while the binding affinities v,'ere 
unaffected, the extent of use-dependent block was reduced (Yarov-Yarovoy et aI., 20(2). 
Despite not showing disinhibition during recovery from inactivation in the presence of 
tetracaine, mutation I381A did not display use-dependent block by tetracaine, and vice versa, 
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mutation 11706A showed use-dependent block despite showing disinh'b't' d . IlIon unng recovery 
from inactivation. The corresponding 11706A mutation in rNa -I 2 ch 1 h \. anne was s own to reduce 
the use-dependent block by etidocaine while the binding affinities were not affected (Ragsdale 
et aI., 1994; Wang et aI., 1998a). The latter mutation in the rNa 14 channel 1 h v . was a so s own to 
reduce the use-dependent block by etidocaine, however, use-dependent block by benzocaine 
was shown to be more pronounced for this mutation (Wang et aI., 1998a). Using quaternary 
local anaesthetics it was proposed that this mutation created another pathway for local 
anaesthetics to dissociate from, and is perhaps not directly involved in the local anaesthetic 
binding site (Ragsdale et aI., 1994; Wang et aI., 1998a). 
For compound A-803467, all mutations showed more pronounced disinhibition (except 
F 171 OA) than wild type Nav 1.8 channels at 10Hz. These results suggest these native residues at 
these positions do not affect the affinity for the inactivated state, but somehow contribute to 
reducing the dis inhibitory effect. Taken together, the S6 segment mutations generally abolished 
the use-dependent block by tetracaine and showed more pronounced use-dependent 
disinhibition of compound A-803467. 
7.3.4 Homology models for the binding of tetracaine and A-803467 
Based on the mutagenesis data in this thesis, Frank Blaney constructed a (unpublished) 
model of the human Nav1.8 channel using homology with the crystal structure of the open rat 
Kv 1.2 channel (Long et aI., 2005) and carried out docking studies with tetracaine and A-
803467. Figure 7.11A,B shows tetracaine docked into the open human Nav1.8 channel, and 
Figure 7.11 C,D shows A-803467. These models suggest that the protonated nitrogen of 
tetracaine and the amide NH of A-803467 interacts with D356 (i.e. the D of the DEKA motif). 
The F1710 residue interacts with the aromatic ring of both compounds by 1[-1[ stacking, and 
L1410 forms a hydrophobic interaction with both drugs. The diethyl amino group of tetracaine 
is able to form a hydrophobic interaction with 1381. In contrast, the methoxy groups of A-
803467 form hydrogen bonds with T354 and S1660 (in the P loops), which lock A-803467 in a 
position where the substituted ring of A-803467 cannot interact with 1381. The Y1717 residue 
can hydrogen bond to the ester carbonyl of tetracaine, but it cannot interact with A-803467. 
Furthermore, this molecular model also suggests interactions with residues not mutated in this 
thesis. Tetracaine might interact with F382, L882, FI713, L1711 and V1714, and A-803467 
might interact with S385, L882 and V1714. All these residues are conserved between all Nay 
channel subtypes. Overall, the experimentally obtained affinities for both compounds support 
this molecular model. However, the selectivity of A-803467 for Nay 1.8 channels is not easily 
understood from the molecular model, nor is the unusual effect of disinhibition. 
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In summary, some of the human Nav 1.8 channel S6 segment residues involved in the resting 
and inactivating state block by tetracaine and A-803467 have been identified. Residues 13S1, 
L 141 0, F 1710, and Y 1717 are involved in the action of tetracaine while only L 141 0 and F 171 0 
were found to be involved in the action of A-803467, indicating differing but partially 
overlapping areas of binding within the pore. For tetracaine, mutation F1710A gave a greater 
percentage reduction in the inactivated state compared to the resting state affinity, while 
compound A-S03467 gave similar percent reductions, suggesting that residue F 1710 does not 
underlie the preference of compound A-803467 for the inactivated state. For both tetracaine and 
A-803467, mutation L1410A showed a striking increase in the affinity for the resting channel, 
and depolarisation was found to cause a "disinhibition" of channel current, supporting the idea 
that disinhibition is the removal of resting block. Furthermore, all mutations studied increased 
the extent of disinhibition of A-S03467, some also caused the disinhibition of tetracaine. Overall 
it is surprising that compound A-S03467 is selective for Nav 1.S, since alignment with other 
human voltage-gated Na+ channel subtype protein sequences (Fig. 7.12) show that the S6 
residues implicated in drug binding (whether by the mutational study or by modelling) are 
almost completely conserved between different voltage-gated Na + channel subtypes. 
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7.4 Future work 
In this thesis, wild type and mutant Nav 1.8 sodium channels were expressed in mammalian 
sensory neuron-derived ND7/23 cells and the functional properties and drug binding sites were 
studied using whole-cell patch clamp. 
In chapter 4, the functional properties were shown to be different between wild type human 
and rat Nav 1.8 channels. To study the difference between the two Nav 1.8 channels further, 
electrophysiological recordings could be made from adult human and rat dorsal root ganglion 
cells, and from human and rat Nav 1.8 channels expressed in different mammalian cell lines. The 
generation of human and rat Nav 1.8 channel chimeras and eventually point mutations could be 
used to study the molecular determinants responsible for the different functional properties 
between these two channels. 
In chapter 5, the action of various drugs on wild type human and rat N av 1. 8 channels were 
studied and potent compounds V102862 and A-803467 showed a novel "disinhibition" during 
recovery from inactivation. The mechanism underlying this effect may be understood further by 
recording from single channels. 
In chapter 6, the functional properties of human and rat Nav 1.8 channels were altered by 
alanine mutations in the S6 segments. By substituting these residues for residues with different 
properties (size, hydrophobicity, aromaticity and charge) it should be possible to determine the 
role of the native amino acid residue side chain. It was proposed here that the two residues 
(N390 and V14l4) stabilise the activated state by interating with other residues in other 
transmembrane segments; mutation the binding partners might determine whether this is the 
case. 
In chapter 7, some of the pore-lining S6 segment mutations were shown to reduce the 
sensitivity of the human N av 1. 8 channel to tetracaine and compound A -803467, suggesting that 
both drugs act on a differing but partially overlapping area within the pore. The selectivity of A-
803467 for the Nav 1.8 channel over other voltage-gated Na+ channel subtypes is therefore 
surprising since the pore lining S6 residues are well conserved. It would be relatively easy to 
substitute all of the Nav1.8 channel S6 segment residues to the Nad.2 channel S6 segment 
residues to assertain whether selectivity of compound A-803467 is determined by the S6 
segements. For mutation L 141 OA both compounds caused complete resting block at wry low 
concentrations; block was disinhibited after depolarisation. Mutation of the L 1410 residue to 
residues with different properties might explain the greatly increased resting state binding 
affinity shown with mutation L 141 OA. Furthermore, single channel recording of mutation 
L 141 OA might also provide a better understanding of the disinhibition effect. 
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